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PA . . . . . . . . . . . . phosphatidate
PAF . . . . . . . . . . platelet activating factor
PAFAH . . . . . . . platelet activating factor acetylhydrolase
PBS . . . . . . . . . . phosphate buffered saline
PC . . . . . . . . . . . phosphatidylcholine
PCYT . . . . . . . . CTP:phosphocholine cytidylyltransfersase
PDH . . . . . . . . . . pyruvate dehydrogenase complex
PDK4 . . . . . . . . pyruvate dehydrogenase kinase 4
PDPK1 . . . . . . . phosphoinositide-dependent kinase 1
PE . . . . . . . . . . . phosphatidylethanolamine
PEMT . . . . . . . . phosphatidylethanolamine N-methyltransferase
PERK . . . . . . . . PKR-like endoplasmic reticulum kinase
PG . . . . . . . . . . . phosphatidylglycerol
PI . . . . . . . . . . . . phosphatidylinositol
PIK3 . . . . . . . . . phosphatidylinositol-4,5-bisphosphate-3-kinase
PIP3 . . . . . . . . . . phosphatidylinositol-3,4,5-trisphosphate
PISD . . . . . . . . . phosphatidylserine decarboxylase
PKA . . . . . . . . . . protein kinase A
PKC . . . . . . . . . . protein kinase C
PL . . . . . . . . . . . . phospholipase
PLA1 . . . . . . . . . phospholipase A1
PLA2 . . . . . . . . . phospholipase A2
PLB . . . . . . . . . . phospholipase B
PLC . . . . . . . . . . phospholipase C
PLD . . . . . . . . . . phospholipase D
PLPP . . . . . . . . . phosphatidate phosphatase
PNPLA . . . . . . . patatin-like phospholipase domain containing
PON1 . . . . . . . . serum paraoxonase/arylesterase 1
PPAR . . . . . . . . peroxisome proliferator-activated receptor
PPRE . . . . . . . . peroxisome proliferator-activated receptor responsive element
PRDX6 . . . . . . . peroxiredoxin 6
PS . . . . . . . . . . . phosphatidylserine
PTDSS . . . . . . . phosphatidylserine synthase
PTX . . . . . . . . . . pertussis toxin
Q-MS . . . . . . . . Quadrupole-Orbitrap mass spectrometry
qPCR . . . . . . . . quantitative polymerase chain reaction
qTOF . . . . . . . . . Quadrupole-time-of-flight
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Lysophosphatidylcholines (LPC) gained particular attention in metabolomics studies
as potential biomarkers for metabolic diseases like obesity, insulin resistance, and
type 2 diabetes mellitus. LPC plasma levels negatively correlate with insulin re-
sistance, inflammatory parameters, and body mass index. Aim of this thesis was
to investigate the physiological role of LPCs as potential regulators of metabolism
and inflammation using skeletal muscle cells as model system. Human primary my-
otubes (HMT) were treated with 10 μM LPC(16:0) or LPC(18:1) for 24 h which were
proven not to induce cytolysis. Microarray analysis and qPCR from total RNA were
performed to study LPC effects. LPC treated HMT displayed activation of peroxi-
some proliferator-activated receptor (PPAR) target genes including PDK4, ANGPTL4,
PLIN2, andCPT1A. The induction ofPDK4 andANGPTL4was sensitive to PPARδ an-
tagonists GSK0660 and GSK3787. The increase of PDK4 was reduced by siRNA
against PPARD. Luciferase assays showed activation of the ligand binding domain
of PPARδ by LPCs. EMSAs demonstrated that LPCs can enhance the DNA binding
activity of the PPARδ/RXRα complex. TR-FRET-based in vitro competitive binding as-
says displayed dose-dependent agonist displacement from the PPARδ ligand binding
domain by both LPCs and by an ether analogue of LPCs proving that LPCs are direct
ligands of PPARδ. The LPC analogue exhibited a robust induction of PDK4/ANGPTL4
confirming the importance of the LPC structure. Both LPCs caused the phospho-
rylation of AMPK. LPC(16:0) marginally increased basal glucose uptake in L6 cells
and palmitate oxidation in HMT. Both LPCs could reduce ER stress and inflamma-
tion caused by palmitate. The anti-inflammatory effects of LPCs were reduced by
GSK0660 treatment. In conclusion, LPCs can activate PPARδ as direct ligands and
AMPK by a yet unknown mechanism in skeletal muscle cells. As a result, LPCs pro-
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tect against lipotoxicity caused by palmitate. This leads to the assumption that in-
creasing plasma LPC levels can be beneficial via activation of PPARδ resulting in




Lysophosphatidylcholine (LPC) erhalten zunehmende Aufmerksamkeit in
Metabolomics Studien, die zeigen, dass diese Lipide als potentielle Biomarker
für Adipositas, Insulinresistenz und Typ 2 Diabetes mellitus fungieren können. Dabei
sind Plasmaspiegel der LPCs negativ mit Insulinresistenz, Inflammation und Body
Mass Index assoziiert. Ziel dieser Dissertation war es, die physiologische Funktion
der LPCs anhand von Skelettmuskelzellen als Modellsystem zu erforschen. Dabei
wurden humane Myotuben (HMT) für 24 h mit 10 μM LPC(16:0) oder LPC(18:1)
behandelt, was nachweislich keine Zelllyse induzierte. Microarray Analysen und
qPCR wurden durchgeführt um LPC Effekte zu ermitteln. Mit LPCs behandelte
HMT zeigen eine Aktivierung von Peroxisome proliferator-activated receptor (PPAR)
Zielgenen wie PDK4, ANGPTL4, PLIN2 und CPT1A. Die Induktion von PDK4 und
ANGPTL4 konnte mit den PPARδ Antagonisten GSK0660 und GSK3787 gehemmt
werden. Zudem reduzierte siRNA gegen PPARδ die Induktion von PDK4. Luciferase
Reportergenassays zeigten die Aktivierung der Ligandenbindungsdomäne von
PPARδ durch LPCs. Eine Verstärkung der PPARδ/RXRα DNA Bindung wurde in EM-
SAs nachgewiesen. In TR-FRET basierten Kompetitionsassays erzielten LPCs und
ein Ether-Analogon der LPCs eine dosisabhängige Verdrängung eines PPAR Agonis-
ten aus der Ligandenbindungsdomäne von PPARδ. Das LPC-Analogon rief zudem
eine ausgeprägte Induktion von PDK4 und ANGPTL4 hervor und bestätigt damit
die Bedeutsamkeit der LPC Struktur. Beide LPCs lösten die Phosphorylierung von
AMPK aus. LPC(16:0) konnte die basale Glukoseaufnahme in L6 Zellen, sowie die
Palmitatoxidation in HMT in begrenztem Ausmaß erhöhen. Beide untersuchten LPCs
verminderten ER-Stress und Inflammation, ausgelöst durch Palmitat Behandlung.
Die anti-inflammatorischen Effekte waren zudem GSK0660-sensitiv. Diese Arbeit
XIX
Zusammenfassung
zeigt auf, dass LPCs PPARδ als direkte Liganden aktivieren und AMPK durch noch
unbekannte Mechanismen in HMT stimulieren. Als Konsequenz schützen LPCs vor
Lipotoxizität, hervorgerufen durch Palmitat. Das führt zu der Annahme, dass erhöhte
Plasma-LPC Spiegel positiv einzustufen sind, da durch sie PPARδ aktiviert wird,
was anti-inflammatorische und anti-diabetische Effekte erzeugt. LPC Plasmaspiegel
könnten daher von pharmakologischer Relevanz sein.
XX
1 Introduction
1.1 The lipid class of glycerophospholipids
Lysophosphatidylcholines (LPCs, formerly known as lysolecithin) are a subgroup of
lipids that belong to the family of glycerophospholipids (GPL) (Schmitz and Ruebsaa-
men, 2010). GPLs are composed of a glycerol backbone with different substituents at
position sn-1 (stereospecific numbering) and sn-2, and a phosphate group at position

































Figure 1.1: Schematic view of glycerophospholipids. The glycerol part is highlighted in blue, phos-
phate in green. The stereospecific numbering (sn) and possible substituents (boxes) at different
position of the glycerophosphate backbone are given. The positions sn-1/sn-2 contain either none
(only hydroxyl groups), acyl, alkyl, or alkenyl groups. The phosphate can be linked to various sub-
stituents. R describes alkyl/alkenyl groups.
The nature of the substituents vary depending on the position. Radyl groups
(alkyl/alkenyl or acyl groups) are located at position sn-1 of the glycerol backbone
while position sn-2 typically contains acyl chains in mammals (Magnusson and Har-
aldsson, 2011; Nagan and Zoeller, 2001; Yamashita et al., 1997). A heterogeneous
1
1 Introduction
spectrum of compounds are attached to the phosphate located at position sn-3 (polar
head group) which includes choline in the GPL class of phosphatidylcholines (PC aka
lecithin), ethanolamine in phosphatidylethanolamines (PE), inositol in phosphatidyli-
nositols (PI), serine in phosphatidylserines (PS), glycerol in phosphatidylglycerols
(PG), phosphatidylglycerol in cardiolipins (CL), and no compound in phosphatidates
(PA), to name a few examples (Yamashita et al., 1997). The nomenclature of these
lipids according to LIPID MAPS (Fahy et al., 2005, 2009) and part of their diversity is
shown exemplarily for several PCs at figure 1.2 on the following page.
Generally, the members of the GPL class are abbreviated according to the polar
headgroup. The appearances, position, and linkage of the two radyl chains on the
backbone are described in brackets: e.g. PC(sn-1/sn-2). The type of linkage of the
radyl group to glycerol is added as prefixes in front of the radyl description: O for
ether (termed plasmanylcholines in case of PC), P for 1Z-alkenyl ethers (termed plas-
menylcholines in case of PC), and no descriptors are attached for ester. Examples
are depicted in figure 1.2 on the next page.
The lyso forms of GPLs contain only one radyl group which changes the nomen-
clature to LPC(sn-1 or sn-2) in case of the lysolipids of PC. A special class of
PCs are platelet activating factors (PAF) with acetyl groups at the sn-2 position and
alkyl/alkenyl groups at sn-1, which are also depicted in figure 1.2 on the following page
































































































































































Figure 1.2: Overview of selected subclasses of phosphatidylcholines. This overview of different
PC subclasses includes the corresponding structures and nomenclature examples. General chem-
ical structures of the subclasses of PCs are depicted atop of the general category name or trivial
name. Below, there is the systematic chemical expression of the subclass in brackets and one ex-
ample of the subclass with the respective abbreviation according to the nomenclature used in this
work and the corresponding chemical structure. The different PC subclasses are grouped in rows
based on the basic forms and one possible example of a lyso form. The grouping in columns is in
accordance with the linkage and type of the radyl chains. PCs with only acyl chains are depicted in
the column acyl form. Mixed forms include both acyl and alkyl substituents. The special subclass of
acetylated PCs are shown in the column acetyl form. Abbreviations: LPC (lysophosphatidylcholine),
PAF (platelet activating factor), PC (phosphatidylcholine), R = alkyl or alkenyl groups.
3
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1.2 Chemical properties of lysophosphatidylcholine
LPCs are monoradylglycerophospholipids composed of only a single radyl group leav-
ing one vicinal located free hydroxyl group at either sn-1 or sn-2 position (requirement
of the lyso-prefix in the term). The unoccupied hydroxyl group enables a quick migra-
tion of acyl chains from sn-1 to sn-2 and vice versa (Pluckthun and Dennis, 1982).
At physiological conditions, pH 7.0 and 37 °C, 20 % of the C18:2 groups at sn-2 of
LPC(18:2) can migrate to the sn-1 position within 2 min (Croset et al., 2000). At equi-
librium and under these conditions the acyl chain at position sn-1 is preferred (Croset
et al., 2000).
LPCs have a special steric shape. The three methyl groups of choline are bulky
while the radyl part sterically resembles a hydrophobic pole. In summary, these fea-
tures create a cone-like shape as depicted in figure 1.3. Furthermore, LPCs are zwitte-
rions under physiological conditions. This results from the pKA of the phosphate group
which is 0.8 in phosphatidylcholine (Moncelli et al., 1994). The phosphate group there-
fore carries a negative charge while choline has a permanent positive charge. LPCs
are also highly hygroscopic due to the choline part (Beyer et al., 2004). In summary,
the shape and amphiphatic (hydrophobic and hydrophilic) nature of LPCs renders
them water-soluble detergents (Small, 1968; Henriksen et al., 2010; Helenius and Si-
mons, 1975).
Figure 1.3: Chemical structure of LPCs. Chemical structure and stereo specific numbering of LPCs
are depicted together with their steric shape of a cone-like form. Abbreviations: sn (stereospecific
numbering)
LPCs are able to reversibly integrate into lipid bilayers with a half-time of 50 - 500
ms (Elamrani and Blume, 1982), and they are able to disrupt the integrity of phys-
iological membranes by their shape, causing membrane curvature stress and pore
4
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Figure 1.4: Disruption of plasma membranes integrity by LPCs acting as detergents. At the
critical micellar concentrations (CMC) of LPCs, or detergents in general, the compound monomers
aggregate to micelles. With increasing concentrations, the detergents start to integrate into plasma
membranes causing curvature stress. At saturation with detergent molecules, the membrane starts
to disintegrate into mixed micelles containing detergents, lipids, and membrane proteins (Arouri and
Mouritsen, 2013; Heerklotz, 2008; Weltzien, 1979).
formation (Yoo and Cui, 2009; Weltzien, 1979; Heerklotz, 2008). This process is de-
picted in figure 1.4. At low concentrations detergent monomers in aqueous solutions
form monolayers between the water and the air barrier or float freely in the solution.
When the concentrations of detergents reach the critical micellar concentration (CMC),
aggregates termed micelles start to form. In aqueous solution which contains plasma
membranes, detergents are able to interact with the membranes. In a first step, de-
tergent molecules associate with membranes until saturation of the membrane. In
this step the membrane experiences curvature stress. If the concentration of deter-
gents is high enough, mixed micelles containing detergents and plasma membrane
components are formed by disintegration of the plasma membrane. At a certain level
of detergents only this mixed micelles exist (Helenius and Simons, 1975; Heerklotz,
2008). The whole process depends on the membrane composition, which influences
the affinity of the detergent for the host membrane and on the shape and length of
5
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Table 1.1: Critical micellar concentration (CMC) of selected compounds. Abbreviations: acyl car-




Triton X-100 0.37 mM 22 °C Busto et al., 2007
LPC(12:0) 0.64-0.7 mM 25 °C Stafford et al., 1989;
Henriksen et al., 2010
0.47 mM 37 °C Matsuzaki et al., 1988
LPE(12:0) 0.33 mM 25 °C Stafford et al., 1989
dodecylphos-
phocholine
1.1 mM 25 °C Stafford et al., 1989
LPC(14:0) 0.045-0.07 mM 25 °C Stafford et al., 1989;
Henriksen et al., 2010
0.048 mM 37 °C Matsuzaki et al., 1988
LPC(16:0) 0.004-0.007 mM 25 °C Stafford et al., 1989;
Henriksen et al., 2010
0.0029 mM 37 °C Matsuzaki et al., 1988
AC(16:0) 0.015 mM 22 °C Requero et al., 1993
C(16:0) CoA 0.035 mM 22 °C Requero et al., 1993
LPC(18:0) 0.00025 mM 37 °C Matsuzaki et al., 1988
PC(O-18:0/O-1:0) 0.035 mM 22 °C Busto et al., 2007
LPC(18:1) 0.002 mM 37 °C Matsuzaki et al., 1988
the detergent determining the extent of disturbance within the membrane (Henriksen
et al., 2010; Heerklotz and Seelig, 2000; Heerklotz, 2008).
The CMCs of different LPCs and other compounds are compared in table 1.1.
The table also shows the CMC of Triton-X 100 (Helenius and Simons, 1975),
a commonly used nonionic detergent and the synthetic PC(O-18:0/O-1:0) also
known as edelfosine (Munder et al., 1979). Acyl carnitines (AC) are intracellular
fatty acid (FA) carriers and are structurally related to LPCs (Goni et al., 1996).
The CMC is often used as predictor for the strength of a detergent but should
be used with caution and only as rough estimation (Heerklotz, 2008; Henriksen
et al., 2010). The hemolytic potency of LPCs on erythrocyte membranes at 37 °C
decreases as follows LPC(18:0)>LPC(16:0)>LPC(14:0)>LPC(18:1)>LPC(12:0),
while the CMCs at 37 °C increase in the following order:
LPC(18:0)<LPC(18:1)<LPC(16:0)<LPC(14:0)<LPC(12:0) (Matsuzaki et al., 1988).
The cytolytic properties of the different LPC species should be considered when the
physiological functions of LPCs are studied (Weltzien, 1979).
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Once integrated into membranes, LPCs can also perform a transbilayer movement
called flip-flop. The flip-flop from the outer to the inner leaflet of plasma membranes
has a half-time of 11 h for LPC(16:0) and 4 h for LPC(18:1) in human erythrocytes and
is strongly dependent on the lipid composition of the plasma membrane and the acyl
chain characteristics of the moving lysolipid (Bergmann et al., 1984).
1.3 LPC biosynthesis in humans
1.3.1 Kennedy pathway and other biosynthetic routes of PC
The biosynthesis and further metabolism of LPCs are shown in figure 1.5 on the follow-
ing page. The de novo synthesis of LPCs is called Kennedy pathway (Kennedy and
Weiss, 1956). This pathway starts with glycero 3-phosphate (G3P), a product of gly-
colysis, gluconeogenesis, or lipolysis. G3P can also originate from the diet in form of
glycerol which is phosphorylated to G3P by glycerol kinase (GK). G3P is acylated at
the position sn-1 by glycerol-3-phosphate acyltransferase (GPAT) to lysophosphati-
date (LPA). LPA is further acylated by 1-acylglycerol-3-phosphate acyltransferases
(AGPAT) to phosphatidate (PA) (Yamashita et al., 2014).
PA is at the crossroad of two pathways. PA can either be metabolized to cytidine
diphosphate diacylglycerols (CDP-DG) or diacylglycerol (DG) (Horvath and Daum,
2013). From CDP-DG, phosphatidylinositol (PI), phosphatidylglycerol (PG), and car-
diolipins (CL) can be formed.
DG is acylated to triacylglycerides (TG) or is directly converted to PC by either
choline phosphotransferase (CHPT) or CDP-choline/ethanolamine phosphotrans-
ferase (CEPT). Both enzymes require CDP-choline as co-substrate (Horvath and
Daum, 2013).
Choline is phosphorylated by choline kinase (CHK) and converted to CDP-choline
via CTP:phosphocholine cytidylyltransferase (PCYT) (Cornell and Ridgway, 2015).
This reaction is supposed to be the rate limiting step in PC synthesis in the endoplas-


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PC can undergo a headgroup exchange for the interconversion of PC, PS and
PE (Kent, 1995). In mammals, PC together with serine can be metabolized by PS
synthase I (PTDSS1) to choline and PS at the mitochondria-associated membranes
(MAM), which are special loci where ER and mitochondria closely interact. PS can
be decarboxylated by PS decarboxylase (PISD) to phosphatidylethanolamine (PE) in
the mitochondrial outer membrane. PE can be re-converted to PS by PS synthase
II (PTDSS2) at the MAM (reviewed in (Vance and Tasseva, 2013)). PE can also be
methylated by phosphatidylethanolamine N-methyltransferases (PEMT) requiring S-
adenosyl methionine as co-substrate to form PC. This triple methylation takes place
only in liver (Vance et al., 1997) and accounts for 30 % of the total hepatic PC synthe-
sis (DeLong et al., 1999; Vance, 2014; Reo et al., 2002). The rest of the PC production
is provided by the de novo synthesis from DG and choline via the Kennedy pathway
(Kent, 1995).
The ether forms of PC are formed in a completely different pathway starting from
dihydroxyacetone phosphate, a product of triose-phosphate isomerase using G3P as
substrate (not shown) (Watschinger and Werner, 2013b).
The acyl chains of PC are subjected to a constant remodeling in order to fulfill its
physiological functions as major plasma membranes and lipoprotein component (Yao
and Vance, 1988; van Meer et al., 2008), signaling lipid transporter (Thomas et al.,
1984; Zhou and Nilsson, 2001), and lung surfactant (Holm et al., 1996). The remod-
eling and maturation pathway or Lands cycle (Lands, 1958), is a sequence of dea-
cylation of PC by phospholipases A (PLA) forming LPC and one FA, followed by the
reacylation to PC by LPC acyltransferases (LPCAT) using acyl coenzyme A (CoA) as
substrate. The FA formed by PLAs are ATP-dependently activated to acyl CoA for
re-entering the metabolic pathways of lipids (Yamashita et al., 2014). It is estimated
that both, the de novo synthesis and the Lands cycle, contribute almost equally to the




The family of phospholipases (PL) is divided into the subclasses PLA1, PLA2, PLB,
PLC, and PLD. Each family has its own cleavage pattern which is depicted in fig-
ure 1.6.
Figure 1.6: Cleavage sites of phospholipases. This figure depicts the cleavage site of PLA1, PLA2,
PLB, PLC, and PLD on PC.
PLA1 cleave the sn-1 position of phospholipid forming sn-2 radyl lysolipids. This
subclass of phospholipases is small with only a few members (Richmond and Smith,
2011). Endothelial lipase (aka lipaseG, LIPG), hepatic lipase (aka lipase C, LIPC), and
lecithin cholesterol acyltransferase (LCAT) possess also PLA1 activity and contribute
to the LPC production in the circulation (Duong et al., 2003; Riederer et al., 2012;
Subbaiah et al., 1992; Shamburek et al., 1996).
LIPG is expressed in liver, kidney, lung, placenta, ovary, thyroid gland, testis,
and macrophages (Bartels et al., 2007; Jaye et al., 1999; Hirata et al., 1999), hy-
drolyzes preferentially PE and PC from high-density lipoproteins (HDL) (Jaye et al.,
1999; Duong et al., 2003; Gauster et al., 2005; Riederer et al., 2012) and has only
low lipase activity toward TGs (McCoy et al., 2002; Jaye et al., 1999; Hirata et al.,
1999). Additionally, LIPG also has PLA2 and lysophospholipase activity (Gauster
et al., 2005). Lysophospholipase describes the ability to hydrolyze the remaining acyl
chain of lysolipids. In case of LPC the product is a FA and α-glycero-3-phosphocholine
(αGPC).
LIPC hydrolyzes TG and to a minor extend PC (Duong et al., 2003). LIPC is ex-
pressed in liver where it is located at the hepatic sinusoids and binds to HDL, very-low-
density lipoproteins (VLDL), and low-density lipoproteins (LDL) (Santamarina-Fojo
10
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et al., 2004). The catalytic activity is regulated by the composition of the lipoproteins.
Sphingomyelin inhibits its general activity and influences its substrate specificity, a
common feature of many PC hydrolyzing enzymes in the circulation including LIPG
and LCAT (Yang and Subbaiah, 2015; Yang et al., 2014; Subbaiah and Liu, 1993).
LCAT does not belong to the family of PLA1 (Richmond and Smith, 2011) but shows
PLA1 activity (Subbaiah and Liu, 1996) and contributes to the LPC pool of the circula-
tion (Subbaiah et al., 1994; Shamburek et al., 1996). LCAT is secreted from the liver
and is associated with the lipoproteins HDL, where it catalyzes the transfer of one acyl
chain from PC to cholesterol, forming cholesterol acyl esters and LPCs (Ossoli et al.,
2016). Concerning the head-group, LCAT favors PC and PE (Pownall et al., 1985;
Grove and Pownall, 1991; Christiaens et al., 2000; Shamburek et al., 1996). LCAT
can also use PAF and oxidized PC as substrates (Liu and Subbaiah, 1994; Goyal
et al., 1997).
LCAT produces predominantly saturated LPCs, while LIPC and LIPG form unsatu-
rated LPCs (Yang and Subbaiah, 2015; Glomset, 1968; Shamburek et al., 1996).
1.3.3 Phospholipase A2
PLA2 are specialized to hydrolyze the sn-2 position of phospholipids releasing a
lysolipid and one free FA. The superfamily of PLA2 has numerous members. The clas-
sification of PLA2 is shown in table 1.2 on the following page (Dennis, 1994; Schaloske
and Dennis, 2006). The PLA2 are divided in groups that are consecutively numbered:
G1 - G16. The numbering has been established 1994 for snake venom PLA2 and has
been expanded ever since (Dennis, 1994). Some groups are summarized in types
according to special requirements of the catalytic activity, their localization in the cell
or other features. Their subgroups are assigned to an alphabetic character (Dennis
et al., 2011; Schaloske and Dennis, 2006). For a more functional classification of the
groups, PLA2 are divided into the following types: secreted PLA2s (sPLA2), cytoso-
lic (cPLA2), calcium-independent (iPLA2), platelet-activating factor acetylhydrolases
(PAFAH), lysosomal PLA2 (LPLA2), and adipocyte-specific PLA2 (AdPLA2) (Dennis
et al., 2011; Schaloske and Dennis, 2006).
11
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Table 1.2: Official types of the human PLA2s. Official types of the human PLA2 class and other
enzymes with PLA2 activity (Dennis et al., 2011; Ghosh et al., 2006; Murakami et al., 2015; Ra-
manadham et al., 2015; Fisher, 2011; Fisher et al., 2016; Rozenberg et al., 2003; Gauster et al.,
2005; Pownall et al., 1985; Subbaiah and Liu, 1996; Maury et al., 2002). The six types of PLA2 (se-
creted PLA2 (sPLA2), cytosolic PLA2 (cPLA2), calcium-independent PLA2 (iPLA2), platelet activating
factor acetylhydrolase (PAFAH), lysosomal PLA2 (LPLA2), and adipocyte specific PLA2 (AdPLA2))
are listed with their groups (symbols: PLA2G1 - PLA2G16) and subgroups (A-F). Also other enzymes
with PLA2 activity are given. Enzymes marked with * also have PLA1 activity. Official symbols are
italicized. Abbreviations: LCAT (lecithin-cholesterol acyltransferase), LIPG (lipase G aka endothe-
lial lipase), Lp-PLA2 (lipoprotein-associated PLA2), PLA (phospholipase A), PLB (phospholipase B),
PNPLA (patatin like phospholipase domain containing), PON1 (serum paraoxonase/arylesterase 1),
PRDX6 (peroxiredoxin 6).
sPLA2 cPLA2 iPLA2
PLA2G1B PLA2G4A 1/2 aka cPLA2α* PLA2G6A aka PNPLA9, iPLA2β*
PLA2G2A PLA2G4B aka cPLA2β* PLA2G6B aka PNPLA8, iPLA2Ɣ*
PLA2G2C PLA2G4C aka cPLA2Ɣ* PLA2G6C aka PNPLA6, iPLA2δ*
PLA2G2D PLA2G4D aka cPLA2δ* PLA2G6D aka PNPLA3, iPLA2ɛ
PLA2G2E PLA2G4E aka cPLA2ɛ* PLA2G6E aka PNPLA2, iPLA2ζ
PLA2G2F PLA2G4F aka cPLA2ζ* PLA2G6F aka PNPLA4, iPLA2η
PLA2G3
PLA2G5 PAFAH LPLA2
PLA2G10 PLA2G7 aka Lp-PLA2 PLA2G15 aka LPLA2*
PLA2G12A PLA2G7B aka PAFAH2








The type of sPLA2 consists of eleven groups that are reviewed elsewhere (Murakami
et al., 2015). They all have a catalytic dyad of histidin and aspartate which require
Ca2+ for their catalytic activity (Murakami et al., 2015). This group of phospholipases
have low selectivity towards the sn-1 or the sn-2 position and low selectivity for the
saturation degree of the acyl chains but show a general preference for PG and PC
(Singer et al., 2002). sPLA2s potentially also contribute to the plasma pool of LPCs
(Gesquiere et al., 2002; Singh and Subbaiah, 2007). PLA2G1B (aka pancreatic PLA2)
is the best studied sPLA2. It is secreted by the acinar cells of the pancreas into the
intestinal lumen and takes part in the digestion and absorption of phospholipids and
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TG, and also affects the plasma LPC levels after a meal (Huggins et al., 2002; Labonte
et al., 2006).
The type of cPLA2 only has one group known as group G4 which consists of six
subgroups (PLA2G4A - F). All of them have a catalytic dyad of serine and aspartate
that requires a conserved arginine residue in the active center. In addition to their
PLA2 activity, they all exhibit PLA1 and lysophospholipase activity (Ghomashchi et al.,
2010). Subgroup C and E are expressed in skeletal muscle (Pickard et al., 1999;
Underwood et al., 1998; Ohto et al., 2005). Except for subgroup C, all cPLA2 has
a C2 domain that binds Ca2+ ions and therefore respond to intracellular Ca2+ rises
which leads tomembrane translocation of the phospholipases and enables the binding
to their substrates (Dennis et al., 2011; Xu et al., 1998; Perisic et al., 1998; Dessen
et al., 1999).
iPLA2 consists of six subgroups PLA2G6A - F (Ramanadham et al., 2015). This
type of PLA2 also have the catalytic dyad of serine and aspartate but lacks the Ca2+-
dependence. The subgroup PLA2G6A (aka patatin-like phospholipase domain con-
taining 9 (PNPLA9), iPLA2β) was the first member discovered in this group and also
has PLA1 (Tang et al., 1997), lysophospholipase (Lio and Dennis, 1998), transacy-
lase (Lio and Dennis, 1998), and acyl-CoA thioesterase activity (Jenkins et al., 2006;
Carper et al., 2008). The transacylase activity describes the transfer of an acyl residue
from PC or LPC onto another LPC (Lio and Dennis, 1998). The thioesterase activity
- the hydrolysis of acyl CoA into FA and HS-CoA - supports FA oxidation in skele-
tal muscle by providing free HS-CoA (Carper et al., 2008). The enzyme has several
splice variants from which two (PLA2G6A1 and PLAG6A2) are known to be active
and at least one is expressed in skeletal muscle (Ma et al., 1999; Larsson et al., 1998;
Carper et al., 2008). The predominant location of this iPLA2 is the cytosol but it was
also found in nucleus, ER, golgi, and mitochondria (Ramanadham et al., 2015). In
latter compartment, the phospholipase is involved in CL remodeling (Malhotra et al.,
2009; Hsu et al., 2013; Ye et al., 2016).
PLA2G6B (aka PNPLA8, iPLA2Ɣ) is expressed in many tissues including skeletal
muscle (Tanaka et al., 2000; Mancuso et al., 2000). The phospholipase is localized
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in the mitochondria, peroxisomes (Kinsey et al., 2007; Mancuso et al., 2007), and ER
(Kinsey et al., 2005). The lipase also shows PLA1, lysophospholipase, and transacy-
lase activity (Yan et al., 2005; Dennis et al., 2011). PLA2G6B is also involved in CL
remodeling (Mancuso et al., 2007; Ye et al., 2016). Knockout of PLAG6B in mice
causes protection against diet induced insulin resistance and obesity (Song et al.,
2010). This is supposed to be a consequence of an altered CL content which com-
promises the mitochondrial FA oxidation (Mancuso et al., 2010; Song et al., 2010;
Yoda et al., 2010).
1.3.4 Etherlipid degradation
The alkyl-acyl (plasmanylcholine) and alkenyl-acyl (plasmenylcholine) forms of PC
are degraded in two steps. The acyl chain is hydrolyzed by PAF acetylhydrolases
(PAFAH). PAFAH is a family of intracellular and extracellular PLA2 of the group
PLA2G7 and PLA2G8, catalyzing the hydrolysis of the sn-2 position of PAF and other
plasmalogens creating lysoPAF or lysoplasmanalogens in general (McIntyre et al.,
2009). There is also an enzyme that specifically cleaves acetyl residues at the sn-2 po-
sition of PAFs called 1-O-alkyl-2-acetylglycerophosphocholine esterase (Blank et al.,
1981; Watschinger and Werner, 2013b).
The ether linked alkyl and alkenyl chains are more stable. Lysoplasmenylcholines
are cleaved into fatty aldehyde and G3P by lysoplasmalogenases (aka transmem-
brane protein 86B, TMEM86B). TMEM86B is expressed in liver, brain, and intes-
tine (Wu et al., 2011; Jurkowitz et al., 1999). Lysoplasmanylcholines with satu-
rated alkyl chains are individually degraded by a tetrahydrobiopterin-dependent mono-
oxygenase named alkylglycerol monooxygenase (AGMO) forming fatty aldehyde and
G3P (Watschinger and Werner, 2013a). AGMO is expressed in rat brain, liver, lung,
intestine, and other tissue types except heart (Snyder et al., 1973; Tietz et al., 1964;
Werner et al., 2007; Watschinger et al., 2010, 2012).
In 1979 a new pharmacological LPC analogue was generated that is resistant to
many degradation pathways by substituting the sn-1 acyl chain by an alkyl chain and
placing an O-methyl group at position sn-2 (Munder et al., 1979). These alkyl phos-
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pholipid (ALP) are not cleavable by PLAs, TMEM86B, and AGMO (Munder et al.,
1979; Kotting et al., 1987; Watschinger and Werner, 2013b). The first ALP was
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine or PC(O-18:0/O-1:0) (aka
edelfosine, ET-18-OCH3). Later, it was shown that ALPs cause apoptosis in can-
cer cells (Mollinedo et al., 1997). Their mechanism of action is still unclear but it is
mainly membrane-related (Kuerschner et al., 2012; Gajate et al., 2012; Jaffres et al.,
2016; Castro et al., 2013; Carrasco et al., 2010).
1.4 LPC converting processes
1.4.1 LPCAT
The half-life of LPC in the circulation is about 6 - 11 min in rats (Stein and Stein, 1966)
with comparable results in squirrel monkeys (Portman et al., 1970). LPCs are taken
up by different organs but predominately by liver (Stein and Stein, 1966; Shamburek
et al., 1996; Portman et al., 1970). The fast elimination of LPCs from the circulation by
uptake into organs is one mechanism to protect the body against the detergent effects
of LPCs (Stein and Stein, 1966). One fate of LPC in organs is the re-acylation to PC
by LPCATs as part of the Lands cycle.
Until today, five enzymes with the ability of acylating LPCs are known: LPCAT1-
4 (Shindou and Shimizu, 2009; Shindou et al., 2009) and peroxiredoxin 6 (PRDX6)
(Fisher et al., 2016). LPCATs have different expression patterns and localizations in
the cell (Shindou and Shimizu, 2009). LPCAT1+2 are targeted to mitochondria and
lipid droplets, while LPCAT3+4 are found in the ER (Moessinger et al., 2011; Shindou
and Shimizu, 2009). Specific data of each LPCAT are displayed in table 1.3 on the
next page. LPCAT1 (gene name: LPCAT1) (Harayama et al., 2008) and LPCAT2
(Shindou et al., 2007) are able to transfer acetyl groups onto lysoPAF and common
acyl LPCs which creates PAF and acyl-PAF (PC with one acyl and an acetyl group),
respectively. The cytosolic enzyme PRDX6 also have PLA activity together with its
LPCAT activity (Fisher, 2011; Fisher et al., 2016).
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Table 1.3: Enzymes with LPC acyltransferase activity. Enzymes with LPC acyltransferase (LPCAT)
activity and their tissue distributions and substrate specificity are listed in this table. Abbreviations:
AGPAT (acylglycerophosphate acyltransferases), AYTL (acyltransferase-like), LysoPAFAT (lysoPAF
acyltransferase), MBOAT (membrane bound O-acyl transferase), PRDX6 (peroxiredoxin 6). Official
symbols are italicized.
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1.4.2 Phospholipase B, C, and D
Enzymes with phospholipases B (PLB) activity which often can act as lysophospho-
lipase, are able to remove acyl chains of LPCs and other phospholipids (Richmond
and Smith, 2011). Phospholipase C (PLC) and phospholipase D (PLD) are responsi-
ble for the removal of the head-groups. A list of enzymes that have at least one of the
mentioned activities on LPCs are given in table 1.4 on the following page.
By definition, the family of PLBs are able to cleave either sn-1 or sn-2 localized acyl
chains (Richmond and Smith, 2011). Three PLB members have been discovered so
far: PLB1 - 3. Only PLB1 is described in humans (Maury et al., 2002).
As mentioned earlier, several PLA2s show robust lysophospholipase activity espe-
cially the subgroup of PLA2G4 (Ghomashchi et al., 2010), as well as some iPLA2 mem-
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Table 1.4: List of enzymes that can convert LPCs. This is a list of enzymes that can convert LPCs into
αGPC (PLB/lysophospholipase activity), MG + phosphocholine (PLC activity), LPA + choline (PLD
activity), or cPA + choline (special PLD activity, marked with *). Abbreviations: ASPG (asparaginase,
aka 60 kDa Lysophospholipase (LPP60)), cPA (cyclic phosphatidate), ENPP (ectonucleotide py-
rophosphatase/phosphodiesterase family member), Gα (heterotrimeric G-protein Gα subunit), GDE
(glycerophosphodiester phosphodiesterase), αGPC (α-glycero-3-phosphocholine), LPA (lysophos-
phatidate), lysoPLA (lysophospholipase), MG (monoacyl glycerol), NRE (neuropathy target esterase
related esterase), PLB (phospholipase B), PLC (phospholipase C), PLD (phospholipase D), PNPLA
(Patatin-like phospholipase domain containing).
activity enzyme reference
PLB/lysoPLA PLB1 Maury et al., 2002
PLA2G4 (aka cPLA2) Ghomashchi et al., 2010
PNPLA9 (aka iPLA2β, PLA2G6A) Lio and Dennis, 1998
PNPLA8 (aka iPLA2Ɣ, PLA2G6B) Yan et al., 2005
PNPLA6 (aka iPLA2δ, PLA2G6C) van Tienhoven et al., 2002
ASPG (aka LPP60) Menniti et al., 2010
PNPLA7 (aka NRE) Kienesberger et al., 2008
LIPG Gauster et al., 2005
PLC ENPP6 Sakagami et al., 2005
ENPP7 (aka alkaline sphingomyelinase) Duan et al., 2003
PLD ENPP2 (aka autotaxin)* Tokumura et al., 2002
PLD1 Selvy et al., 2011
PLD2* Tsukahara et al., 2010
Gαq and Gβ1 Aoyama et al., 2011
GDE4 Ohshima et al., 2015
GDE7 Ohshima et al., 2015
bers like PLA2G6A - C (Yan et al., 2005; Lio and Dennis, 1998; Tang et al., 1997; van
Tienhoven et al., 2002; Dennis et al., 2011) . Beyond the class of PLA2s, also 60 kDa
lysophospholipase (LPP60 aka asparaginase, official symbol: ASPG) (Menniti et al.,
2010), neuropathy target esterase-related esterase (NRE, official symbol: PNPLA7)
(Kienesberger et al., 2008), and LIPG (Gauster et al., 2005) exhibit lysophospholipase
activity.
The final product of the lysophospholipase activity on LPC - αGPC - is an osmolyte
(Nakanishi et al., 1990) which is degraded by ectonucleotide pyrophosphatase/phos-
phodiesterase (ENPP) 6 (Morita et al., 2016) to glycerol and phosphocholine and by
glycerophosphocholine phosphodiesterases (GDE) 2 and 5 (Corda et al., 2014) to
choline and G3P. Phosphocholine is hydrolyzed in the circulation by still unknown en-
zymes to choline which can be taken up by the liver and other tissues and can be
re-used to form PC (Morita et al., 2016; Gallazzini et al., 2008).
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ENPP6 and ENPP7 have PLC activity and cleave LPCs intomonoacyl glycerol (MG)
and phosphocholine (Sakagami et al., 2005; Duan et al., 2003).
ENPP2 (aka autotaxin) has PLD activity and is able to cleave LPC into lysophos-
phatidate (LPA) and choline, and PC into DG and choline (Umezu-Goto et al., 2002;
Tokumura et al., 2002). ENPP2 prefers saturated LPCs and PCs that are lipoprotein
associated (Tokumura et al., 1999, 2002). Both, PLD1 (Hammond et al., 1995) and
PLD2 (Colley et al., 1997) produce PA in the expense of PC and are able to cleave
LPCs (Colley et al., 1997; Hammond et al., 1995; Tsukahara et al., 2010; Selvy et al.,
2011). Other enzymes with PLD activity are GDE4, GDE7, and the two heterotrimeric
G-protein subunits Gαq and Gβ1 (Ohshima et al., 2015; Aoyama et al., 2011).
Cyclic phosphatidate (cPA) (Tsukahara et al., 2010) is a product of ENPP2 (Tsuda
et al., 2006) and PLD2 (Tsukahara et al., 2010) with LPCs as substrates. cPA is bound
by serum albumin (ALB) in the circulation (Kobayashi et al., 1999). cPA(16:0) has a
serum concentration of ≈9 nM and cPA(18:1) ≈16 nM (Shan et al., 2008).
1.4.3 LPCs in the blood
LPCs can be found in many body fluids including breast milk (Shoji et al., 2006), tear
fluid (Brown et al., 2016), cerebro-spinal fluid (Illingworth and Glover, 1971), seminal
fluid (Glander et al., 2002), urine (Bouatra et al., 2013), and blood. The plasma/serum
concentration of LPCs in healthy humans range from approximately 100 to 300 μM
(Barber et al., 2012; Croset et al., 2000; Heimerl et al., 2014; Sutter et al., 2016; Ojala
et al., 2007; Kishimoto et al., 2002; Rabini et al., 1994) comprising 8 - 20 % of total
phospholipid content in plasma (Switzer and Eder, 1965; Nelson, 1967). It was shown
that males have higher LPC levels than females (Weir et al., 2013; Gillett and Bester-
man, 1975). The plasma/serum LPC compositions of healthy subjects obtained from
various studies are displayed in table 1.5 on the next page. This table highlights the
relative abundance of different LPC species in serum/plasma. LPC(16:0) is the most









































































































































































































































































































































































































































































































































































































































































































































































































































In the circulation LPCs are mainly bound by serum proteins like ALB (Switzer and
Eder, 1965; Ojala et al., 2006) and α1-acid glycoprotein (aka Orosomucoid, ORM)
(Ojala et al., 2006). LPCs are the most abundant phospholipid species bound by
ORM and ALB (Ojala et al., 2006). The binding of LPCs by serum proteins effectively
prevents the rather high plasma concentration of LPCs to be cytolytic and also elimi-
nates some of the physiological effects of LPCs (Klibansky and De Vries, 1963; Ojala
et al., 2006; Mochizuki et al., 1982; Soga et al., 2005; Klingler, 2012).
ALB is the most abundant serum protein with a physiological range of 37 - 56 g/L
(Lockitch et al., 1988; Hostmark et al., 2005; Reijnierse et al., 2015) (equals 560 -
848 μM) and accounts for around 50 - 60 % (Simard et al., 2006) of the total plasma
proteins (Simard et al., 2006). ALB is expressed and secreted by the liver (Peters
and Anfinsen, 1950). Human ALB has seven binding sites for FA of which three are
high affinity sites and four low affinity sites which are presumably reserved for other
ligands (Peters, 2008; Simard et al., 2006). The molar ratio of LPC bound by human
ALB is around 3:1 (Ojala et al., 2006). The affinity of different lipids for ALB is as
follows: FA>LPA>LPS>LPC>LPE>lysoPAF with lower affinity for unsaturated lipids
(Ojala et al., 2006).
ORM is a acute phase protein, secreted by the liver with a plasma concentration of
0.5 g/L (equals 12 μM) with up to 4 g/L during inflammation (Ojala et al., 2006). While
ALB mainly carries LPC(16:0), ORM complexes unsaturated LPCs like LPC(18:1),
LPC(18:2), and LPC(20:4) (Ojala et al., 2006). ORM binds LPCs in a molar ratio of 1:1
and has higher affinity for LPCs than for FA (Ojala et al., 2006). The affinity increases
as follows: LPC>LPS>LPE>FA>lysoPAF>LPA (Ojala et al., 2006). Additionally the
more unsaturated and the longer the acyl chain the higher the affinity for ORM (Ojala
et al., 2006).
In cells, LPCs can bind to lipid binding proteins termed fatty acid binding proteins
(FABP). This protein family consists of ten members in humans (Smathers and Pe-
tersen, 2011): FABP1-9 and FABP12. FABP3 (aka heart/muscle-FABP (H-FABP)),
FABP4 (aka adipocyte FABP), and FABP5 (aka epidermal FABP (E-FABP)) are known
to be expressed in skeletal muscle (Smathers and Petersen, 2011). FABPs are able
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to bind lipids and lipid-like compounds to facilitate their transport within the cell to dif-
ferent organelles for instance nucleus or ER (Lawrence et al., 2000; Tan et al., 2002;
Smathers and Petersen, 2011). FABP1 (aka liver-FABP (L-FABP)) has been shown
to transport LPCs (Burrier and Brecher, 1986). FABPs are also able to transfer FA or
other ligands to their nuclear receptors like PPARs by direct interaction of both PPARs
and FABPs (Tan et al., 2002; Wolfrum et al., 2001).
1.4.4 LPCs in lipoproteins
About 80 % of total LPCs in the plasma are found in the serum protein fraction, while
the rest of it is mainly located in the lipoprotein fraction including HDL and LDL (Ojala
et al., 2006; Croset et al., 2000; Dashti et al., 2011). The lipoproteins mostly en-
riched with LPCs are intermediate-density lipoproteins (IDL) and oxidized low-density
lipoproteins (oxLDL) (Chen et al., 1997; Kugiyama et al., 1990; Dashti et al., 2011).
In fact, during conversion of native LDL into oxLDL, the LPC content increases from
about 1 - 5 % of total phospholipid mass to up to 40 - 50 % (Chen et al., 1997; Stein-
brecher and Pritchard, 1989; Parthasarathy et al., 1985). The oxidation can occurs in
PCs containing unsaturated acyl chains by the influence of reactive oxygen species
(Panasenko et al., 1994; van den Berg et al., 1993). Oxidized PC can decay to LPCs
spontaneously or via enzymes like LCAT or paraoxonase 1 (PON1) (Arnhold et al.,
2001, 2002; Rosenblat et al., 2006; Rozenberg et al., 2003; Goyal et al., 1997). Sat-
urated LPCs with a length of ≥C(16:0) are dominating in oxLDLs (Chen et al., 1997;
Sasabe et al., 2014).
1.4.5 Dietary uptake of LPCs
Dietary PC is taken up during the passage through the jejunum in large part as LPCs
(Ikeda et al., 1987), the cleavage product of PC by PLA2G1B (pancreatic PLA2). LPCs
formed by PLA2G1B are also supporting the absorption of cholesterol and TG from
the gut (Richmond et al., 2001; Huggins et al., 2002).
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LPCs absorbed into the mucosa are then processed into PC or hydrolyzed into
products like αGPC (Ikeda et al., 1987; Parthasarathy et al., 1974). Only 15 % are not
reacylated and travel as LPCs (Ikeda et al., 1987). The acylated PCs then find their
way to the liver mainly via the portal vein (Ikeda et al., 1987).
1.5 Regulation of plasma LPC concentration
The LPC levels in the circulation are fueled by many sources. The aforementioned
phospholipases LIPC (Shamburek et al., 1996), LIPG (Gauster et al., 2005; Riederer
et al., 2012), LCAT (Shamburek et al., 1996; Schmid et al., 2003; Morimoto et al.,
2010), and sPLA2 (Boyanovsky and Webb, 2009) play a pivotal role. Substantial
amounts of LPCs are also provided by the diet as PC or LPCs (Huggins et al., 2002;
Labonte et al., 2006). During an oral lipid tolerance test the amount of saturated LPCs
like LPC(16:0) and LPC(18:0) rise and decrease 300 min afterwards (Morris et al.,
2015). Unsaturated LPCs like LPC(18:1), LPC(18:2), LPC(20:4) decrease first and
rise again after 300 min (Morris et al., 2015). During an oral glucose tolerance test,
LPC(16:0), LPC(16:1), LPC(18:1), LPC(18:2) rise all together significantly from time
point 0 to 120 min, while LPC(18:0) peaked already after 90 min (Zhao et al., 2009).
After a complex meal, LPCs decline until 45 min with a rise to baseline at 60 min and a
subsequent second decline (Shrestha et al., 2015). Special diets can increase levels
of certain LPCs. For instance, fish oil diet leads to increased levels of LPC(20:5) and
LPC(22:6) (Abdolahi et al., 2014).
The liver is supposed to perform a substantial secretion of LPCs (Sekas et al., 1985;
Krautbauer et al., 2016; Brindley, 1993). Notably, it has been shown that exercise
can increase LPC levels in liver and muscle of mice (Hoene et al., 2016) while no
changes are observed in exercising humans (Hansen et al., 2015). The secreted LPCs
are mainly unsaturated (about 62 %) LPC(20:4)>LPC(18:2) or LPC(18:0) (in female
rats) (Sekas et al., 1985; Baisted et al., 1988; Brindley, 1993). The LPC release is
enhanced by the presence of acceptors like ALB and is not related to secreted lipases
or lipoproteins. It is increased by a combination of dexamethasone and insulin, is
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inhibited by cyclic adenosinemonophosphate (cAMP) and glucagon, and is dependent
on intracellular Ca2+ levels (Baisted et al., 1988; Brindley, 1993).
During atherosclerosis, oxLDL are formed, which are also a source of LPCs (Rosen-
blat et al., 2006; Rozenberg et al., 2003; Goyal et al., 1997; Arnhold et al., 2001, 2002).
LPC levels are actively reduced by enzymes with PLB/lysophospholipase, PLC and
PLD activity fromwhich ENPP2 is of relevance in the circulation (Pamuklar et al., 2009;
Reeves et al., 2015), together with the clearing of LPCs by acylation via LPCATs in
different organs but predominantly in liver (Stein and Stein, 1966; Shamburek et al.,
1996; Portman et al., 1970).
A reduction of serum LPCs can be found during prolonged fasting of 36 h with sig-
nificant decreases in LPC(18:0), LPC(18:1), and LPC(18:2) levels in humans (Rubio-
Aliaga et al., 2011).
1.6 LPCs as biomarkers
In recent years metabolomics approaches gained importance as tool in the search
of reliable clinical biomarkers and individual pathophysiological blood parameters in
order to avoid invasive methods for the early detection of diseases (Guo et al., 2015).
By higher sensitivity and reproducibility of mass spectrometry, LPCs reached the focus
as powerful biomarkers (Xiao et al., 2000). The outcome of many diseases rely on
an early diagnosis or prediction, amongst them also diabetes mellitus type II (T2DM)
(Tabak et al., 2012). In general, studies investigating the association of systemic LPC
levels with markers of glucose tolerance or insulin sensitivity point to an decrease in
LPCs at each stage of the development of T2DM (table 1.6 on page 25) (Rhee et al.,
2011; Ferrannini et al., 2013; Wang-Sattler et al., 2012; Gall et al., 2010; Zhao et al.,
2010a; Pietilainen et al., 2007; Drogan et al., 2015; Barber et al., 2012; Floegel et al.,
2013; Tonks et al., 2016; Wallace et al., 2014). These studies also include follow-
up studies where the patients were characterized up to 12 years before the onset of
T2DM (Rhee et al., 2011; Fernandez et al., 2013). This association is found for several
LPC species, rendering them a risk marker for T2DM (Roberts et al., 2014).
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Table 1.7 on page 26 shows the correlation of LPCs with different parameters like
BMI, adipose tissues mass, and inflammatory markers like C-reactive protein (CRP).
T2DM is associated with obesity (Boden and Shulman, 2002), cardiovascular dis-
eases (CVD) (Pietilainen et al., 2007), and other morbidities, which are all summarized
in the term metabolic syndrome (Laaksonen et al., 2002). The metabolic syndrome
is often accompanied by a low-grade inflammatory response (Donath and Shoelson,
2011; Spranger et al., 2003; Hotamisligil, 2006). The table shows a negative asso-
ciation of LPCs with body mass index (BMI), CVD risk and the inflammatory marker
CRP. This summary of data confirms the robustness of LPCs as biomarker not only
for T2DM but also for other aspects of the metabolic syndrome.
Lower LPC levels are also observed in non-alcoholic fatty liver disease (NAFLD),
a strong risk factor of T2DM (Oresic et al., 2013; Roden, 2006). LPC(16:0) can dis-
criminate between insulin-resistant and insulin-sensitive NAFLD with higher levels of
LPC(16:0) in insulin-sensitive NAFLD patients (Lehmann et al., 2013). In addition to
that, saturated LPCs species are reduced in decompensated liver cirrhosis (Kraut-
bauer et al., 2016).
LPCs are also important diagnostic parameters for other diseases. LPC(26:0)
was found to be a robust biomarker for peroxisomal disorders like X-linked
adrenoleukodystrophy and is analyzed in dried blood spot extracts from newborns
(Haynes and De Jesus, 2016; Theda et al., 2014). LPCs are also biomarkers for
various cancer types. LPC(20:4) and LPC(16:1) are blood parameters that can help
to distinguish between different breast cancer subtypes with different prognoses and
therapeutic responses (Fan et al., 2016). In addition to that, reduced LPC(18:0) lev-
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.7 Physiological functions of LPCs
1.7.1 LPC receptors
It has been proposed for years that LPCs bind to cell surface receptors thereby ini-
tiating intracellular signaling cascades. In 2001, two LPC receptors have been dis-
covered: G-protein coupled receptor 132 (GPR132 aka G2 accumulation (G2A))
(Kabarowski et al., 2001) and G-protein coupled receptor 4 (GPR4) (Zhu et al., 2001).
But the original publications demonstrating that LPCs bind to the two receptors have
been retracted. The attempt to reproduce the experiments by other working groups
failed for both GPR132 (Witte et al., 2005) and GPR4 (Bektas et al., 2003; Peter
et al., 2008). Nevertheless, some actions of LPCs are demonstrated to be GPR132-
dependent (Peter et al., 2008; Qin et al., 2014; Wang et al., 2005; Yang et al., 2005).
The effects are not due to direct ligand binding but rather by influencing receptor lo-
calization and trafficking (Wang et al., 2005).
GPR132 is a G-protein coupled receptor (GPCR) and coupled to various small G-
proteins likes Gq, G13 (Yang et al., 2005), Gi (Kabarowski et al., 2001), and Gs (Lin and
Ye, 2003). GPCRs like GRP132 transduce their signal across the plasma membrane
via these heterotrimeric small G-protein subunits (Syrovatkina et al., 2016). Gs is able
to stimulate the intracellular adenylate cyclase (ADCY) to convert adenosine triphos-
phate (ATP) to cAMP, an important second messenger (Syrovatkina et al., 2016). Gi
inhibits ADCY, Gq activate PLCs, and G13 stimulates members of the Rho family of G-
proteins (Syrovatkina et al., 2016). GPR132 expression is restricted to immune cells
like T-, B-lymphocytes, monocytes, and macrophages (Weng et al., 1998).
Four years later, G-protein coupled receptor 119 (GPR119) was discovered as an-
other LPC receptor (Soga et al., 2005). LPCs are only weak and unspecific ligand for
GRP119 (Lan et al., 2009; Overton et al., 2006; Hansen et al., 2011). The potency
to activate GRP119 decreases as follows: LPC(18:1)<LPC(16:0)<LPC(18:0) (Soga
et al., 2005). GRP119 is mainly expressed in pancreas but also in the gastrointesti-
nal tract (Odori et al., 2013), skeletal muscle (Cornall et al., 2013), liver (Yang et al.,
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2016), and testis (Soga et al., 2005). GPR119 is coupled to the Gα subunit type Gs
(Overton et al., 2006; Chepurny et al., 2013; Moss et al., 2016).
To date, GPR132 and GPR119 are the only two known LPC-responsive receptors.
1.7.2 Effects of LPCs on insulin-glucose axis
As reviewed in section 1.6 on page 23, plasma LPC levels correlate negatively with
insulin resistance and T2DM. In addition to that, LPCs are known to influence in-
sulin secretion. In perfused rat pancreas LPC(18:1) enhances insulin secretion dose-
dependently in the presence of 16.5 mM glucose (Soga et al., 2005). This finding was
confirmed with NIT-1 cells (5 μM LPC(18:1)) (Soga et al., 2005), INS-1 cells (86 μM
LPC(18:2)) (Ferrannini et al., 2013), and MIN6c4 cells (10 μM LPC(18:1)) (Ning et al.,
2008). The effects are GRP119-dependent and are mediated by increasing intra-
cellular cAMP and Ca2+ levels, two essential signaling events for insulin secretion
(Soga et al., 2005; Ning et al., 2008). However, in RINm5f cells which do not express
GRP119, LPC(18:1) also slightly increase the insulin secretion, pointing to a still un-
known GPR119-independent mechanism (Ning et al., 2008).
Intravenous (Yea et al., 2009) or intraperitoneal (Takahashi et al., 2014) injection
of LPC(16:0) leads to the reduction of blood glucose levels in mice (Takahashi et al.,
2014; Yea et al., 2009). An enhanced glucose uptake caused by LPC(16:0) has been
described in the 3T3-L1 adipocyte cell line (Takahashi et al., 2014; Yea et al., 2009).
These findings are in contrast to findings showing that postprandial LPCs and in-
traperitoneal injection of LPCs can inhibit glucose uptake of various tissues (Labonte
et al., 2006). In rat skeletal muscle cell line L6 it was demonstrated that LPCs inhibit
insulin-dependent glucose uptake (Han et al., 2011).
It was also shown that LPCs can cause insulin resistance. A LPC concentration
of 25 μM for 5 min causes the inhibition of insulin-dependent phosphorylation of AKT
serine/threonine kinase (AKT aka protein kinase B, v-akt murine thymoma viral onco-
gene homolog) at Ser473 in rat vascular smooth muscle cells (Motley et al., 2002)
and already 10 μM for 3 h in L6 cells (Han et al., 2011). In L6 cells it was demon-
strated that LPC are responsible for palmitate-mediated insulin resistance (Han et al.,
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2011). Inhibition of PLA2 activity resulting in lower LPC production which ameliorates
the reduction in insulin-dependent glucose uptake caused by palmitate treatment (Han
et al., 2011).
To summarize, the effects of LPCs on insulin-glucose axis are mechanistically not
well understood and controversial data are reported.
1.7.3 LPC in inflammation and atherosclerosis
It is known that LPCs play a pivotal role in inflammatory and atherogenic pathways.
It has been reported that LPC(16:0) have pro-inflammatory effects when injected in-
tracutanously leading to edema, erythema, and mixed cellular infiltrates containing
T-lymphocytes, neutrophils as well as monocytes in humans (Ryborg et al., 2000). It
is known that LPCs are chemoattractants for T-lymphocytes (Ryborg et al., 1994; Mc-
Murray et al., 1993) and monocytes (Rong et al., 2002; Quinn et al., 1988). LPC also
promote the transition of differentiated monocytes to dendritic cells (Coutant et al.,
2002).
LPCs are part of the so called find-me signal to attract phagocytes to apoptotic
cells (Lauber et al., 2003) via GPR132 (Peter et al., 2008). Intravenous injection of
LPC(16:0) or LPC(18:0) causes an increase in the cytokines interleukin (IL)6 and IL5
in serum (Bach et al., 2010). LPCs also help to maintain the pro-inflammatory M1
phenotype of macrophages and promote the release of pro-inflammatory cytokines
like IL6 and tumor necrosis factor α (TNFα, official symbol: TNF) (Ngwenya and Ya-
mamoto, 1986; Qin et al., 2014). In fact, as natural adjuvants they have the potential
to be used in vaccines to boost the immune response (Perrin-Cocon et al., 2006; Bach
et al., 2010).
Atherosclerosis and other metabolic diseases are often associated with an inflam-
matory reaction (Hotamisligil, 2006). It was reported that LPCs produced in oxLDL are
able to modulate the immune response (Steinberg, 1997; Coutant et al., 2004, 2002)
and influence endothelial cells (EC) as sites of atherosclerotic lessions (Di Pietro et al.,
2016). LPC stimulate the expression of adhesion molecules for monocytes on EC,
a pro-atherogenic phenotype of these cells (Kume et al., 1992). Furthermore, LPC
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induce mitochondrial ROS production in EC via Ca2+ entry into cytosol and mitochon-
dria (Li et al., 2016). This also contributes to the pro-atherogenic phenotype of EC (Li
et al., 2016). Especially LPC(16:0) stimulate coronary artery smooth muscle cells to
secrete IL6, IL8, growth factors, and arachidonic acid leading to the transition of the
smooth muscle cells to a proliferative/secretory phenotype which can contributes to
atherosclerosis (Aiyar et al., 2007).
Despite of being pro-atherogenic and pro-inflammatory, LPCs also display anti-
inflammatory effects. LPC(22:6) inhibits the production of lipopolysaccharide-induced
TNFα in RAW 264.7 cells (mouse monocyte cell line) (Hung et al., 2011) and in MM6
cells (human monocyte cell line) (Jackson et al., 2008). It was shown that the protec-
tive effects in MM6 cells are in part GPR132-dependent (Jackson et al., 2008). Serum
LPC levels of septic patients are reduced (Cho et al., 2012; Park et al., 2014; Drob-
nik et al., 2003; Ferrario et al., 2016). When administrated orally to mice, LPC(22:6)
and LPC(20:4) can inhibit Zymosan-A induced peritonitis (Hung et al., 2009, 2011) as
well as peritoneal sepsis and pneumonia caused by Acinetobacter baumannii (Smani
et al., 2015). It was also reported that LPCs can enhance the immuno-repressive func-
tion of regulatory T lymphocytes GPR132-dependently (Hasegawa et al., 2011). LPC
administration during sepsis can prevent and treat the disease in mice (Yan et al.,
2004). Most effective LPCs are LPC(18:0) and LPC(18:1) (Yan et al., 2004). The
protective effect of LPCs on sepsis is GPR132- (Yan et al., 2004) and adenosine
monophosphate-activated protein kinase (AMPK)-dependent (Kim et al., 2015).
In summary, the effects of LPCs on inflammation are controversial, but LPCs surely
can act as modulators of an immune response.
1.7.4 LPC and brain function
When labeled LPCs are injected intravenously into squirrel monkeys, 1 % of labeled
LPCs are found in the brain within 20 min after injection (Illingworth and Portman,
1972). In the brain, about 70 % of LPCs are converted to PC while the rest is hy-
drolyzed to serve as choline source in the form of acetylcholine, betaine, and phospho-
choline (Illingworth and Portman, 1972). Choline is a conditional essential compound
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during pregnancy and lactation, and during development of fetuses and neonates
(Blusztajn, 1998). LPCs are one source and transporter of choline as it was shown
for hepatocytes (Brindley, 1993).
LPCs can be transported across the blood-brain barrier (Illingworth and Portman,
1972). Recently, major facilitator superfamily domain containing 2A (MFSD2A) has
been identified as a LPC carrier expressed in the blood brain barrier (Nguyen et al.,
2014; Quek et al., 2016), liver (induced by fasting), intestine, kidney, brown adipose
tissue (Angers et al., 2008), and in the retinal pigment epithelium in embryonic eyes
(Wong et al., 2016). MFSD2A is a sodium-dependent symporter for LPCs with a chain
length of >C14 with highest affinity for unsaturated LPCs (Nguyen et al., 2014). This
transporter does not transport FAs (Nguyen et al., 2014). The importance of LPCs
in the brain are shown by MFSD2A defects causing severe microcephaly syndrome
due to insufficient omega-3 fatty acid delivery into the brain and an increase in total
plasma LPC levels which is especially pronounced in unsaturated LPCs (Alakbarzade
et al., 2015; Guemez-Gamboa et al., 2015). LPCs are important carriers for essential
FAs that are also targeted to brain where they support development and cognitive
functions (Alakbarzade et al., 2015; Oresic et al., 2012).
1.7.5 Effects of LPC on liver
In the liver, LPC influence the hepatic metabolism by inhibiting hepatic cholesterol
biosynthesis (Shin et al., 1999) and activating peroxisome proliferator activator recep-
tor (PPAR) α (official symbol: PPARA) (Takahashi et al., 2014). The latter feature of
LPCs also have effects on LPC levels itself. It was shown in mice that bezafibrate, a
pan-PPAR agonist (Willson et al., 2000; Krey et al., 1997), lowers blood glucose and
increases LPC(16:0) in plasma and liver (Takahashi et al., 2014). In vitro, bezafibrate
and fenofibrate (PPARα agonist) both increase LPC(16:0) in the cell culture media
of primary hepatocytes (Takahashi et al., 2014). Bezafibrate treatment of the cells
causes an elevation of PLA2G7, a PPARα target gene which influences the hepatic
secretion of LPC(16:0) (Takahashi et al., 2014).
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Although, PPAR agonists are beneficial and increase LPC levels at the same time,
the intravenous injection of 60 mg/kg LPC in mice causes an increase in aspartate
transaminase and alanine transaminase - two liver damage markers - after 24 h and
hepatitis after 3 d (Han et al., 2008). It was also reported that LPCs inhibit insulin-
dependent glycogen synthesis and FA oxidation in liver (Labonte et al., 2006, 2010).
In addition to that, it is demonstrated that LPCs are the major cause of lipotoxicity
mediated by palmitate treatment in liver Chang cells (Han et al., 2008).
1.7.6 Primary skeletal myotubes as model cell system
Due to the described glucose lowering effects of LPCs, skeletal muscle is considered
as interesting target for LPCs. Skeletal muscle is a major organ in the human body
with about 20 - 25 kg on average in men (Morgan and Partridge, 2003) and determines
the major resting energy expenditure (Zurlo et al., 1990). It is also the most important
tissue for insulin-dependent glucose uptake and therefore contributes to peripheral
insulin sensitivity (DeFronzo et al., 1985; Baron et al., 1988).
Skeletal muscle consists of bundles of multinucleated post-mitotic myofibers. The
myofibers are the product of proliferation and fusion of mononucleated and fusiform
satellite cells which can undergo proliferation as myoblasts (Hawke and Garry, 2001;
Shi and Garry, 2006). Satellite cells reside between the sarcolemma and the basal
membrane (Muir et al., 1965) in a quiescent state where they wait for being activated
for proliferation and fusion (Pallafacchina et al., 2010). Their stem-cell like behavior
(Gross and Morgan, 1999) is required for muscle repair (Schultz et al., 1986; Watt
et al., 1987) and hypertrophy (Rosenblatt et al., 1994) of the muscle.
Mononucleated satellite cells can be isolated by enzymatic digestion of biopsymate-
rial (Yasin et al., 1977). After isolation, the cells can be cultured during which they be-
come proliferativemyoblasts. At a certain confluency the serum content of themedium
is reduced in order to stimulate differentiation of myoblasts to myotubes (Henry et al.,
1995; Blau and Webster, 1981).
Fully differentiated human myotubes (HMT) display a cellular model system that is
very close to the in vivo situation (Meola, 1991). Human skeletal muscle expresses
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three myosin heavy chain (MYH) types in different expression levels according to the
muscle function and muscle phenotype (Smerdu et al., 1994; Caiozzo et al., 2003;
Harridge et al., 1996): MyHC-β (MYH7), MyHC-2A (MYH2), and MyHX-2X (MYH1).
Cultured HMT express all three markers after differentiation (Nikolic et al., 2012;
Bonavaud et al., 2001; Gaster et al., 2001; Aas et al., 2013). HMT carry donor specific
properties, e.g. individual PPARδ (official symbol: PPARD) responsiveness (Ordel-
heide et al., 2011), adaptability of FA oxidation on higher substrate supply (Ukropcova
et al., 2005), and stearoyl CoA desaturase 1 expression levels (Peter et al., 2009),
and are therefore a valuable model system.
1.7.7 Effects of LPC on skeletal muscle and own previous work
(diploma thesis)
Notmuch is known about the function of LPCs in skeletal muscle. In mousemyoblasts,
the LPC content decreases during differentiation and LPCs influence the fusion and
differentiation of myotubes (Blondelle et al., 2015). LPC can inhibit the formation of
myotubes, a process that strongly depends on plasma membrane interactions and
their physical fusion (Reporter and Raveed, 1973; Leikina et al., 2013). The inhibi-
tion of membrane fusion processes by LPCs has been reproduced in artificial mem-
brane systems (Yeagle et al., 1994), other biological membranes (Chernomordik et al.,
1993), and during viral fusion processes (Ciechonska andDuncan, 2014). This agrees
with findings showing that LPC can inhibit the disassembly of protein complexes that
are important for vesicle fusion, which could prolong the fusion process (Shin et al.,
2012).
During my diploma thesis, I have started investigating biological effects of LPCs on
HMT. The concentration at which cytolytic effects occur were examined for LPC(16:0)
and LPC(18:1) on HMT. The release of intracellular creatine kinase (CK) and lactate
dehydrogenase (LDH) are suitable markers for cytoplasm leakage of different tissues
including skeletal muscle and is routinely measured in clinical diagnostics. Here, the
cell culture supernatants were analyzed for the amount of CK and LDH after LPC
treatment for 24 h. According to the results (figure 1.7 on the next page), cytolytic
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Figure 1.7: Effects of LPCs on CK and LDH release. HMT were stimulated with different concen-
trations of LPC(16:0) (black marks) or LPC(18:1) (gray marks) for 24 h. The release of (A) creatine
kinase (CK) and (B) lactate dehydrogenase (LDH) were quantified in the cell culture supernatant.
Data were fitted to an exponential model (LPC(16:0) black solid line, LPC(18:1) gray dashed line)
according to equation y=Y0·ek·x. Data are shown as mean ±SEM. * p < 0.05 vs solvent as control
(n=6). Reprinted from (Klingler et al., 2016), with permission from Elsevier.
effects increased exponentially with the applied LPC concentration. Thereby, the two
LPCs tested in this assay behaved differently. LPC(16:0) at 50 μM or higher led to a
significant release of LDH/CK, while for LPC(18:1) higher concentrations of 100 μM
were needed for detectable cytolysis. Both assays, CK and LDH release, displayed
similar results.
The non-cytolytic concentration range (< 50 μM) of the two LPCs was further ex-
amined. It is known that some lipids especially saturated fatty acids are capable of
activating various stress pathways including inflammation and ER stress (Brookheart
et al., 2009). To analyze potentially activated stress signaling cascades, the mRNA
levels of three different transcripts were quantified: activating transcription factor 3
(ATF3, official symbol: ATF3), IL6 and chemokine (C-X-C motif) ligand 3 (aka growth-
regulated protein Ɣ, official symbol: CXCL3). The increase of ATF3 mRNA can be a
result of ER stress (Schroder and Kaufman, 2005), while IL6 andCXCL3 are activated
markers after nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB, of-
ficial symbol: NFKB) stimulation (Weigert et al., 2004; Anisowicz et al., 1991). LPC
concentrations of 1 to 25 μM were applied to differentiated HMT for 24 h. The RNA
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levels of the three transcripts showed no significant response to the LPCs at the given
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Figure 1.8: Stress marker responses to different concentrations of LPCs. HMT were stimulated
with different concentrations of (A) LPC(16:0) or (B) LPC(18:1). Total RNA was extracted. mRNA
levels of ATF3 (black), IL6 (dark gray), and CXCL3 (light gray) were quantified by qPCR. Data are
mean ±SEM related to solvent. Solvent control was set as 1 (dashed line) (n=8). Reprinted from
(Klingler et al., 2016), with permission from Elsevier.
For further experiments a suitable working concentration was necessary. This con-
centration should fulfill the requirement of being non-toxic for the given cellular model
system HMT and should be in the physiological range of the plasma LPC concentra-
tions. Based on the present results, a working concentration of 10 μM was used in
further experiments in my diploma thesis and in this work.
It was demonstrated in that pyruvate dehydrogenase kinase 4 (PDK4) and
angiopoietin-like 4 (ANGPTL4) were induced by LPC treatment (Klingler, 2012). This
effect is potentially PPARδmediated as studied in C2C12 cells (mouse skeletal muscle
cell line). siRNA targeted against Ppard could block the induction of Angptl4 mRNA
by LPC(16:0) in C2C12 myotubes (data not shown).
The kinetics of the induction of PDK4 (figure 1.9A,C on the following page) and
ANGPTL4 (figure 1.9B,D) evoked by LPC treatment were analyzed. In a time frame
of 30 min to 8 h, both LPCs induced a similar response. PDK4 increased after 8 h.
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Figure 1.9: Kinetics analysis of the PDK4 and ANGPTL4 response to LPC treatment. HMT were
treated with (A+B) LPC(16:0) or (C+D) LPC(18:1) for the indicated time points. Total RNA was
isolated. mRNA of PDK4 and ANGPTL4 were quantified by qPCR. Data are shown as mean ±SEM
related to solvent treatment (set as 1). * < 0.05 vs. solvent (n=4). Reprinted from (Klingler et al.,
2016), with permission from Elsevier.
1.8 Aims of the thesis
LPCs are important in many physiological processes including fatty acid transport,
immunological reactions, and metabolism. LPCs may also be involved in pathophys-
iological conditions like T2DM. The plasma level and acyl composition of LPCs is dy-
namic and mirrors diseases and benign conditions. Hence, LPCs are widely studied
biomarkers. The question if LPCs are actively influencing body metabolism has been
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investigated insufficiently and findings are inconsistent. To this end, the metabolic
effects of LPCs should be studied in more detail.
Aim of this PhD thesis is to explore the physiological functions of LPCs on HMT.
Skeletal muscle is a major representative tissue for energy expenditure, insulin sen-
sitivity, and whole body metabolism. HMT differentiated from myoblasts isolated from
biopsy material are a convenient model system that sufficiently resembles the in vivo
tissue. LPC(16:0) and LPC(18:1), which are highly abundant in the circulation and
differ in their length and saturation, were chosen as representative LPC species.
The specific aims of this PhD thesis are:
1) Examination of the global effects of LPCs on RNA levels
2) Are the nuclear receptors PPARs activated by LPC treatment?
3) What are the mechanism of the PPARδ activation by LPCs?
4) Are LPCs mediators or protectors of lipotoxicity in HMT?
The methods applied are microarray analysis, quantitative PCR, electromobility shift
assay, thin layer chromatography, luciferase reporter assays, glucose uptake assay,
palmitate oxidation analysis, Western blotting, XBP1 splicing assay, TR-FRET-based
assays, and siRNA-based gene knockdown.
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2.1 Materials
2.1.1 Chemicals and consumables
Table 2.4: List of chemicals.
chemicals manufacturer
acetic acid (glacial) 100 % Merck Millipore, Darmstadt
(Germany)
ammonium persulfate (APS) Sigma-Aldrich, Munich (Germany)
ampicillin Sigma-Aldrich, Munich (Germany)
Bam HI Roche, Mannheim (Germany)
Bio-Rad protein assay dye reagent
concentrate
Bio-Rad, Hercules (US-CA)
collagenase B from Clostridium
histolyticum
Roche, Mannheim (Germany)
boric acid Sigma-Aldrich, Munich (Germany)
bovine serum albumin, lyophilized powder
(BSA)
Sigma-Aldrich, Munich (Germany)
bovine serum albumin, 20 mg/mL Roche, Mannheim (Germany)
bromphenol blue sodium salt Sigma-Aldrich, Munich (Germany)
calcium chloride dihydrate AppliChem, Darmstadt (Germany)
2’,7’-dichlorofluorescein spray solution Carl Roth, Karlsruhe (Germany)
dithiothreitol (DTT) Sigma-Aldrich, Munich (Germany)
DNA polymerase I, large (Klenow)
fragment
New England BioLabs, Ipswich,
(US-MA)
dNTPs set Eurogentec, Cologne (Germany)
EDTA disodium salt dihydrate Sigma-Aldrich, Munich (Germany)
EDTA solution pH 8 0.5 M Sigma-Aldrich, Munich (Germany)
EGTA Carl Roth, Karlsruhe (Germany)
Glo lysis buffer 1X Promega, Madison (US-WI)
glycerol Carl Roth, Karlsruhe (Germany)
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Carl Roth, Karlsruhe (Germany)
HindIII Roche, Mannheim (Germany)
hydrochloric acid Merck Millipore, Darmstadt
(Germany)




HRP substrate luminol reagent
Merck Millipore, Darmstadt
(Germany)
4-iodophenol Sigma-Aldrich, Munich (Germany)
LB agar Sigma-Aldrich, Munich (Germany)
LB broth Sigma-Aldrich, Munich (Germany)
luminol Sigma-Aldrich, Munich (Germany)
magnesium chloride Sigma-Aldrich, Munich (Germany)
magnesium sulfate solution 1 M AppliChem, Darmstadt (Germany)
β-mercaptoethanol Sigma-Aldrich, Munich (Germany)
nitrogen, liquified 4.8 EN ISO 14175-N1-N
99.998 % purity
Westfalen AG, Münster (Germany)
Nonidet® P40 (NP-40) Affymetrix, Santa Clara (US-CA)




potassium chloride Merck Millipore, Darmstadt
(Germany)
potassium hydroxide solution AppliChem, Darmstadt (Germany)
Precision Plus protein dual color standards Bio-Rad, Hercules (US-CA)
PSTI Roche, Mannheim (Germany)
Quick-Loadr 1 kbp DNA ladder New England BioLabs, Ipswich,
(US-MA)
Quick-Loadr 100 bp DNA ladder New England BioLabs, Ipswich,
(US-MA)
Rothiphorese Gel 30 (37.5:1) Carl Roth, Karlsruhe (Germany)
Rothiphorese Gel 40 (29:1) Carl Roth, Karlsruhe (Germany)
scandicaine Astra Zeneca, Wedel (Germany)
sodium chloride VWR, Darmstadt (Germany)
sodium fluoride Sigma-Aldrich, Munich (Germany)
sodium hydroxide AppliChem, Darmstadt (Germany)
sodium lauryl sulphate/sodium dodecyl
sulfate (SDS)
Carl Roth, Karlsruhe (Germany)




spermidine Sigma-Aldrich, Munich (Germany)
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SuRE/Cut buffer B Roche, Mannheim (Germany)
SuRE/Cut buffer H Roche, Mannheim (Germany)
Taq DNA polymerase with standard Taq
buffer
New England BioLabs, Ipswich,
(US-MA)
tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe (Germany)
TRIS EDTA buffered solution Sigma-Aldrich, Munich (Germany)
Triton X-100 Sigma-Aldrich, Munich (Germany)
Trizma base Sigma-Aldrich, Munich (Germany)
xylene cyanol FF Sigma-Aldrich, Munich (Germany)
Table 2.7: List of consumables and other equipment.
consumables and other equipment manufacturer
Amersham Protran 0.45 μm nitrocellulose
blotting membrane
GE Healthcare Life science, Little
Chalfont (UK)
Assistent® Neubauer counting chamber,
0.100 mm depth, 0.0025 mm2
Glaswarenfabrik Karl Hecht GmbH &
Co KG, Sondheim v. d. Rhön
(Germany)
BAS-IP MS 2025 imaging plate Fujifilm, Düsseldorf (Germany)
Biosphere Filter tips 20 neutral Sarstedt, Nümbrecht (Germany)
Cellstar tubes, 50 mL, PP, graduated,
conical bottom with support skirt, sterile
Greiner bio-one, Frickenhausen
(Germany)
Cell Strainer, 40 μm, blue BD Bioscience, Heidelberg
(Germany)
Combitips advanced 5 mL Eppendorf, Hamburg (Germany)
CoolCell® cell freezing container BioCision, San Rafael (US-CA)
costar 5 mL Stripette disposable serologial
pipette
Corning, Wiesbaden (Germany)
costar 10 mL Stripette disposable
serologial pipette
Corning, Wiesbaden (Germany)
costar 25 mL Stripette disposable
serologial pipette
Corning, Wiesbaden (Germany)
costar 50 mL Stripette disposable
serologial pipette
Corning, Wiesbaden (Germany)
Cryotubes 1.8 mL SI INT, foot, round Thermo Fisher Scientific, Waltham
(US-MA)
disposable cell scrapers, blade length 3.1
cm
Sarstedt, Nümbrecht (Germany)
ep Dualfilter T.I.P.S. 2-100 PCR clean Eppendorf, Hamburg (Germany)
ep Dualfilter T.I.P.S. 2-200 PCR clean Eppendorf, Hamburg (Germany)
Eppendorf 0.1-2.5 research plus pipette Eppendorf, Hamburg (Germany)
Eppendorf 2-20 research plus pipette Eppendorf, Hamburg (Germany)
Eppendorf 20 research pipette Eppendorf, Hamburg (Germany)
Eppendorf 100 research pipette Eppendorf, Hamburg (Germany)
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Eppendorf 1000 research pipette Eppendorf, Hamburg (Germany)
Falcon 50 mL Polypropylene Conical Tube Corning, Wiesbaden (germany)
fine needle punch biopsy technique Peter Pflugbeil GmbH, Zorneding
(Germany)
LightCycler 480 Multiwell plate 96, white Roche, Basel (Swiss)
LightCycler 480 sealing foil Roche, Basel (Swiss)
Microplate PS, 96 well, F-bottom (Chimney
well), white, Lumitrax, med. binding
Greiner bio-one, Kremsmünster
(Austria)








Multiply-Pro cup 0.5 mL, PP Sarstedt, Nümbrecht (Germany)
neoLab-caps 8 mm, with septum silicone
white/PTEE red
neoLab, Leonberg (Germany)
neoLab-Wheaton Sample Vials ND8, 1,5
mL brown glass 32x11,6 mm
neoLab, Leonberg (Germany)
NuncTM CryoTubes® cryogenic vial, 1.8 mL Thermo Fisher Scientific, Waltham
(US-MA)
Oasis HLB extraction cartridge 1 cc/30 mg Waters, Eschborn (Germany)
Parafilm Pechineay Plastic Packaging,
Menasha (US-WI)
PerfectBlueTM Twin-Gel ExW S
electrophoresis system
VWR, Darmstadt (Germany)
Safe-Lock tubes 0.5 mL Eppendorf, Hamburg (Germany)
Safe-Lock tubes 1.5 mL Eppendorf, Hamburg (Germany)
Safe-Lock tubes 2 mL Eppendorf, Hamburg (Germany)
Safe-Lock tubes 5 mL Eppendorf, Hamburg (Germany)




Tissue culture dishes 100 Ø100x20 mm TPP, Trasadingen (Swiss)
Tissue culture dishes 150 147.8 cm2 TPP, Trasadingen (Swiss)
Tissue culture testplate 6 TPP, Trasadingen (Swiss)
Tissue culture testplate 12 TPP, Trasadingen (Swiss)








Whatman gel blotting papers, grade
GB005, 1.5 mm thick
Whatman, Maidstone (UK)
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Table 2.1: List of lipids/stimulants/recombinant proteins used for this work.
lipids/stimulants/recombinant proteins manufacturer
BAPTA-AM Sigma-Aldrich, Munich (Germany)
bovine serum albumin, solution 10 % in
DPBS (BSA) (FA-free)
Sigma-Aldrich, Munich (Germany)
cytochalasin B Sigma-Aldrich, Munich (Germany)
1,2-dioleyl-sn-glycero-3-phosphocholine
(PC(18:1/18:1))




Avanti Polar Lipids, Alabaster
(US-AL)
(+)-etomoxir sodium salt Sigma-Aldrich, Munich (Germany)
forskolin AppliChem, Darmstadt (Germany)
L-α-glycero-3-phosphocholine Sigma-Aldrich, Munich (Germany)
GSK0660 TOCRIS, Bristol (UK)
GSK3787 TOCRIS, Bristol (UK)
GW501516 Santa Cruz, Dallas (US-TX)
H-89, dihydrochloride Cell Signaling Technology, Leiden
(The Netherlands)
insulin solution human Sigma-Aldrich, Munich (Germany)
ionomycin calcium salt from Streptomyces
conglobatus
Sigma-Aldrich, Munich (Germany)
lipopolysaccharides from Escherichia coli
0111:B4
Sigma-Aldrich, Munich (Germany)




palmitic acid Sigma-Aldrich, Munich (Germany)
1-palmitoyl-sn-glycero-2,3-cyclic
phosphate ammonium salt (cPA(16:0))








PPAR delta (human recombinant) Cayman, Ann Arbor (US-MI)
recombinant RXR-α protein Active Motif, La Hulpe (Belgium)
WY14643 Sigma-Aldrich, Munich (Germany)
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Table 2.2: List of radiochemicals used for this work.
radiochemicals manufacturer
[α-32P]dATP Hartmann Analytics, Braunschweig
(Germany)
2-[1,2-3H(N)]-deoxy-D-glucose Perkin Elmer, Waltham (US-MA)
Packard unquenched standards Perkin Elmer, Waltham (US-MA)






Table 2.3: List of cell culture reagents.
cell culture reagents manufacturer
amphothericin B solution Sigma-Aldrich, Munich (Germany)
AlphaMEM Eagle w/o L-glutamine LONZA, Cologne (Germany)
AlphaMEM with deoxyribonucleotides and
ribonucleotides and UltraGlutamine 1
LONZA, Cologne (Germany)
carbondioxide, liquified C1 EN ISO 14175
99.8 % purity
Westfalen AG, Münster (Germany)
chicken embryo extract - lyophilized Seralab, Haywards heath (UK)
Dulbecco’s phosphate buffered saline
(DPBS)
Sigma-Aldrich, Munich (Germany)
FBS Superior, Lot# 1149C Merck Millipore, Darmstadt
(Germany)
GeneCellin BioCellChallenge, Toulon (France)
L-glutamine LONZA, Cologne (Germany)
Ham’s F12 medium with L-glutamine LONZA, Cologne (Germany)
MEM Eagle with Earle’s BSS, without
L-glutamine
LONZA, Cologne (Germany)
OptiMEM Thermo Fisher Scientific, Waltham
(US-MA)
penicillin-streptomycin stock, 10K/10K LONZA, Cologne (Germany)
5X siRNA buffer GE Dharmacon, Lafayette (US-CO)
Trypan Blue 0.4 %, 0.85 % NaCl LONZA, Cologne (Germany)
Trypsin EDTA 200mg/L EDTA, 170.000
U/L Trypsin
LONZA, Cologne (Germany)
Viromer®Blue Lipocalyx, Halle (Saale) (Germany)
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Table 2.5: List of organic solvents.
organic solvents manufacturer
chloroform for analysis Merck Millipore, Darmstadt
(Germany)
dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe (Germany)
ethanol 96% AnalaR NORMAPUR VWR, Darmstadt (Germany)
formic acid Merck Millipore, Darmstadt
(Germany)
isopropanol VWR, Darmstadt (Germany)
methanol VWR, Darmstadt (Germany)
ULTIMA GOLD high flash-point LSC
cocktail
Perkin Elmer, Waltham (US-MA)
Table 2.6: List of commercial kits.
kits manufacturer
Dual-Glo Luciferase Assay System Promega, Madison (US-WI)
GelRed Nucleic Acid Gel Stain Biotium, Hayward (US-CA)
MinElute PCR Purification Kit QIAGEN, Hilden (Germany)
QIAquick Nucleotide Removal Kit QIAGEN, Hilden (Germany)
QIAGEN Plasmid Mini Kit QIAGEN, Hilden (Germany)
QIAGEN Plasmid Maxi Kit QIAGEN, Hilden (Germany)
QuantiFast SYBR Green PCR Kit QIAGEN, Hilden (Germany)
RNeasy Mini Kit QIAGEN, Hilden (Germany)
RNase-Free DNase Set QIAGEN, Hilden (Germany)
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2.1.2 Software and devices
Table 2.8: List of devices.
device manufacturer
Axiovert 40 C inverted microscope Carl Zeiss, Oberkochen (Germany)
Benchtop-Transilluminator ECX-20.C LTF lLbortechnik GmbH & Co. KG,
Wasserburg (Germany)
Biofuge fresco centrifuge Heraeus, Hanau (Germany)
Biofuge pico centrifuge Heraeus, Hanau (Germany)
Biofuge primo R Heraeus, Hanau (Germany)
BioPhotometer Eppendorf, Hamburg (Germany)
block thermostat BT 200 Kleinfeld Labortechnik, Gehrden
(Germany)
Centrifuge 5415 R Eppendorf, Hamburg (Germany)
Centrifuge 5810 Eppendorf, Hamburg (Germany)
ChemiDoc Touch imager Bio-Rad, Hercules (US-CA)




Glomax Multi Detection System Promega, Madison (US-WI)
Heraeus HERA cell incubator Thermo scientific, Waltham (US-MA)
incubator hood TH 30 Edmund Bühler GmbH, Hechingen
(Germany)
IP plate eraser raytest, Straubenhardt (Germany)
LightCycler 480 Roche, Basel (Swiss)
liquid scintillation analyzer Tri-Carb
2900TR
Perkin Elmer, Waltham (US-MA)
Magnetic stirrer RCT basic IKA Labortechnik, Staufen/Breisgau
(Germany)
Mastercycler gradient Eppendorf, Hamburg (Germany)
Microplate Reader Model 680 Bio-Rad, Hercules (US-CA)
PowerShot A710 IS digital camera Cannon, Tokio (Japan)




Selphy CP910 compact photo printer Cannon, Tokio (Japan)
Semidry-blotter, 24-200 GEWO Feinmechanik GmbH,
Wörth/Hörlkofen (Germany)
Thermomixer comfort Eppendorf, Hamburg (Germany)
universal shaker SM 30 Edmund Bühler GmbH, Hechingen
(Germany)
VF2 vortexer Janke & Kunkel, Staufen/Breisgau
(Germany)
Vortex Genie 2 Scientific Industries Inc., Bohemia
(US-NY)
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Vortex VV3 VWR, Darmstadt (Germany)
WALLAC 1420, Victor3 V multilabel
counter
Perkin Elmer, Waltham, (US-MA)
water bath serie MP Julabo, Seelbach (Germany)
1003 water bath, 14 liters GFL Gesellschaft für Labortechnik
mbH, Burgwedel (Germany)




Table 2.9: List of software.
software version
ACD/Labs ChemSketch 12.01
Adobe Photoshop Elements 6.0
Bio-RAD Image Lab Touch Software 5.2 build
14
GraphPad PRISM 6.05
IBIS Biosciences Bioedit 7.0.9
ImageJ (dev. by Rasband W. at the National Institutes of Health) 1.47
JabRef (dev. by JabRef Development Team; Morten OA., Nizar
N. Batada, et al.)
3.1
Microsoft Excel 2010
MiKTeX (dev. by Schenk C.) 2.9
R: A Language and Environment for Statistical Computing (dev.
by R Core Team; Ihaka R., Gentleman R. et al.)
3.2.2
raytest Advanced image Data Analyzer for windows V3.44.035
raytest Control Software for FujiFilm BAS and FLA scanners V3.14
Roche LightCycler 480 Software 1.5
TeXnicCenter (dev. by The TeXnicCenter Team; Wiegand S.,
Weinkauf T. et al.)
2.02
Thomson Reuters Endnote X7.4
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2.2 Methods
2.2.1 Cell culture
Human satellite cells were isolated from biopsy material of non-diabetic patients.
Biopsy material was gained by percutaneous needle-biopsy of the vastus lateralis
portion of the musculus quadriceps femoris (Bergstrom, 1975; Krutzfeldt et al., 2000).
The patients were informed and gave written consent to the biopsy. The protocol was
approved by the ethical committee of the Tübingen University Medical Department.
Before the punctuation with a fine needle punch biopsy technique, a 2 % solution
of the local anesthetic scandicaine was injected into the biopsy area. The biopsy ma-
terial was transferred into ice cold Ham’s F12 medium. The material was macerated
in a sterile filtered and freshly prepared collagenase solution (table 2.10 on the next
page) for 15 min at 37 °C and 1200 rpm agitation. The digested biopsy material was
sedimented by short centrifugation on a table top centrifuge. To stop the collagenase
digestion, 10 volumes of growth medium (GM) (table 2.11 on the following page) was
added. The supernatant was stored at 37 °C and 5%CO2. The pellet was digested re-
peatedly to a total of three digestion cycles. The supernatants were united and filtered
through a 40 μm cell strainer. The filtrate was centrifuged for 8 min at 2,580 g and am-
bient temperature. The pellet was resuspended in GM and dispensed on 147.8 cm2
cell culture dishes. Pre-plating was performed for 3 h to enrich satellite cells (Richler
and Yaffe, 1970). The supernatants containing the satellite cells were cultured to a
confluency of approximately 80 % before trypsinization and cryopreservation in liquid
nitrogen for long-term storage.
For trypsinization, myoblasts were washed with Dulbecco’s phosphate-buffered
saline (DPBS) and incubated with 850 U trypsin-EDTA solution per 15 cm2 cell culture
dish for 5 - 10 min at 37 °C and 5 % CO2. Trypsinization was stopped by 10 mL GM.
The cell suspension was centrifuged for 5 min at 900 g and ambient temperature. The
pellet was resuspended in cryopreservation medium (fetal bovine serum (FBS) with
10 % DMSO), transferred into cryogenic vials, and frozen overnight at -80 °C by using
a cell freezing container and long-term stored in liquid nitrogen.
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Table 2.10: Collagenase solution
final conc. substance
85 % (V/V) Ham’s F12
15 % (V/V) PBS
1.5 % (W/V) BSA
0.5 % (W/V) collagenase B
Table 2.11: HMT growth medium (GM)
final conc. substance
40 % (V/V) alphaMEM
40 % (V/V) Ham’s F12




0.5 μg/mL amphotericin B
1 % (V/V) chicken embryo
extract
After thawing, the cells were seeded in GM in cell culture dishes of different sizes
according to the experiments. Medium was changed to fresh GM every 2 - 3 d until
the cells reach a confluency of 70 - 80 %. Medium was changed to differentiation
medium (DM) (table 2.12) with medium change every 2 - 3 d for a total of 5 - 8 d for
differentiation to multinucleated HMT. HMT were used for experiments after medium
change to stimulationmedium (SM) (table 2.13) if not stated otherwise. In experiments
that examined insulin signaling pathways (figure 3.15 on page 90), the cells were
serum starved by incubation in DM without FBS for 3 h.








0.5 μg/mL amphotericin B








0.5 μg/mL amphotericin B
The rat skeletal muscle cell line L6GLUT4myc (provided by The Hospital of Sick Chil-
dren, Toronto, Ontario (Canada)) is stably transfected with a myc epitope tagged rat
Scl2A4 cDNA (Kishi et al., 1998). Cells were thawed and cultured in L6 GM (table 2.14
on the following page). The medium was changed every 2 - 3 days. Before the cells
reach a confluency of 60 %, the cells were passaged and seeded for glucose uptake
assays in 12-well dishes at 0.8X105cells/well in L6 DM (table 2.15 on the next page).
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For cell counting, the cells were trypsinized as described before. An aliquot of the
cell suspension is diluted 1:10 with Trypan Blue solution. Trypan Blue solution visu-
alizes living cells by the dye exclusion method. Cells with intact cell membrane are
not stained, while dead cells with permeable plasma membrane are stained blue. Liv-
ing cells in 10 μL of this stained suspension were counted in a Neubauer counting
chamber and seeded in the desired cell amount on cell culture dishes. Medium was
renewed every 2 - 3 days. After 7 d, the cells were stimulated and glucose uptake
assays were performed (section 2.2.12 on page 63).
Table 2.14: L6 growthmedium (L6 GM)
final conc. substance




10 % (V/V) FBS
100 U/mL penicillin
100 U/mL streptomycin
Table 2.15: L6 differentiation medium
(L6 DM)
final conc. substance




2 % (V/V) FBS
100 U/mL penicillin
100 U/mL streptomycin
2.2.2 Handling and storage of lipids
LPC(16:0) and LPC(18:1) were purchased from Sigma Aldrich (Munich, Germany).
The purity of LPC(16:0) was given as ≥98.5 % as ascertained by gas chromatogra-
phy (GC), and ≥99 % by thin layer chromatography (TLC). A purity of ≥99 % was
assessed by GC and TLC analysis for LPC(18:1). The compounds were purchased
as lyophilized powder and were aliquoted into brown glass vials, overlaid with nitrogen
gas, and long-term stored at -20 °C. Before experimental usage, LPCs were dissolved
in 100 % ethanol at a stock concentration of 10 mM. LPC(18:1) readily dissolves in
ethanol, while LPC(16:0) requires to be incubated in a 37 °C water bath for 5 min for
solubilization. The stock solutions were used for experiments or short-term stored at
-20 °C.
For the experiment in figure 3.9 on page 81, LPCs and the other compounds were
incubated in SM at a concentration of 10 μM at 37 °C for 3 h in 50 mL tubes under
49
2 Material and Methods
mild agitation of 150 rpm. Stock concentrations and final solvent concentrations in
the medium are depicted in table 2.16. The medium containing the compounds was
directly added on the cells for 24 h.
Table 2.16: Solvents, stock concentrations, and corresponding solvent concentrations of the com-
pounds used in experiment of figure 3.9 on page 81.
compound solvent stock final solvent
conc.
LPC(16:0) ethanol 10 mM 1 ‰ (V/V)
LPC(18:1) ethanol 10 mM 1 ‰ (V/V)
cPA(16:0) DMSO 2 mM 0.5 % (V/V)
PC(O-16:0/O-1:0) ethanol 10 mM 1 ‰ (V/V)
αGPC water 10 mM 1 ‰ (V/V)
PC(16:0/16:0) ethanol 10 mM 1 ‰ (V/V)
PC(18:1/18:1) ethanol 10 mM 1 ‰ (V/V)
palmitate ethanol 10 mM 1 ‰ (V/V)
oleate ethanol 10 mM 1 ‰ (V/V)
In the remaining experiments, the saturated FA palmitate was complexed to BSA in
order to increase the solubility in aqueous media and for increasing the physiological
availability (Pond et al., 1992; Fillerup et al., 1958; Brodersen et al., 1989). Palmitate
was dissolved in 100 % ethanol at a concentration of 200 mM at ambient temperature
by mixing. The stock solution was added to a commercial FA-free and sterile 10 %
BSA (1.5 mM) solution at a concentration of 6 mM palmitate. After adding the ethanol-
palmitate stock solution to BSA, a cloudy precipitates appeared, which dissolved after
an incubation time of 24 h at 37 °C under 150 rpm agitation. Clear and complexed
palmitate-BSA solution was used for experiments. BSA at a concentration of 63.3 μM
was used as vehicle control.
2.2.3 Quantitative PCR
For assessing the mRNA levels of a transcripts of interest, quantitative polymerase
chain reaction (qPCR) was performed. HMT were grown in 6-well plates. After stim-
ulation, total RNA was isolated via QIAGEN RNease Kit. The cells were harvested
by vigorous resuspension in lysis buffer provided of the kit in the cell culture dish and
running through QIAshredder spin columns as method for disruption of the cells and
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homogenization. RNA was isolated according to the manufacturer’s protocol. The
RNA isolation included a step with DNase digestion of the total nucleic acid fraction to
remove genomic DNA contamination. The eluation from the columns was performed
with 30 μL PCR grade water. The eluate was re-applied to the column for higher
yields. After isolation the RNA content was assessed at 280 nm using a spectropho-
tometer. For qPCR, the RNA was reversely transcribed to cDNA with the help of
ROCHE Transcriptor First strand cDNA synthesis kit. The reverse transcription was
performed according to the manufacturer’s manual for multiple reactions cDNA syn-
thesis with random hexamer primers and 1 μg total RNA (table 2.17). The synthesis
reaction was performed in a Eppendorf gradient PCR cycler (table 2.18).
Table 2.17: Reverse transcription reaction mix
final conc. substance
0.5 U/μL Transcriptor reverse transcriptase
1X Transcriptor RT reaction buffer
1 U/μL Protector RNase inhibitor
1 mM each dNTP mix
60 μM random hexamer primers
50 ng/μL total RNA
Table 2.18: cDNA synthesis PCR program for multiple reactions with random hexamer primers.
step target temp. hold cycles
random hexamer prime 25 °C 10 min 1X
cDNA synthesis 55 °C 30 min 1X
inactivation 85 °C 5 min 1X
The qPCR was performed with 2 μL of the reverse transcription product and the
QuantiFast SYBR Green PCR kit according to the manual for Two-Step RT-PCR for
QuantiTect Primer Assays with QIAGEN QuantiTect Primer Assays using a ROCHE
LightCycler 480 (table 2.19 on the next page).
QIAGEN QuantiTect Primer Assays were provided as ready-to-use mix of a primer
pair that are designed to be intron-spanning and therefore are useful to avoid the
amplification of genomic DNA which would result in false positive values. Accuracy
of the amplifications were controlled by melting curve analysis. The primer sets are
listed in table 2.20 on the following page.
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Table 2.19: QuantiFast Two-Step RT-PCR for QuantiTectr Primer Assays.
step target
temp.
hold ramp rate cycles
denaturation 95 °C 3 min 4.4 °C/s 1X
denaturation 95 °C 3 s 4.4 °C/s 40Xannealing/elongation 60 °C 30 min 2.2 °C/s
melting 95 °C 10 s 4.4 °C/s
62 °C 5 s 2.2 °C/s 1X
98 °C 0.11 °C/s
cooling 40 °C 30 s 2.2 °C/s 1X
Table 2.20: Primer list of Qiagen QuantiTectr Primer Assays for SYBRr Green-based quantitative
RT-PCR.
gene assay name detected transcript
ACTB Hs_ACTB_2_SG NM_001101, XM_006715764
ANGPTL4 Hs_ANGPTL4_1_SG NM_016109, NM_139314,
XM_005272484






IL6 Hs_IL6_1_SG NM_000600, XM_005249745
LPCAT1 Hs_LPCAT1_1_SG NM_024830, XM_005248373
LPCAT2 Hs_LPCAT2_1_SG NM_017839, XM_006721211
LPCAT3 Hs_LPCAT3_1_SG NM_005768
PDK4 Hs_PDK4_1_SG NM_002612
PLA2G6A Hs_PLA2G6_1_SG NM_001004426, NM_003560,
XM_005261766
PLA2G6B Hs_PNPLA8_1_SG NM_001256007, NM_015723,
XM_005250396
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The PCR reactions were run with internal standards of known amplificate concen-
tration ranging from 5 ag/μL - 0.5 pg/μL DNA. This enabled an absolute quantification
of the PCR product to determine the absolute mRNA levels of the transcripts.
For relative quantification the absolute values of the samples were related to mRNA
levels of β-actin (gene name: ACTB) as reference transcript. The resulting values
were further related to control conditions.
2.2.4 Microarray analysis
To gain a global and unbiased overview of the effects of LPCs, microarray analysis
was performed. Microarray analysis is a high-throughput method to analyze different
types of nucleic acid sample material on a gene chip on trancriptome level.
Total RNA was isolated from human differentiated myotubes by using QIAshred-
der and RNeasy Mini Kit from Qiagen (Hilden, Germany). Extracted mRNA was fur-
ther processed and analyzed on an Affymetrix Human Genome U219 Genechip Array
by the Microarray Genechip Facility Tübingen Service. This chip provides probes
from more than 36,000 transcripts and variants annotated in the National Center for
Biotechnology Information (NCBI) RefSeq v36 database (13 July 2009), UniGene
database 219 (build date March 30, 2009), and full-length human mRNA’s from Gen-
Bank (downloaded May 12, 2009). The facility provided scaled, normalized, anno-
tated, and quality controlled data sets. The data was analyzed using Microsoft Excel
software. Fold changes were calculated and subjected to Student’s t-test analysis.
Student’s t-test was applied to obtain a rough overview of regulated transcripts by
LPC treatment. Imaging of the fold changes as heatmap was performed by using R
programming language and software environment for statistical computing. Array raw
data were uploaded and published on the NCBI Gene Expression Omnibus server
with the GEO accession number: GSE77337.
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2.2.5 Thin layer chromatography
A method to visualize the lipid profile of a cell is thin layer chromatography (TLC). The
cellular lipids were isolated by a solvent-based extraction method (Folch et al., 1957).
The lipids of the extracts were separated by TLC.
LPC(16:0) labeled with tritium was used as tracer to examine uptake and
metabolism of LPCs. To this end, HMT grown on 15 cm2 cell culture dishes were
stimulated with 56 nCi/mL (0.93 nM) L-α-[palmitoyl-9,10-3H]-LPC together with 10 μM
non-radioactive LPC(16:0) for different time points in 15 mL SM (Stoll et al., 1992). An
aliquot of 1 mL cell culture supernatant was collected for each time point for quantifi-
cation of the remaining radioactivity in the medium. The cells were washed once with
cold PBS containing 4.16 g/L (63.13 μM) BSA (FA-free) (Stoll et al., 1992) and twice
with cold PBS. The cells were scraped off the plate and pelleted with 16,000 g for
1 min at 4 °C. For homogenization and disruption of the cell membrane, a freeze/thaw
cycle was applied and the cells were resuspended vigorously in 20 μL 0.9 % NaCl.
An aliquot of 2 μL was counted for radioactivity to calculate the total LPC uptake in
relation to the remaining radioactivity in the supernatant. 100 μL chloroform/methanol
2:1 (V/V) (Stoll et al., 1992; Folch et al., 1957) was added to the cell suspension and
mixed vigorously for 2 min, followed by shaking for 20 min at ambient temperature
and 1400 rpm. The phases separation was accelerated by centrifugation for 10 min
at 500 g and 4 °C. Both the aqueous and organic phases were collected, combined,
and the remaining debris were extracted once again with 100 μL chloroform/methanol
2:1 (V/V). Again, the two phases were collected and combined. The collected ex-
tracts were applied to a silica TLC plate. Previously, the plate was pre-conditioned
by soaking with 1.2 % boric acid in ethanol/water 1:1 (V/V) sparing the origin line
for a better separation of the lipids (Fine and Sprecher, 1982), followed by drying at
100 °C for 1 h. The plate was run in a chamber containing chloroform/methanol/formic
acid/water 60:30:7:3 (V/V/V/V) (Penzo et al., 2004) for approximately 1.75 h till the
mobile phase front migrated a distance of 16.5 cm. The dried plate was sprayed
partially with 2’,7’-dichlorofluorescein spray solution to visualize non-radioactive lipid
standards (150 nmol LPC(16:0), PC(16:0/16:0), or palmitate) that were also run on the
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TLC plates. 2’,7’-dichlorofluorescein spray solution stained lipophilic compounds as
bright yellow spots that additionally show fluorescence under UV light irradiation. Ac-
cording to the migration of the non-radioactive standards, LPC, PC, and FA fractions
were scraped off the plate into scintillation vials containing 5 mL scintillation cocktail.
Tritium was quantified in a 0 to 18.5 keV window with a count time of 5 min at 18 °C
by the use of a liquid scintillation counter. Background was subtracted and counting
efficiency was assessed by unquenched standards and amounted to 63 %.
2.2.6 RNA interference
A useful tool to reduce mRNA level of a transcript of interest in living cells is siRNA-
based gene silencing. With this method, siRNA targeted to one or more transcripts of
a gene are transfected into the cells. siRNAs are 19 - 22 bp RNA duplexes with a two
nucleotide 3’-overhang (Leung and Whittaker, 2005). The duplexes are processed
in the cytosol by the RNA-induced silencing complex (Leung and Whittaker, 2005)
which degrades the target mRNA and therefore prevents the translation of the protein
(Leung and Whittaker, 2005).
To enable the entry into the cell, siRNA was complexed to the transfection reagent
Viromer®Blue, which is a zero-charged synthetic polymer. The reagent-siRNA com-
plex can enter the cell via endocytosis by mimicking the influenza virus cell penetrating
peptides. In the cell interior, the endocytotic vesicle fuses with the endosome leading
to the acidification of the vesicle. The low pH changes the charge of the reagent-
siRNA complex that enables the secretion of the complex from the endosome into the
cytosol. The pH difference in the cytosol leads to the release of the siRNA which can
be recognized by the RNA-induced silencing complex causing the degradation of the
target mRNA.
For transfection, HMT were grown on 6-well plates. Medium was changed to fresh
DM. HMT were transfected with 20 nM Thermo Scientific human siGENOME SMART-
pool siRNA and Viromer®Blue according to the manual of Lipocalyx Viromer®Blue for
24 h at 37 °C and 5 % CO2. Thermo Scientific human siGENOME SMARTpool siRNA
is a set of four siRNA targeting a single gene of interest for an efficient gene silenc-
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Table 2.21: List of Thermo Scientific human siGENOME SMARTpool siRNA.
target
gene
target transcripts order number






















Table 2.22: List of eurofins mwg operon siRNA.






ing. The siRNA sets used in this work are listed in table 2.21. siRNA targeted against
luciferase is used as a control (siCon) (table 2.22). The medium was changed to
SM afterwards and the cells were subjected to stimulation with different compounds.
Efficacy of the RNA interference was checked by qPCR.
2.2.7 Luciferase reporter assay
In order to detect direct activation of the PPARδ ligand binding domain (LBD), lu-
ciferase assays were performed. Human primary myotubes were co-transfected with
two different plasmids (figure 2.1 on the next page and 2.2 on the following page)
(Fauti et al., 2006; Rieck et al., 2008; Jerome and Muller, 1998) obtained as kind gift
from Prof. Dr. Rolf Müller (University of Marburg (Germany)). Plasmid LexA_PPARd-
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Figure 2.1: Gene map of plasmid
LexA_PPARd-LBD fusion. The
pcDNA3.1zeo vector contains a fu-
sion protein of the LBD of mouse
PPARδ and the bacterial transcrip-
tion factor LexA with a Kozak se-
quence and nuclear translocation
signal. Selection antibiotic re-
sistance marker is ampicillin and
zeocin.
Figure 2.2: Gene map of plasmid
7LTATA-I_Luc. The pGL3 basic lu-
ciferase vector contains 7 repeats
of the LexA binding site behind
a TATA initiator and the firefly lu-
ciferase gene. Selection antibiotic
resistance marker is ampicillin.
LBD fusion contains the LBD fragment of mouse Pparδ which is fused to the bacterial
transcription factor LexA (Butala et al., 2009) together with a Kozak sequence (Kozak,
1987) and the nuclear translocation signal. The Kozak sequence is necessary for the
initiation of the eukaryotic translation process (Kozak, 1987). The nuclear transloca-
tion signal guides the translated fusion protein to the nucleus.
The other plasmid contains the binding sites of LexA in front of a TATA initiator and
a firefly luciferase gene. The constitutive binding of the LexA-PPARδ-LBD to the LexA
binding sites is unproductive unless there is a ligand that activates the PPARδ LBD
which then acts as an activation switch for the recruitment of the transcriptional pro-
tein complex of the cells (Dowell et al., 1997; Godowski et al., 1988). This leads to
the transcription and subsequent expression of the firefly luciferase, which can be
detected by luminescence quantification after offering the natural substrates luciferin,
ATP, and oxygen (Ugarova, 1989). In a Mg2+-dependent reaction AMP, pyrophos-
phate, and oxyluciferin are produced together with luminescence emission at 562 -
570 nm (Ugarova, 1989).
In order to transfect the two plasmids simultaneously, HMT were grown on 12-
well plates. The medium was changed to fresh DM (1 mL per well). The plasmid
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DNA was complexed with the polymer-based transfection reagent GeneCellin ac-
cording to the manual. For an optimal result, 0.2 μg (0.2 μg/mL final concentration)
LexA_PPARd-LBD or 0.2 μg (0.2 μg/mL final concentration) pCDNA3.1 as control and
0.8 μg (0.8 μg/mL final concentration) 7LTATA-I_Luc plasmid DNA were complexed
with 4 μL GeneCellin in 100 μL OptiMEM for 15 min at ambient temperature and was
added to one well. The medium was changed to SM for stimulation 24 h later.
After stimulation, the cells were rinsed with PBS and lysed with 50 μL 1X Glo Lysis
buffer per well for 10min at ambient temperature. 50 μL Promega Dual-Glo was added
for 10 min at ambient temperature before luminometric detection of the luciferase sig-
nal by a luminometer. The luminescence protocol of the luminometer was adjusted to
0.5 s detection time. Technical triplicates were assessed per condition and biological
replicate.
2.2.8 Transformation and isolation of plasmid DNA
To amplify the DNA plasmids LexA_PPARd-LBD fusion and 7LTATA-I_Luc in E. coli,
0.5 μg plasmid DNA was added to 100 μL competent DH5α genotype of competent
E. coli (Thermo Fisher Scientific, Waltham (US-MA)) and mixed for 5 s, followed by
incubation of 30 min on ice and 2 min at 42 °C in a water bath. 1 mL Luria broth (LB)
medium was added for 30 min at 37 °C. The bacteria were pelleted for 2 min and
4000 g. The pellet was plated on a LB agar plate containing 0.1 mg/mL ampicillin.
The colonies were grown over night at 37 °C and were picked for plasmid DNA isola-
tion applying QIAGEN MiniPrep Kit according to the manufacturer’s protocol. Control
digests with restriction enzymes were performed for the isolated DNA. To this end,
approximately 8 μg DNA was incubated with 5 U of each restriction enzymes HindIII
and BamHI in 1X SuRE/cut buffer B and a total volume of 10 μL for 1 h at 37 °C. The
products were separated by gel electrophoresis in a 1% (W/V) agarose gel. HindIII cut
site were located before either insert (7X LexA binding sites or lexA_PPARd-LBD) and
BamHI downstream of the inserts. The gel was prepared as described in section 2.2.9
on the next page and run at 70 V for 3 h. The cut resulted in two expcected products
of 4986 bp (vector) and 1582 bp (lexA_PPARd-LBD) in case of LexA_PPARd-LBD
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fusion plasmid and four expected products 3022 bp, 151 bp (7X LexA binding sites),
30 bp and 1951 bp (luciferase) for the plasmid 7LTATA-I_Luc.
To propagate the colonies, 2 mL LB medium with 0.1 mg/mL ampicillin were inocu-
lated with transformed bacteria for 9 h at 37 °C in a 15 mL reaction tube under 150 rpm
agitation. The culture was added to 100 mL LB medium with 0.1 mg/mL ampicillin in
a 1 L Erlenmeyer flask for 16 h at 37 °C and under 150 rpm agitation. The plasmid
DNA was isolated form the culture by using QIAGEN MaxiPrep Kit according to the
manual in order to increase the amount of plasmid DNA. The products were controlled
by agarose gel electrophoresis.
2.2.9 Agarose gel electrophoresis of DNA
For the separation of DNA of various length, agarose gel electrophoresis was used.
The DNA was previously stained by GelRed Nucleic Acid Gel Stain. To this end, the
10,000X stock of the stain was diluted 1:100 in DNA tracker dye (table 2.23) and was
added to the sample at a final concentration of 16.7X.
Table 2.23: DNA tracker dye
final conc. substance
0.1 % (V/V) bromophenol
blue sodium
salt
0.1 % (V/V) xylene cyanol
FF
60 % (V/V) glycerol
10 % (V/V) TAE buffer
Table 2.24: 50X TAE buffer
final conc. substance
25 mM TRIS base
5,71 % (V/V) glacial acetic
acid
50 mM EDTA
The agarose gel was prepared by adding agarose powder in 1X TAE buffer
(table 2.24) and boiling in a microwave oven until the agarose was melted and com-
pletely dissolved. The gel was poured into the electrophoresis tray and cooled down.
After sample loading, constant voltage of 50 - 70 V was applied for approximately 3 h
in 1X TAE buffer. The negatively charged DNA travels in the agarose gel according
to their length. DNA stained by the intercalating DNA dye GelRed can be detected by
UV light illumination at 254 nm on a tabletop UV-transilluminator. The size of the DNA
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fragments was estimated by a DNA ladder, which was run simultaneously together
with the samples. The fluorescence image was digitalized by a digital camera and
densitometrically analyzed by ImageJ software.
2.2.10 EMSA
Electromobility shift assay (EMSA aka gel shift assay) is a method to detect protein-
DNA interactions. DNA fragments containing the binding site for the protein or tran-
scription factor are incubated together with the protein of interest. In this work the
transcription factors PPARδ and its essential co-receptor RXRα (Kliewer et al., 1992;
Desvergne and Wahli, 1999), and the PPARδ binding site termed PPARδ responsive
element (PPRE) were used. The PPRE was designed based on consensus PPREs
of type II PPARδ target transcripts (Adhikary et al., 2011). The DNA fragments were
20 bp in length and are designed as two complementary DNA strands with an over-
hang of three bases at the 5’-ends. The overhang contains one thymidine for the
labeling procedure with radioactively labeled dATP. The single stranded DNA (pur-
chased from TIB MOLBIOL, Berlin (Germany)) were annealed at a concentration of
10 μM in 1X DNA annealing buffer (table 2.25) in a total reaction volume of 100 μL for
2 min at 90 °C (table 2.26) and cooled down slowly.
Table 2.25: 10X DNA annealing buffer
final conc. substance










10 μM PPRE strand #1
5’-gATAAgTAggggAAAggTCA-3’
10 μM PPRE strand #2
5’-gATTgACCTTTCCCCTACTT-3’
1X annealing buffer
After annealing, the double stranded DNA oligos were subjected to the labeling
process via 5’→3’ fill-in reaction (table 2.27 on the following page) catalyzed by Klenow
fragment which is the large subunit of the bacterial DNA polymerase I. [32P]-dATP was
added in place of unlabeled dATP for being attached by the polymerase on the oligos.
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The reaction was performed in a total volume of 20 μL for 15 min at 25 °C. To stop
the polymerase reaction, EDTA solution (pH 8.0) at a final concentration of 24 mM
was added. The polymerase was heat inactivation for 20 min at 75 °C. The labeled
DNA oligos were purified by applying QIAGEN nucleotide removal Kit according to the
manufacturer’s protocol and eluted with 30 μL water. The purified DNA oligos were
used in the protein-DNA binding reaction (table 2.29). 20,000 cpm labeled oligo DNA
were incubated together with the human recombinant PPARδ and RXRα proteins. For
heterodimerization of the receptors, the two recombinant proteins were pre-incubated
in 1X DNA binding buffer (table 2.28, adapted from (Mochizuki et al., 2001)), glycerol,
and poly(dI-dC). Approximately 50X molar excess (≈0.83 μM) of unlabeled annealed
oligo DNA was added to one sample to determine the specific DNA-protein band after
gel electrophoresis.
Table 2.27: Fill-in reaction
final conc. substance
5 μM annealed oligo dsDNA
250 μM each dGTP, dTTP, dCTP
1X Klenow fragment buffer
5 mU/μL DNA Polymerase I, Large (Klenow) Fragment
0.5 μCi/μL (0.16 μM) [32P]-dATP
Table 2.28: 4X DNA binding buffer
final conc. substance





0.2 % (V/V) NP-40
Table 2.29: DNA binding reaction
final conc. substance
500 ng/μL Poly(dI-dC)
1X DNA binding buffer
1.875 ng/μL rec. hPPARδ
1.875 ng/μL rec. hRXRα
11.25 % (V/V) glycerol
≈1,000 cpm/μL labeled oligo PPRE
5 % (V/V) LPC, GW501516,
PC(O-16:0/O-1:0), or
solvent
The pre-incubation was performed on ice for 30 min. Subsequently, labeled oligo
DNA together with different compounds or solvent were added for 30 min at ambi-
ent temperature. To detect the potency of the compounds to activate the binding of
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the nuclear receptors to their consensus binding sequence, native gel-electrophoresis
in a 6 % acrylamide gel (table 2.30) was performed. This procedure separates fast
migrating free PPRE from slow migrating PPRE-PPAR/RXR complexes.




16.5 % (V/V) Rotiphorese Gel
40
1 ‰ (V/V) TEMED
0.05 % (W/V) APS
Table 2.31: 10X EMSA running buffer
final conc. substance
250 mM TRIS base pH 8
1.9 M glycine
10 mM EDTA
To remove substances that might interfere with the DNA-protein complex stability
during the gel loading and to pre-cool the gel, a pre-run of the gel was carried out
for 30 min at 4 °C and constant amperage of 30 mA in 1X EMSA running buffer (ta-
ble 2.31). The gel was loaded with the incubated samples and run for 2.5 h at 4 °C
and constant amperage of 30 mA. The gel was wrapped between plastic foils and
exposed to a phospho-imager screen over night at ambient temperature to detect the
radioactivity of the labeled DNA in the gel.
According to the manufacturer, the screen is a complex sensor plate consisting
of a protective layer, a radio-sensitive layer, and a support layer. The sensor layer
containing BaFBr grains of 5 μm in size. When the screen is exposed to radioactive
material, a mirror image of the material is created on the screen (Takahashi et al.,
1984; Yasuo et al., 1994). To read out the image on the screen, a monochromatic
laser light of 633 nm was applied causing photostimulated luminescence at 400 nm
which can be detected by a fluorescent image analyzer.
The digitalized pictures of the gels are processed by raytest Advanced image Data
Analyzer software and densitometrically analyzed using ImageJ. The exposed plate
was placed in an IP plate erase to fully remove the image from the phospho-imager
screen after reading the image in the fluorescent image analyzer.
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2.2.11 Palmitate oxidation
FA oxidation is an important energy supply pathway that takes place in the mitochon-
dria. End products of the FA oxidation are CO2 and H2O. If one of the H atoms of the
FA is labeled with tritium, the FA oxidation end product will be tritium labeled water,
which can be detected by scintillation counting (Kler et al., 1992).
HMT were grown and differentiated in 6-well plates and stimulated for 24 h with dif-
ferent compounds. Medium was changed to 1 mL/well EMEM without supplements.
The cells were stimulated with 3H-palmitate at a total (1H+3H)-palmitate concentration
of 33 μM and 0.5 μCi/mL 3H-palmitate for 4 h at 37 °C and 5%CO2. Etomoxir at a con-
centration of 100 μM for 30 min was added to one well to determine non-mitochondrial
FA oxidation. Etomoxir is an antagonist of carnitine palmitoyl transferase 1 (CPT1).
Water produced during FA oxidation of palmitate can also be found in the supernatant
of the cells. Therefore, the supernatants were collected and extracted by universal
reverse-phase sorbent containing cartridges. The extraction cartridges were equili-
brated with 1 mL methanol and 1 mL water before loading with 200 μL incubated cell
culture supernatant. The loaded cartridges were washed with 800 μL water. The re-
sulting eluates containing tritiated water were collected in scintillation vials filled with
5 mL scintillation cocktail. Lipophilic substances were retained in the sorbent material
of the cartridges. Tritiated water in the eluate was quantified by a liquid scintillation
counter at 18 °C with a count time of 5 min and a count region of 0 - 18.5 keV. Technical
triplicates were assessed per condition and biological replicate.
2.2.12 Glucose uptake
Glucose uptake of skeletal muscle cells mainly relies on two glucose transporters:
solute carrier family 2A1 (official symbol: SLC2A1 aka GLUT1) and solute carrier
family 2A4 (official symbol: SLC2A4 aka GLUT4) (Klip and Paquet, 1990; Sarabia
et al., 1992) fromwhich SLC2A4 is able to translocate quickly to the plasmamembrane
in an insulin-dependent manner, while SLC2A1 is responsible for the basal glucose
transport (Olson and Pessin, 1996).
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To study the effects of different compounds on the insulin-dependent and indepen-
dent glucose uptake, 2-deoxy glucose (2DOG) was used as tracer (Mitsumoto et al.,
1991). 2DOG is taken up by the cell and is phosphorylated by hexokinases. The
product 2-deoxy-glucose-6-phosphate cannot leave the cell anymore but also cannot
be further metabolized and is therefore metabolically trapped in the cytosol (Hansen
et al., 1994).
L6GLUT4myc cells (Kishi et al., 1998) were used as a model cell system to study basal
and insulin-dependent glucose uptake. The cells were grown and differentiated to
myotubes on 12-well dishes. After stimulation for 24 h with LPCs or GW501516 in
SM, the cells were serum starved in alphaMEM with Deoxyribonucleotides and Ri-
bonucleotides without any other supplements for 3 h to reduce effects of insulin and
growth hormones contained in FBS. The cells were stimulated with or without 100 nM
human insulin for 20 min. The cells were washed once with HEPES buffered saline
(HBS) (table 2.32). 350 μL of glucose transport solution, containing 0.25 μCi/mL
(31.25 pmol/mL) 2-[1,2-3H(N)]-deoxy-D-glucose and 11.25 μM deoxy-D-glucose in
HBS was added to the cells for 7 min at 37 °C and 5 % CO2. 10 μM Cytochalasin
B was added to control cells with or without insulin and with glucose transport solution
in order to determine non-specific uptake. Cytochalasin B is an antagonist of SLC2A1
and SLC2A4 (Joost and Thorens, 2001). Afterwards, the cells were placed on ice and
washed three times with cold 0.9 % NaCl. The cells were lysed in 350 μL lysis buffer
(table 2.33) for 15 min at 4 °C. The lysate was added to 5 mL scintillation cocktail.
Tritium was quantified by a liquid scintillation counter at 18 °C with a count time of







2.5 mM CaCl2 ·2H2O
Table 2.33: lysis buffer
final conc. substance




10 % (V/V) glycerol
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5 min and a count region of 0 - 18.5 keV. Technical triplicates were assessed for each
condition and biological replicate.
2.2.13 SDS-polyacrylamide gel electrophoresis and Western
blotting
Western blotting is a method that can be used for the quantification of protein expres-
sion. HMT were cultured in tissue culture dishes of Ø100x20 mm. After stimulation
the cells were lysed with 200 μL lysis buffer (table 2.33 on the previous page) including
1X phosphatase inhibitor (table 2.35). The lysate was scraped from the plate by using
cell scrapers and incubated at 4 °C for 20 min on a rotation wheel followed by centrifu-
gation at 4 °C for 5 min at maximum speed on a table top centrifuge. The supernatants
were collected and stored at -80 °C. Aliquots were used for determination of the pro-
tein concentration by staining proteins with Coomassie Brilliant Blue G-250 (Bradford,
1976). For the staining, the samples were diluted 1:200 in 200 μL 1X Bio-Rad Brad-
ford protein assay solution. The dye was incubated for 5 min at ambient temperature
and analyzed by a Bio-Rad ELISA reader at 595 nm. For quantification of the protein
amount via a standard curve, BSA standards were included at a concentration range
of 0.05 - 0.5 μg/μL. The samples were adjusted to an equal protein amount per exper-
iment ranging from 20 - 40 μg. Loading buffer (table 2.34) was added to the samples
to a final concentration of 1X followed by boiling for 7 min at 95 °C.
Table 2.34: 5X sample buffer
final conc. substance
60 mM TRIS base pH 6.8
25 % (V/V) glycerol
69.35 mM SDS
5 % (V/V) β-mercaptoethanol
0.1 % (V/V) bromophenol blue
sodium salt
Table 2.35: 10X phosphatase inhibitor
final conc. substance
10 mM NaF







In order to separate the proteins of the lysates, SDS-polyacrylamide gel elec-
trophoresis was performed. To this end, discontinuous acrylamide gels were pre-
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pared. The discontinuous acrylamide gels used in this work were 1.5 mm thick. A
gels consist of a stacking gel part and a running gel part. Two running gels of different
acrylamide concentrations, 5.0 and 7.5 % (table 2.36 and 2.37), were used. 7.5 %
gels resolve a protein size range of 30 - 100 kDa (AKT), while 5 % gels were used
for larger proteins of 50 - 300 kDa (MYHC, ACC, AMPK). The boiled lysates were
loaded on the stacking gel (table 2.38). The samples were run for 2 - 3 h at ambient
temperature in 1X running buffer (table 2.39) in a gel running chamber.
Table 2.36: 7.5 % acrylamide running
gel
final conc. substance
0.375 M TRIS base pH
8.8
0.5 % (W/V) SDS
25 % (V/V) Rotiphorese
Gel 30
0.0675 % (W/V) APS
0.165 % (V/V) TEMED
Table 2.37: 5.0 % acrylamide running
gel
final conc. substance
0.375 M TRIS base pH
8.8
0.5 % (W/V) SDS
16.7 % (V/V) Rotiphorese
Gel 30
0.0675 % (W/V) APS
0.165 % (V/V) TEMED
Table 2.38: 3.7 % acrylamide stacking gel
final conc. substance
0.115 mM TRIS base pH
6.8
15.96 mM SDS
12 % (V/V) Rotiphorese
Gel 30
0.1 % (W/V) APS
0.33 % (V/V) TEMED
Table 2.39: 10X running buffer
final conc. substance
0.25 M TRIS base
1.92 M glycine
34.67 mM SDS
Table 2.40: 10X blotting buffer
final conc. substance
0.48 M TRIS base
0.39 M glycine
13.87 mM SDS
20 % (V/V) methanol
SDS in the running buffer, is an anionic detergent and binds to the hydrophobic
parts of the denatured proteins which will lead to a negative net charge of the pro-
teins regardless of their original net charge. The newly gained net charge enables a
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homogenous electrophoretic mobility of the proteins in the gel that is only affected by
their size. A stained protein size marker was also loaded on the gel for estimating
the protein sizes. After the run, the acrylamide gel was transferred on a nitrocellu-
lose membrane and wrapped between Whatman gel blotting papers. The blotting
sandwich is soaked in 1X blotting buffer (table 2.40 on the preceding page). In a blot-
ting chamber for semi-dry blotting, the proteins of the acrylamide gel are transferred
onto the nitrocellulose membrane at constant amperage of 0.8 A/cm2 of membrane
for 3 h at ambient temperature. After blotting, the membranes were incubated in 1X
NaCl-EDTA-TRIS-gelatine (NET-G) buffer (table 2.42 on page 69) for 1 h at ambient
temperature on an orbital shaker. This prevents the unspecific binging of antibodies
by blocking unspecific binding sites. IgG antibodies listed in table 2.41 on the following
page were probed on the membranes over night at 4 °C under mild agitation. After-
wards, the membranes were washed three times with 1X NET-G buffer for 45 min in
total to remove unbound antibodies.
Secondary antibodies against rabbit or mouse IgG were applied at a dilution of
1:1000 in 1X NET-G buffer for 45 min at ambient temperature, followed by washing
of the membranes. The secondary antibody are coupled to horse radish peroxidase
and can be detected by enhanced chemiluminescence (ECL) reaction. To this end,
the membranes were soaked in ECL working solution (table 2.43 on page 69) for the
detection of normal or in commercial ECL solution for weak antibody binding. The
ECL solutions contain H2O2 and luminol, which are substrates of the peroxidase. The
enzymatic reaction causes light emission of 428 nm which can be detected and digi-
talized by the ChemiDoc Touch chemiluminescence imaging system. The data were
densitometrically analyzed by the software ImageJ.
For re-probing with antibody against total protein as loading control and reference,
the membranes were incubated in stripping buffer (table 2.44 on page 69) for 30 min at
56 °C in a water bath to remove remaining antibodies. The membranes were washed
and re-probed with antibodies as described before.
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Table 2.41: List of IgG antibodies used in this work for Western blotting
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500 mM TRIS base pH
7.4
0.5 % (V/V) Triton X-100
2.5 % (W/V) gelatine









0.0075 % (V/V) H2O2




50 % (V/V) solution A
50 % (V/V) solution B
Table 2.44: Stripping buffer
final conc. substance
66 mM TRIS base pH 6.8
0.5 % (V/V) β-mercaptoethanol
2 % (W/V) SDS
2.2.14 XBP1 splicing assay
X-box protein 1 (XBP1) mRNA splicing is a consequence of ER stress (Han and
Kaufman, 2016) and can easily be quantified by agarose gel electrophoresis. Stimu-
lated HMT were lysed for RNA isolation. The isolated RNA was reversely transcribed
to cDNA. The cDNA of total XBP1 was amplified via PCR reaction (tables 2.45 on the
next page, 2.46 on the following page) (Calfon et al., 2002; Calligaris et al., 2009).
Primers were purchased from TIB MOLBIOL, Berlin (Germany). To separate spliced
from unspliced XBP1, the PCR product was cut by the restriction enzyme PST1. To
this end, 10 μL of the PCR product in 1X SuRE/Cut buffer H was cut with 10 U/μL
PST1 in a total volume of 25 μL for 1 h at 37 °C. The DNA products of the reaction
were stained by GelRed and were separated via electrophoresis in a 2 % agarose
gel. GelRed stained DNA was visualized via UV light radiation and quantified via
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densitometric analysis by ImageJ. Relative splicing of XBP1 was calculated as the
ratio of the band intensity of uncut and spliced vs. cut and unspliced product.
Table 2.45: XBP1 PCR reaction mix
final conc. substance
1X Taq polymerase buffer
200 μM dNTP mix
200 nM hXBP1.3S 5’-AAACAgAgTAgCAgCTCAgACTgC-3’
200 nM h/mXPB1.12AS 5’-TCCTTCTgggTAgACCTCTgggAg-3’
4 ng/μL (0.1 μg) cDNA
5 % (V/V) DMSO
25 mU/μL Taq polymerase
25 μL total volume




denaturation 94 °C 4 min 1X
denaturation 94 °C 10 s
annealing 66 °C 30 s 35X
elongation 72 °C 30 s
elongation 72 °C 10 min 1X
2.2.15 In vitro time-resolved fluorescence resonance energy
transfer assay
Ligand binding was determined by time-resolved fluorescence energy transfer (TR-
FRET)-based in vitro assays (Stafslien et al., 2007) using LanthaScreen PPAR-
beta/delta competitive binding assay kit and coactivator assay kit (Thermo Fisher Sci-
entific, Waltham, MA) according to the manufacturer’s instructions. Assays were per-
formed by Dr. Till Adhikary (working group leader: Prof. Dr. Rolf Müller) at the Institute
of Molecular Biology and Tumor Research of the University of Marburg (Germany).
The competitive binding assay was performed for 30 min at ambient temperature
in FRET assay buffer (table 2.47 on the next page). GW501516 was dissolved in
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DMSO, αGPC was dissolved in water, and LPCs were dissolved in ethanol at a 10 mM
stock concentration each. Measurements were performed on a VICTOR3 Vmultilabel
counter with instrument settings as described in the manufacturer’s instructions for
LanthaScreen assays.
Table 2.47: FRET assay buffer
final conc. substance
20 mM TRIS base pH 7.9
100 mM KCl




Data depicted in this work are mean ±SEM (standard error mean), if not stated
otherwise. In order to compare groups of data, Student’s t-test was applied using
Microsoft Excel software. P-values < 0.05 were considered as statistically significant.
2.4 Nomenclature
The symbols of proteins and genes used in this thesis are in accordance with Human
Genome Gene Nomenclature Committee guidelines (Wain et al., 2002). In short,
gene and protein symbols are equal, except that gene symbols are italicized while
protein symbols are not. In this work, symbols commonly found in publications (e.g.
PPARδ instead of the official symbol: PPARD) were used for a better understanding
but the official symbols are also mentioned to avoid misleading.
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3.1 Characterization of LPC effects
To examine transcriptome wide effects caused by LPCs on HMT, global RNA analysis
by Affymetrix microarray analysis was performed. HMT were stimulated with 10 μM
LPC(16:0) or LPC(18:1) for 24 h. The isolated RNA was subjected to microarray
analysis performed by the Microarray Genechip Facility Tübingen service. The data
were processed according to the material and methods section. The quality controlled
data were used to calculate fold change values.
The data showed a maximal fold change of 4.72 compared to solvent as control
(figure 3.1 on the following page). The two most upregulated transcripts were PDK4
and ANGPTL4. Together with PLIN2 (Perilipin 2 aka Adipose differentiation-related
protein) and CPT1A (carnitine palmitoyltransferase 1A (liver)) amongst the ten most
up regulated genes, this pointed to an activation of the nuclear receptors family of
PPAR (Adhikary et al., 2011).
To confirm the results of the microarray analysis, qPCR was performed under the
same conditions (figure 3.2 on the next page). mRNA levels of PDK4 and ANGPTL4
were elevated by LPC treatment to a similar extend as shown by the microarray anal-
ysis. It was tested if the co-stimulation of the two LPCs have effects different than
single LPC treatment. A LPC(16:0)/LPC(18:1) ratio of 1:1 was used as well as a ratio
close to the physiological situation (table 1.5 on page 19) of 2:1. The mixtures showed
similar results and were not different to stimulation with single LPCs.
In my diploma thesis, kinetics analysis of LPC treatment caused a cellular response
on ANGPTL4 mRNA levels already after 1 h (figure 1.9 on page 36). Hence, LPCs
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LPC(16:0)    LPC(18:1)
Figure 3.1: Microarray analysis ofmRNAafter LPC treatment. HMTwere treated for 24 h with 10 μM
LPC(16:0), LPC(18:1), or solvent. mRNA was subjected to microarray analysis. Raw data were
uploaded in NCBI Gene Expression Omnibus homepage with the accession number GSE77337.
The 20 of most upregulated transcripts were depicted in a heatmap. Fold changes related to solvent
are given as mean in white font as well as a color code from blue=0, black=1 to red=5. Values were
ordered for decreasing fold changes of LPC(18:1) treatment. * p < 0.05 vs. solvent (n=4). Adapted
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Figure 3.2: PDK4 and ANGPTL4 induction by LPC(16:0) and LPC(18:1). HMT were treated for
24 h with 10 μM LPC(16:0), 10 μM LPC(18:1), 1:1 and 2:1 mixtures of LPC(16:0)/LPC(18:1) (10 μM
LPC in total), or solvent (con). Total RNA was isolated and the mRNA levels of (A) PDK4 and (B)
ANGPTL4 were quantified by qPCR. Data are shown as mean ±SEM related to solvent (set as 1).
* < 0.05 vs. solvent (n=4). Reprinted from (Klingler et al., 2016), with permission from Elsevier.
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presumably enter the cell within less than 1 h. To examine the uptake of LPCs into
the cells, 10 μM LPC(16:0) were used together with 56 nCi/mL (0.93 nM) 3H-labeled
LPC(16:0) as a tracer. The uptake was analyzed at different time points of the treat-
ment. The ratio of remaining 3H-labeled LPC(16:0) in the supernatant and 3H-labeled
compounds in the cells were assessed as measurement for LPC uptake (figure 3.3A).
A significant cellular uptake of 3H-LPC(16:0) was detected 30 min after administration.
24 h after stimulation, 80 % of the 3H-labeled LPC was taken up by the cells.
Furthermore, the fate of 3H-LPC(16:0) was examined by TLC of lipid extracts (fig-
ure 3.3B). The radioactivity of the lipid fractions LPC, PC, and FA were quantified for
different time points after 3H-LPC(16:0) treatment. The incorporation of 3H-LPC(16:0)
into PC was significant after 30 min and increased over time. No significant changes























































































































































Figure 3.3: Uptake and metabolic fate of LPC(16:0) in HMT. HMT were treated with 56 nCi/mL
(0.93 nM) 3H-LPC(16:0) together with 10 μM LPC(16:0) for the indicated time points. (A) To verify
LPC(16:0) uptake, the ratio of 3H in the cells and 3H in the supernatant was calculated. Data are
depicted as mean ±SEM. * < 0.05 vs. cells stimulated for 3 min with 3H-LPC(16:0) n=(4-5). (B)
The lipids in the treated cells were extracted by chloroform/methanol 2:1 and separated by TLC.
3H-incorporation into the different lipid fractions were quantified by liquid scintillation counting and
are related to the amount of 3H-LPC(16:0) applied to the cells. Data are mean ±SEM. * < 0.05 vs.
stimulation time of 3 min (n=4 - 5).
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3.2 PDK4 and ANGPTL4 induction caused by LPCs is
PPARδ dependent
Microarray results pointed to a PPAR activation. The induction of the top two tran-
scripts was confirmed via qPCR and was examined further to unravel the mech-
anism behind the induction. Three members of the PPAR family are known:
PPARα (PPARA), PPARβ/δ (PPARD), and PPARƔ (official symbol: PPARG). Accord-
ing to the literature, PDK4 and ANGPTL4 inductions in skeletal muscle cells point to
a PPARα or PPARδ activation (Staiger et al., 2009; Wu et al., 1999; Muoio et al.,
2002; Adhikary et al., 2011). The synthetic agonist of PPARδ GW501516 and of
PPARα WY14643 (aka Pirinixic acid) were tested in HMT for their efficacy to increase
PDK4 and ANGPTL4 mRNA levels. The results indicated that PPARδ activation and
not PPARα caused the induction of PDK4 and ANGPTL4 in HMT (figure 3.4). The






















































































































































Figure 3.4: PDK4 and ANGPTL4 are PPARδ target genes in HMT. HMT were stimulated with 1 μM
GW501516 (PPARδ agonist) or 1 μM WY14643 (PPARα agonist) for 24 h. Total RNA was isolated.
mRNA levels of (A) PDK4 and (B) ANGPTL4 were quantified by qPCR. Data are shown as mean
±SEM related to solvent treatment (set as 1). * < 0.05 vs. solvent (n=4). Reprinted from (Klingler
et al., 2016), with permission from Elsevier.
To confirm a PPARδ participation in the LPC effects on PDK4/ANGPTL4, two
antagonists of PPARδ, GSK3787 and GSK0660, were examined on the palmitate
evoked induction of ANGPTL4. Palmitate is an endogenous PPARδ agonist (Xu et al.,
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1999). GSK3787 is an irreversible antagonist of PPARδ (Shearer et al., 2010), while






















































































































































Figure 3.5: Effects of PPARδ antagonists/inverse agonists on PDK4/ANGPTL4 mRNA levels.
HMT were stimulated with either DMSO as solvent, 10 μM GSK3787 (PPARδ antagonist) or 10 μM
GSK0660 (PPARδ inverse agonist) for 2 h. Subsequently, (A) 250 μM palmitate complexed to BSA
or BSA alone as control were added for 24 h. ANGPTL4mRNA levels were quantified by qPCR. Data
are shown as mean ±SEM related to solvent treatment (set as 1). * p < 0.05 vs. cells treated with
BSA, # p < 0.05 vs. cells treated with palmitate (n=6). (B+C) HMT were stimulated with 10 μM
LPC(16:0) or LPC(18:1) for 24 h after GSK3787 or GSK0660 treatment. PDK4 and ANGPTL4
mRNA levels were quantified by qPCR. Data are shown as mean ±SEM related to solvent treat-
ment (set as 1). * p < 0.05 vs. cells treated with solvent, # p < 0.05 vs. cells treated with LPC w/o
GSK3787/GSK0660 (n=6). Reprinted from (Klingler et al., 2016), with permission from Elsevier.
The results showed that palmitate increased ANGPTL4 mRNA levels and that this
induction was inhibited by the compounds GSK3787 and GSK0660 (figure 3.5A). The
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same effects were seen with LPC(16:0) and LPC(18:1) administration. The induc-
tions of PDK4 and ANGPTL4 caused by LPC treatment were completely blocked by
GSK3787 and GSK0660 pre-treatment (figure 3.5B,C). GSK3787 or GSK0660 itself
had no effects on PDK4 mRNA levels but reduced ANGPTL4 mRNA abundance of
approximately 25 % in the absence of LPCs.
It was tested if silencing of PPARD can influence the LPC-mediated induction of
PDK4 and ANGPTL4. HMT were transfected with siRNA targeted against PPARD
prior to LPC treatment. The presence of siRNA against PPARD reduced the mRNA
levels of PPARD by approximately 75% (figure 3.6A). This reduction of PPARDmRNA
resulted in a significant decline of LPC-mediated PDK4 induction (figure 3.6B). The
induction of ANGPTL4 by LPCs was not affected by siPPARD (figure 3.6C). In the
absence of LPCs, siPPARD caused a significant increase of bothPDK4 andANGPTL4
mRNA levels. This effect was most prominent for ANGPTL4 with 50 % increased
mRNA levels.
To confirm that LPCs activate the LBD of PPARδ, luciferase reporter assays were
conducted. The plasmids for this assay were kindly provided by Prof. Dr. Rolf Müller
from the University of Marburg (Germany) (Fauti et al., 2006; Rieck et al., 2008). The
two plasmids (figure 2.1 and 2.2 on page 57) were co-transfected for 24 h followed
by stimulation with LPC(16:0), LPC(18:1), solvent, and GW501516 as positive control
for further 24 h. The plasmids LexA_PPARd-LBD fusion encodes for a fusion protein
of the bacterial (E. coli (strain 12)) transcription repressor LexA and the PPARδ LBD
behind a TATA box (figure 2.1 on page 57). The plasmid 7LTATA-I_Luc contains seven
tandem repeats of the LexA binding site downstream of the firefly luciferase gene (fig-
ure 2.2 on page 57). In the presence of a PPARδ ligand the expressed fusion protein
recruits co-activators and other transcriptional factors due to activation of the LBD of
PPARδ (Dowell et al., 1997; Godowski et al., 1988). This recruitment of transcriptional
machinery results in the expression of the firefly luciferase gene. That expression was
verified via luminescence signal quantification.
Both LPCs caused the activation of the PPARδ LBD indicated by an increased lu-

























































































































































Figure 3.6: Effects of siRNA against PPARD on PDK4 and ANGPTL4 mRNA levels. HTM were
transfected with siRNA against PPARD for 24 h followed by treatment with 10 μM LPC(16:0), 10 μM
LPC(18:0), or solvent for 24 h. (A) PPARD, (B) PDK4, and (C) ANGPTL4mRNA levels were quanti-
fied by qPCR. Data are shown as mean±SEM related to siCon transfected cells treated with solvent
(set as 1). * p < 0.05 vs. cells transfected with siCon and treated with solvent, # p < 0.05 vs. cells
transfected with siPPARD and treated with LPC (n=4). Reprinted from (Klingler et al., 2016), with
ermission from Elsevier.
accounted for 2.4- and 2.5-fold vs. control, respectively, while the synthetic PPARδ ag-
onist GW501516 had a 10-fold response vs. solvent control (figure 3.7 on the next
page). Cells transfected with the empty vector pcDNA3.1 instead of the plasmid
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Figure 3.7: LPC treatment caused the activation of the PPARδ LBD in luciferase reporter assays.
HMT were co-transfected with two plasmids for 24 h. One plasmid contained the fusion protein of
PPARδ LBDwith LexA and the other plasmid included LexA binding sites in front of a firefly luciferase
gene. As mock control the former was replaced by an empty pcDNA3.1 plasmid. Afterwards, the
cells were treated with 10 μM LPC(16:0), 10 μM LPC(18:1), 1 μMGW501516 for 24 h. The luciferase
activity was quantified by luminescence reading. Data are depicted asmean±SEM related to solvent
as control (set as 1). * p < 0.05 vs. solvent as control (n=4). Reprinted from (Klingler et al., 2016),
with permission from Elsevier.
3.3 LPCs are PPARδ ligands
It was tested if LPCs can activate PPARδ directly as endogenous ligands. For
this purpose, EMSAs were conducted with the recombinant human PPARδ and
RXRα (retinoid X receptor α, official symbol: RXRA) proteins together with a con-
sensus PPAR responsive element (PPRE) of PPARδ target transcripts with a type II
response. Type II PPARδ target transcripts fulfill two criteria (Adhikary et al., 2011):
(a) induction of the PPARδ target gene by the presence of siRNA targeted against
PPARδ and (b) induction of the PPARδ target gene by PPARδ agonist GW501516.
Both criteria are fulfilled by PDK4 and ANGPTL4 as showed by figure 3.4 on page 75
and figure 3.6 on the previous page.
The EMSAs showed that the two recombinant proteins caused a shift of the free
PPRE probe in the acrylamide gel. The shifted complex of PPRE and PPAR/RXR
appeared as weak band marked as ”PPARδ/RXRα” (figure 3.8A on the next page).
This band became more prominent in the presence of the potent PPARδ agonist
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Figure 3.8: LPCs increased the DNA binding activity of PPARδ/RXRα complex. EMSA was per-
formed with recombinant human PPARδ, and RXRα together with an oligo DNA sequence containing
the consensus binding site for PPARδ named PPRE. The PPRE was radioactively end-labeled with
[32P]dATP. For the binding reaction, 1.875 ng/μL of each recombinant protein together with approx.
20,000 cpm radioactively end-labeled PPRE were used in the presence of 5 μM GW501516 or in-
creasing concentrations of LPC(16:0) or LPC(18:1) or 50x molar excess of unlabeled PPRE. The
radioactivity was visualized via phospho-imaging. (A) One representative gel is depicted. (B) Den-
sitometrical evaluation was performed. Data are mean of values related to total PPARδ/RXRα band
intensities per experiment ±SEM . * p < 0.05 vs. solvent (n=4 - 6). Reprinted from (Klingler et al.,
2016), with permission from Elsevier.
The band almost disappeared in the presence of 50X molar excess of non-radioactive
PPRE indicating the specificity of the band. The strongest DNA binding activity was
caused by LPCs was detected for 0.5 μM LPC(18:1) and 1 μM LPC(16:0). The effects
of GW501516, 1 and 5 μM LPC(16:0), and 0.5 - 5 μM LPC(18:1) on the DNA binding
activity of the proteins were statistically significant different from control samples. In-
creasing concentration of LPCs in the reaction mix reduced the DNA binding activity
of the PPARδ/RXRα complex on the PPRE (figure 3.8B). This effect was observed for
both LPCs.
To gain insights into which LPC metabolite is also capable of increasing PDK4 and
ANGPTL4mRNA levels and to compare LPC effects with their efficacy, a spectrum of
compounds (figure 3.9A on the next page) was applied at equimolar concentrations for
24 h on HMT. The compounds were previously complexed for 3 h at 10 μM in SM con-
taining 2 % FBS to provide comparable stimulation conditions among the compounds.




























































































































































































Figure 3.9: Effect of different compounds on PDK4 and ANGPTL4 mRNA levels. HMT were stim-
ulated with (A) different compounds at 10 μM each for 24 h. RNA was isolated. The mRNA levels
of (B) PDK4 and (C) ANGPTL4 were quantified by qPCR. Data are shown as mean ±SEM related
to solvent treatment (set as 1 displayed as dashed line). * < 0.05 vs. solvent (n=6). Reprinted from
(Klingler et al., 2016), with permission from Elsevier.
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to the class of ALPs and was used as compound that structurally resembles LPCs.
This particular lipid is not hydrolyzable by phospholipases of the class A1 and A2.
The FA palmitate and oleate displayed similar efficacy as LPCs on the induction of
PDK4 and ANGPTL4 (figure 3.9B,C). Also the cyclic compound cPA(16:0) displayed
a robust induction of the two transcripts. Furthermore, PC(O-16:0/O-1:0) caused the
strongest response among the set of compounds. The metabolites PC(16:0/16:0),
PC(18:1/18:1), and αGPC demonstrated no effect on PDK4 or ANGPTL4 mRNA lev-
els.
To confirm that LPCs are potential direct ligands of PPARδ, a LanthaScreen TR-
FRETPPARδ competitive binding assay was performed in cooperation with Dr. Till Ad-
hikary at the University of Marburg. This assay uses Fluormone Pan-PPAR GreenTM,
a fluorescein-labeled pan-PPAR ligand that binds to the GST-tagged LBD of PPARδ. A
terbium-labeled anti-GST antibody is added which generates a TR-FRET signal when
the ligand is bound. Terbium acts as donor fluorophore for the acceptor fluorophore
fluorescein. Fluorescein emits light at 520 nm via FRET when terbium is excited with
a light source of 340 nm. The emission signal of terbium at 495 nm acts as reference.
When the pan-PPAR ligand is competitively displaced by a non fluorescent ligand
the TR-FRET signal at 520 nm declines. LPC(16:0), LPC(18:1), PC(O-16:0/O-1:0),
PC(16:0/16:0), and αGPC as well as GW501516 were tested at different concentra-
tions for their efficacy to replace the pan-PPAR ligand. The dose response curves
were fitted to a three-parameter regression model according to equation 3.1 in order




This assay demonstrated that LPC(16:0), LPC(18:1), and PC(O-16:0/O-1:0) were
equally potent in displacing the pan-PPAR ligand from the LBD of PPARδ (figure
3.10A on the next page). Their potency at 10 μM was moderate compared to
100 nM GW501516 (figure 3.10B). PC(16:0/16:0) and αGPC were not able to re-
place the ligand. EC50 values could only be estimated for LPC(16:0), LPC(18:1), and
































































































































































































Figure 3.10: TF-FRET PPARδ competitive binding assay with different compounds. TR-FRET
PPARδ competitive binding assay was performed with LPC(16:0), LPC(18:1), αGPC, PC(16:0/16:0),
PC(O-16:0/O-1:0), GW501516, and the corresponding solvents. (A) The reduction of the fluores-
cence ratio of 520 nm/495 nm indicates replacement of the pan-PPAR ligand form the PPARδ LBD by
the compounds at the indicated concentrations. Data are mean±SEM. * p < 0.05 vs. solvent (n=3
technical replicates). Reprinted from (Klingler et al., 2016), with permission from Elsevier. (B) The
values of 100 nm GW501516 and 10 μM LPC(16:0), LPC(18:1), PC(16:0/16:0), PC(O-16:0/O-1:0)
are displayed as bar chart. Data are mean±SEM. * p < 0.05 vs. corresponding solvent (n=3 techni-
cal replicates). (C-E) Dose response curves were created by plotting logarithmized concentrations
against the FRET ratio of the single compounds (C) LPC(16:0), (D) LPC(18:1), (E) PC(O-16:0/O-1:0).
The curves were fitted to equation 3.1 on the previous page. Fitting parameters are displayed in ta-
ble 3.1 on the following page.
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evaluated. The results (table 3.1) were similar for all three compounds under the given
error means and 95 % confidential interval (CI) and amounted for approximately 30,
31 and 24 μM for LPC(16:0), LPC(18:1), and PC(O-16:0/O-1:0), respectively. The
EC50 of the three compounds was in a similar range as the endogenous PPAR lig-
ands palmitate and oleate (table 3.2).
Table 3.1: Fitting parameters of the dose response curves fitted to a three-parameter logistic model ac-
cording to equation 3.1 on page 82 using GraphPad PRISM software. Abbreviations: CI (confidential
interval), AU (arbitrary units).
parameter LPC(16:0) LPC(18:1) PC(O-16:0/O-1:0)
bottom±SEM [AU] 0,067±0,006 0,051±0,006 0,063±0,006
top±SEM [AU] 0,207±0,005 0,212±0,005 0,208±0,005
EC50±SEM [μM] 30,54±1,21 31,45±1,18 24,31±1,19
Hill slope±SEM [μM-1] 0,140±0,007 0,160±0,007 0,145±0,006
95 % CI LPC(16:0) LPC(18:1) PC(O-16:0/O-1:0)
bottom [AU] 0.054 to 0.08 0.038 to 0.064 0.051 to 0.075
top [AU] 0.197 to 0.217 0.201 to 0.222 0.198 to 0.219
EC50 [μM] 20.54 to 45.41 22.24 to 44.46 16.87 to 35.02
Hill slope [μM-1] 0.126 to 0.154 0.147 to 0.174 0.132 to 0.158
R2 0,957 0,967 0,961
Table 3.2: EC50 of selected synthetic and endogenous PPAR ligands. Abbreviations: n.d. (not de-
tected)
ligand EC50 [nM] reference
PPARδ PPARα PPARƔ
GW501516 1 1100 850 Sznaidman et al., 2003
WY14643 >100,000 630 32,000 Willson et al., 2000
MBX-8025 2 too high too high Bays et al., 2011
GFT505 100-150 10-20 n.d. Cariou et al., 2011
GSK0660 155 >10,000 >10,000 Shearer et al., 2008
GSK3787 6.6 too high too high Shearer et al., 2010
PC(O-16:0/O-1:0) ≈24,000 n.d. n.d.
LPC(16:0) ≈30,000 n.d. n.d.
palmitate 7,400 1,500 >30,000 Xu et al., 1999
LPC(18:1) ≈31,000 n.d. n.d.
oleate 5,300 600 4,100 Xu et al., 1999
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3.4 LPCs protect against palmitate-mediated
lipotoxicity
The physiological consequences of LPC treatment on skeletal muscle were studied.
PPARδ has been shown to have effects on many metabolic pathways amongst them
the enhancement of FA oxidation. LPCs as activators of PPARδ might also improve
FA oxidation of HMT. Therefore, oxidation of 3H-labeled palmitate was quantified by
scintillation counting of tritiated water as an end product of FA oxidation. Tritiated
water was isolated by column solid phase extraction of the cell culture supernatants.
The overall effects of LPC and GW501516 treatment for 24 h on palmitate oxidation
were moderate. LPC(16:0) at 5 μM increased palmitate oxidation 1.24-fold. 10 μM
LPC(16:0) were not effective. LPC(18:1) also had no detectable impact on palmitate
oxidation in HMT. GW501516 significantly increased palmitate oxidation with a fold
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Figure 3.11: Effect of LPCs on palmitate oxidation. HMT were stimulated with 1 μM GW501516, 5
or 10 μM LPC(16:0), or 5 or 10 μM LPC(18:1) for 24 h. Subsequently, the cells were treated with
0.5 μCi/mL (33 μM total palmitic acid) [3H] labeled palmitate for 4 h. The supernatant was applied
to solid phase extraction columns to isolate tritiated water for scintillation counting as measurement
for enhanced palmitate oxidation. Data are shown as mean ±SEM related to solvent. * p < 0.05 vs.
solvent (n=7 - 8).
It was also tested if LPCs might affect glucose uptake as it was reported the liter-
ature. 20 μM LPCs for 3 h in L6 myotubes (Han et al., 2011) are supposed to de-
crease glucose uptake while enhanced glucose uptake was demonstrated with 1 μM
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LPC(16:0) for 10 min in 3T3-L1 adipocytes (Yea et al., 2009). HMT are not suitable
to study insulin-dependent glucose uptake since they have low SLC2A4 levels (Sara-
bia et al., 1992; Ciaraldi et al., 2005; Stuart et al., 2006). Therefore, L6GLUT4myc my-
otubes (rat skeletal muscle) were used which had a mean increase in glucose uptake
of 2.2-fold upon 100 nM human insulin stimulation for 20 min (figure 3.12). L6GLUT4myc
myotubes work are stably transfected with cDNA of rat homologue of SLC2A4 tagged
with amyc epitope. The cells were treated with 10 μM LPCs for 24 h followed by serum
starvation. The starved cells were treated with or without 100 nM human insulin for
20 min followed by administration of 3H-labeled 2DOG as tracer for glucose uptake.










































Figure 3.12: Effect of LPCs on glucose uptake of L6 skeletal muscle cells. L6GLUT4myc myotubes
were stimulated with 10 μM LPC(16:0), 10 μM LPC(18:1), 1 μM GW501516, or solvent for 24 h. The
cells were serum starved for 3 h and exposed to 0.25 μCi/mL [3H]-labeled 2DOG (11.28 μM total
2DOG) for 7 min. The cells were washed and lysed. Lysate were analyzed for 3H incorporation via
scintillation counting as measurement for 2DOG uptake. Data are shown as mean ±SEM related to
solvent without insulin as control (set as 1). * p < 0.05 vs. solvent as control (n=4).
LPC(16:0) and GW501516 but not LPC(18:1) marginally increased basal 2DOG
uptake in L6GLUT4myc myotubes (figure 3.12). No significant effects of the compounds
were observed when 100 nM insulin was present.
AMPK is a serine/threonine kinase and an important regulator of cell metabolism.
AMPK activates glucose uptake and FA oxidation (Hardie et al., 2012). It was therefore
examined if LPCs could trigger the activation of AMPK by phosphorylation at thr172
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and the phosphorylation of its downstream target acetyl CoA carboxylase (ACC, of-
ficial symbol: ACAC) at ser79. HMT were stimulated with LPC(16:0) and LPC(18:1)
for different time points.
LPC(16:0) + +--- + 
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Figure 3.13: Effect of LPCs on the phosphorylation of AMPK. HMT were stimulated with 10 μM
LPC(16:0), 10 μM LPC(18:1), or solvent for 10 min, 4 h, or 24 h. Afterwards, cells were lysed.
The lysates were subjected to Western blotting and probed with anti-pAMPK thr172 and anti-pACC
ser79 antibodies. Before re-probing with antibodies against anti-AMPK α1 and anti-MYH, the mem-
brane were stripped off any antibodies. Representative blots are depicted (A). ECL signal of the
secondary antibodies were detected, digitalized and quantified densitometrically. (B) The relative
ratio of pAMPK thr172/AMPK protein and (C) values of pACC ser79 are given with MYH as loading
control. Data are shown as mean ±SEM related to solvent as control (set as 1). * p < 0.05 vs.
solvent as control (n=8). Reprinted from (Klingler et al., 2016), with permission from Elsevier.
The data (figure 3.13) showed that LPC stimulation for 10 min caused the phos-
phorylation of thr172 on AMPK. On later time points the phosphorylation declined to
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base line levels. The kinetics of the phosphorylation of ACC were similar compared
to AMPK but persisted for 4 h. Both LPCs had comparable effects on the phosphory-
lation of both proteins.
As summarized in table 1.7 on page 26, LPCs negatively correlate with inflamma-
tory markers like CRP. In addition, it is also known that PPARδ activation has anti-
inflammatory effects (Wahli and Michalik, 2012; Vazquez-Carrera, 2016). Therefore,
experiments were conducted to examine a potential anti-inflammatory role of LPCs
during lipotoxicity. Lipotoxicity in HMT was provoked by stimulation with the saturated
FA palmitate for 24 h. Lipotoxic results in the induction of cytokines like IL6 andCXCL3
(Peter et al., 2009) as well as the manifestation of ER stress with detectable splicing
of XBP1 mRNA (Yoshida et al., 2001; Calfon et al., 2002; Calligaris et al., 2009) and
the induction of ATF3 (Jiang et al., 2004). A potential protective role of LPCs was
examined by LPC pre-incubation for 24 h prior to palmitate treatment of the cells.
With 250 μM palmitate, the cells had manifested lipotoxicity apparent by the induc-
tion of IL6, ATF3, and CXCL3 (figure 3.14A - C on page 89) together with enhanced
XBP1 mRNA splicing (figure 3.14D,E). The induction of the transcripts and the XBP1
splicing by palmitate were reduced by more than 50%when the cells were pre-treated
with LPCs or GW501516. LPCs and GW501516 had comparable efficacy in the pro-
tection against the lipotoxic effects caused by palmitate.
Palmitate treatment can also compromise insulin signaling as another part of lipotox-
icicity (Belfort et al., 2005; Aas et al., 2005). Furthermore, LPCs negatively correlate
with parameters of insulin resistance (table 1.7 on page 26). It was examined if LPCs
could act in a protective manner on the palmitate-mediated impairment of insulin sig-
naling. HMT were stimulated with LPC(16:0), LPC(18:1), or solvent for 24 h followed
by palmitate stimulation for 24 h. To assess insulin-mediated AKT phosphorylation at
ser473 and thr308 as markers for insulin sensitivity, the cells were serum starved for
3 h followed by stimulation with 100 nM human insulin for 10 min.
The results showed that the insulin-dependent phosphorylation of both sites on
AKT was significantly abolished in the presence of palmitate (figure 3.15 on page 90).
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Figure 3.14: Protective effects of LPC on lipotoxicity. HMT were pre-treated with 10 μM LPC(16:0),
10 μM LPC(18:1), 1 μM GW501516 (abbreviated as GW) or solvent for 24 h, followed by adminis-
tration of 250 μM palmitate complexed to BSA or BSA as control for 24 h. Total RNA was isolated.
mRNA levels of (A) IL6, (B) ATF3, and (C) CXCL3 were quantified by qPCR. XBP1 RNA (transcript
NM_005080.3) was amplified by PCR from isolated total RNA, cut with the restriction enzyme PST1
and quantified densitometrically after agarose gel electrophoresis. (D) A representative agarose gel
is shown. (E) The ratio of spliced and PSTI resistant XBP1s (PCR product expected at 448 bp) to
unspliced and PSTI cut XBP1 (PCR products expected at 285 + 189 bp) was calculated as indicator
of ER stress. Data are mean±SEM. * p < 0.05 vs. BSA + solvent, # p < 0.05 vs. palmitate + solvent
(n=4). Reprinted from (Klingler et al., 2016), with permission from Elsevier.
by palmitate. The phosphorlyation of thr308 was only protected by LPC(18:1) and not
by LPC(16:0).
To test if the protective effect of LPCs on lipotoxicity potentially was PPARδ-
dependent, GSK0660 was pre-incubated for 2 h prior to LPC/GW501516 treatment
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Figure 3.15: Effect of LPCs on insulin resistance in HMT. HMT were stimulated with 10 μM
LPC(16:0), 10 μM LPC(18:0), or solvent for 24 h followed treatment with 250 μM palmitate or BSA
as control for further 24 h. The cells were serum-starved for 3 h and stimulated with 100 nM human
insulin for 10 min. Afterwards, the cells were lysed. The lysates were subjected to Western blotting
and probed with (A) anti-pAKT ser473 and (B) anti-pAKT thr308 antibodies. Before re-probing with
antibodies against anti-AKT protein, the membranes were stripped off any antibodies. ECL signal of
the secondary antibodies was detected via chemiluminescence imaging system and quantified den-
sitometrically. Data are shown as mean±SEM related to solvent + palmitate + insulin treatment. * p
< 0.05 vs. solvent + BSA + insulin stimulation, # p < 0.05 vs. solvent + palmitate + insulin stimulation
(n=8).
for 24 h and the addition of palmitate/BSA for further 24 h. The mRNA levels of IL6,
ATF3, and CXCL3 were used as read-out.
The pre-incubation with the PPARδ reverse agonist GSK0660 increased the mRNA
abundance of IL6, ATF3, and CXCL3 in the presence of palmitate (figure 3.16 on the
following page). GSK0660 treatment prevented the protective effect of both LPCs




























+ -+ --- -
LPC(18:1) - +- +-- -


























+ -+ --- -
LPC(18:1) - +- +-- -


























+ -+ --- -
LPC(18:1) - +- +-- -
































Figure 3.16: Inhibition of the protective effect of LPCs by GSK0660. HMT were stimulated with
10 μM GSK0660 or DMSO for 2 h followed by addition of 10 μM LPC(16:0), 10 μM LPC(18:1), or
solvent. After 24 h, 250 μM palmitate complexed to BSA or BSA alone was added for further 24 h.
Total RNAwas isolated. mRNA levels of (A) IL6, (B) ATF3, and (C)CXCL3were quantified by qPCR.
Data are shown as mean±SEM related to BSA + solvent treatment without LPCs or GSK0660 (set
as 1). * < 0.05, # p < 0.05 vs. palmitate treatment w/o LPCs and GSK0660 (n=7). Reprinted from
(Klingler et al., 2016), with permission from Elsevier.
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3.5 Effects of interferences in the LPC metabolism on
palmitate-mediated lipotoxicity
LPCs protected against lipotoxicity caused by palmitate. It was expected that also
a reduced turn-over of LPCs to PCs might have similar effects as LPC administra-
tion on palmitate-mediated lipotoxicity. Therefore, LPCATs were chosen according to
their mRNA levels determined by microarray analysis (data not shown), literature data
about their tissue expression profile (table 1.3 on page 16), and their relevance in in-
flammatory reactions (Shindou et al., 2007) and other metabolic aspects (Zhao et al.,
2008). LPCAT1+2+3 were silenced by siRNA.
The efficiency of the silencing was higher than 50 % for all three transcripts (fig-
ure 3.17 on the following page). Silencing of LPCAT1 and LPCAT2 and the combina-
tion of all three had comparable effects and moderately reduced IL6 induction caused
by palmitate treatment. Silencing of LPCAT3 had no effects on IL6 levels during palmi-
tate challenge. However, this effect was not observed for ATF3 and CXCL3. None of
the siRNAs could affect the palmitate caused induction of these two stress markers.
It was also examined if a reduced formation of LPCs by inhibition of PLA2s could in-
tensify palmitate-mediated lipotoxicity. In this approach different PLA2 inhibitors were
administrated. Bromoenol lactone (BEL aka haloenol lactone suicide substrate) is a
commonly used suicide inhibitor of iPLA2 (Dennis et al., 2011; Jenkins et al., 2002;
Balsinde et al., 2006; Hazen et al., 1991; Song et al., 2006; Han et al., 2011). BEL
is a chiral compound. The S enantiomer inhibits preferentially PLA2G6A, while the R
enantiomer blocks PLA2G6B (Jenkins et al., 2002). FKGK11 belongs to the class of
polyfluoro ketones and inhibits iPLA2 in general with high specificity (Baskakis et al.,
2008). The inhibitors were co-stimulated with palmitate.
The enantiomers of BEL had no effect on the palmitate-mediated induction of IL6,
ATF3, and CXCL3 (figure 3.18 on page 94). As opposed to this, FKGK11 treat-
ment dose-dependently fortified the effects on IL6, ATF3, and CXCL3 mRNA abun-

















































































































Figure 3.17: Effect of LPCAT1/2/3 knockdown on palmitate-mediated lipotoxicity. HMT were
transfected with siRNA targeted against LPCAT1, LPCAT2, LPCAT3 and the combination of all for
24 h. 250 μM palmitate complexed to BSA or BSA alone as control was administrated for further
24 h. Total RNA was isolated. mRNA levels of (A) LPCAT1 (black bars), LPCAT2 (light gray bars),
LPCAT3 (dark gray bars), (B) IL6, (C) ATF3, and (D) CXCL3 were quantified by qPCR. Data are
shown as mean ±SEM related to siCon transfected cells with BSA treatment (set as 1). * < 0.05
vs. siCon transfected cells with BSA treatment, # p < 0.05 vs. siCon transfected cells with palmitate
treatment (n=6). Reprinted from (Klingler et al., 2016), with permission from Elsevier.
and FKGK11 and to exclude side effects of the inhibitors, siRNA targeted against





















































































Figure 3.18: Effects of different PLA2 inhibitors on palmitate-mediated IL6 induction. HMT were
co-stimulated with either 10 μM (S)-BEL, 10 μM (R)-BEL, 5 μM or 10 μM FKGK11 together with
250 μM palmitate complexed to BSA or BSA alone as control for 24 h. Total RNA was isolated and
mRNA levels of (A) IL6, (B) ATF3, and (C) CXCL3 were quantified by qPCR. Data are shown as
mean ±SEM related to cells treated with solvent (set as 1). * < 0.05 vs. BSA treatment, # < 0.05
vs. palmitate without inhibitors (n=4). Reprinted from (Klingler et al., 2016), with permission from
Elsevier.
Palmitate treatment significantly increased mRNA levels of PLA2G6B and reduced
PLA2G6A (figure 3.19A on the following page). siPLA2G6A had comparable effects
as palmitate treatment on PLA2G6A mRNA levels, although not statistically signifi-
cant. In the presence of siRNA targeted against PLA2G6B, the increase of this par-
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ticular PLA2 caused by palmitate was reduced to control levels. On the other hand
silencing of PLA2G6B increased PLA2G6AmRNA levels. The co-transfection of both
siPLA2G6A and siPLA2G6B equalized both transcript levels to as comparable level
as siCon treated cells without palmitate.
siPLA2G6A and siPLA2G6B but not co-transfection significantly fortified IL6 induc-
tion caused by palmitate treatment (figure 3.19B). These effects were not observed












































































































Figure 3.19: Effects of silencing of PLA2G6A and PLA2G6B on palmitate-mediated lipotoxicity.
HMT were transfected with siRNA targeted against PLA2G6A and PLA2G6B for 24 h followed by
administration of 250 μM palmitate complexed to BSA or BSA alone as control for 24 h. Total RNA
was isolated. mRNA levels of (A) PLA2G6A (black bars), PLA2G6B (gray bars), (B) IL6, (C) ATF3,
(D) CXCL3 were quantified by qPCR. Data are shown as mean±SEM related to siCon transfected
cells with BSA treatment (set as 1). * < 0.05 vs. siCon transfected cells with BSA treatment, # p <
0.05 vs. siCon transfected cells with palmitate treatment (n=6).
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3.6 Other signaling pathways might contribute to LPC
effects and PPARδ activation
It is known that LPCs can transiently activate extracellular signal-regulated kinases 1
and 2 (ERK1 and ERK2, official symbol: MAPK3 andMAPK1) and c-Jun N-terminal ki-
nase 1 and 2 (JNK1 and JNK2, official symbol: MAPK8 andMAPK9) and inhibit protein
kinase A (PKA, official symbol: PRKA) (Klingler, 2012; Han et al., 2011; Burkholder,
2009). It might be possible that these signaling events can contribute to an activa-
tion of PPARδ and its target genes via phosphorylation of the nuclear receptor in the
absence of ligands (Burns and Vanden Heuvel, 2007). Forskolin activates the intra-
cellular ADCY resulting in elevated cAMP levels. This triggers the activation of PKA.
Forskolin was supplied to the cells for different time points to examine its effect on
PDK4 and ANGPTL4 mRNA levels.
Forskolin stimulation led to an increase of PDK4 mRNA abundance over time with
first significant effects at 4 h (figure 3.20A). ANGPTL4 mRNA levels declined starting























































































































Figure 3.20: Effects of forskolin on PDK4 andANGPTL4 RNA over time. HMT were stimulated with
20 μM forskolin for the indicated time periods. Total RNA was isolated. mRNA levels of (A) PDK4
and (B) ANGPTL4 were quantified by qPCR. Data are shown as mean ±SEM related to solvent
treatment (set as 1). * p < 0.05 vs. solvent treatment (n=4).
It was examined if the PKA inhibitor H-89 could compensate for the effects of
forskolin. H-89 and forskolin were administrated for 4 h. H-89 stimulation increased
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PDK4 mRNA levels and reduced the effects of forskolin on PDK4 mRNA abundance
significantly. H-89 had no effect on ANGPTL4 mRNA levels and also not in combina-























































































































Figure 3.21: Effects of forskolin and H-89 treatment on PDK4 and ANGPTL4 mRNA. HMT were
stimulated with 20 μM forskolin and/or 30 μM H-89 for 4 h. Total RNA was isolated. mRNA levels of
(A) PDK4 and (B) ANGPTL4 were quantified by qPCR. Data are shown as mean ±SEM related to
solvent treatment (set as 1). * p < 0.05 vs. solvent treatment, # p < 0.05 (n=4).
Putative LPC receptors are GPCRs that transduce their signal via various classes
of Gα subunits including Gq (chapter 1.7.1 on page 27). Gq is able to increase intracel-
lular Ca2+ levels. Apart from receptor-mediated alterations of intracellular Ca2+ levels,
LPCs might also change membrane fluidity, ion channel activity, or influence the intra-
cellular Ca2+ levels by other still unknownmechanisms (Jabr et al., 2000; Tanaka et al.,
2011). It was investigated if alterations of intracellular Ca2+ levels could affect PDK4
and ANGPTL4 mRNA abundance. Ionomycin is an ionophore that increases cytoso-
lic Ca2+ levels (Dedkova et al., 2000). BAPTA-AM is a strong chelator of Ca2+ ions
that can cross the plasma membrane and inactivate cytosolic Ca2+ by complexation
(Naraghi and Neher, 1997). Ionomycin had no effects on neither PDK4 or ANGPTL4
mRNA levels. BAPTA-AM increased PDK4 mRNA levels with borderline significance
(figure 3.22A on the next page). Ionomycin in combination with BAPTA-AM increased
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PDK4 mRNA levels to a similar extend as BAPTA-AM alone. BAPTA-AM and in com-
























































































Figure 3.22: Effects of ionomycin and BAPTA-AM treatment on PDK4 andANGPTL4mRNA.HMT
were stimulated with 1 μM ionomycin and/or 10 μM BAPTA-AM for 4 h. Total RNA was isolated.
mRNA levels of (A) PDK4 and (B) ANGPTL4 were quantified by qPCR. Data are shown as mean
±SEM related to solvent treatment (set as 1). * p < 0.05 vs. solvent treatment, # p < 0.05 (n=4).
3.7 Ether LPC analogue PC(O-16:0/O-1:0) is another
PPARδ ligand
In figure 3.9 on page 81 and figure 3.10 on page 83 it was shown that
PC(O-16:0/O-1:0) is able to activate PPARδ and its target transcripts.
PC(O-16:0/O-1:0) structurally resembles LPCs but is not metabolized in the cell.
The effects of this compound might give a hint about the relevance of the chemical
structure of LPCs. EMSAs were performed to confirm that PC(O-16:0/O-1:0) also
can act as a PPARδ activator.
The results of the EMSAs demonstrated that PC(O-16:0/O-1:0) enhanced the
DNA binding activity of the PPARδ/RXRα complex to its consensus binding se-
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Figure 3.23: PC(O-16:0/O-1:0) increased the DNA binding activity of the PPARδ/RXRα complex.
EMSA was performed with recombinant human PPARδ, RXRα and an oligo DNA sequence contain-
ing the consensus binding site for PPARδ named PPRE. The PPRE was radioactively end-labeled
with [32P]dATP. For the binding reaction, 1.875 ng/μL (37.5 ng) of each recombinant protein to-
gether with approx. 20,000 cpm radioactively end-labeled PPRE were used in the presence of 5 μM
GW501516 or increasing concentrations of PC(O-16:0/O-1:0) (”ether”), LPC(16:0), and LPC(18:1).
The radioactivity was visualized via phospho-imaging. (A) One representative gel is depicted. (B)
Densitometrically evaluation was performed. Data are mean of values related to total radioactivity
per replicate ±SEM. * p < 0.05 vs. solvent (n=4-6).
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4.1 PDK4 and ANGPTL4 induction by LPCs is
PPARδ mediated
Previous data from my diploma work showed that LPC(16:0) and LPC(18:1) can
cause the induction of PDK4 and ANGPTL4 mRNA in HMT (figure 1.9 on page 36).
This was confirmed in this work by microarray experiments (figure 3.1 on page 73),
where both LPCs increased the abundance of PDK4 and ANGPTL4. ANGPTL4 and
PDK4 are PPAR target genes (Staiger et al., 2009; Adhikary et al., 2011; Degenhardt
et al., 2007). PPARs belong to the nuclear receptors superfamily (Mangelsdorf et al.,
1995). The PPAR receptor family consists of three members: PPARα (official symbol:
PPARA), PPARδ/β (official symbol: PPARD), and PPARƔ (official symbol: PPARG).
PPARα is expressed in liver, kidney, heart, skeletal muscle, and adipose tissue (Isse-
mann and Green, 1990; Loviscach et al., 2000; Su et al., 1998; Tontonoz et al., 1994;
Escher et al., 2001). PPARδ is ubiquitously expressed except in testis and only low
expression levels are found in liver (Braissant et al., 1996; Kliewer et al., 1994; Girroir
et al., 2008; Escher et al., 2001). PPARƔ is predominantly expressed in adipose tis-
sue (Tontonoz et al., 1994; Chawla et al., 1994; Vidal-Puig et al., 1997; Escher et al.,
2001). In skeletal muscle all three members are expressed (Loviscach et al., 2000;
Su et al., 1998). In HMT, the mRNA transcripts of all three PPARs were detected in
microarray experiments (data not shown). Transcripts of PPARD and PPARA mR-




It is shown in HMT (Staiger et al., 2009) and by different in vitro approaches (De-
genhardt et al., 2007), that ANGPTL4 and PDK4 are activated by PPARδ (Staiger
et al., 2009; Adhikary et al., 2011; Degenhardt et al., 2007). In previous experiments
of my diploma thesis, a participation of PPARδ in the LPC(16:0)-mediated induction of
Angptl4 was indicated by RNA interference experiments in mouse C2C12 myotubes
(Klingler, 2012). Several findings in this thesis support that LPCs activate PPARδ. Be-
side PDK4 and ANGPTL4, also other PPARδ target genes were found to be induced
by both LPCs, including CPT1A and PLIN2 (figure 3.1 on page 73) (Adhikary et al.,
2011). Furthermore, the effects of LPCs on PDK4/ANGPTL4mRNA levels were mim-
icked by PPARδ agonist GW501516 but not by PPARα agonist WY14643 (figure 3.4
on page 75). PDK4 and ANGPTL4 induction caused by LPCs was blocked in the
presence of the PPARδ antagonists GSK0660 and GSK3787 (figure 3.5 on page 76).
siRNA targeted against PPARD reduced LPC-mediated PDK4 induction (figure 3.6
on page 78). Activation of the LBD of PPARδ by LPCs was observed in luciferase
reporter assays (figure 3.7 on page 79).
PPARs are nuclear receptors and are activated by ligand binding. But also ligand-
independent modes of action that either lead to the induction or repression of PPAR
target transcripts are known (Feige et al., 2006). siRNA experiments of this work
pointed to the complexity of the impact of PPARδ on its target genes in the absence
of PPARδ ligands. The presence of siRNA targeted against PPARD increased the
mRNA levels of ANGPTL4 and PDK4 compared to the siCon transfected cells when
no PPARδ ligands were administrated (figure 3.6 on page 78). This observation is
also reported in the literature (Adhikary et al., 2011). It is postulated that PPARδ can
act as repressor on some of its target genes in the absence of ligands (Santos et al.,
2011). This repressive effect is apparently reduced in the presence of siPPARD.
Upon PPARδ antagonist treatment, mRNA levels of ANGPTL4 were reduced in
the absence of PPARδ activators (figure 3.5 on page 76). This is in contrast to the
siRNA experiments and might be explained by the fact that antagonists per se do
not necessarily lead to reduced PPARδ levels in contrast to siPPARD. In addition, lig-
and binding can increase the biological half-life of PPARs (Wadosky and Willis, 2012;
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Genini and Catapano, 2007; Rieck et al., 2007). Therefore, silencing and antagonism
of PPARδ had opposing effects on ANGPTL4mRNA levels. The discrepancy in the re-
sponse of PDK4 and ANGPTL4mRNA levels might be attributed to different amounts
of PPREs located at their promoter regions. ANGPTL4 has three PPREs while PDK4
only has two PPREs in the regulatory region of their gene (Adhikary et al., 2011; De-
genhardt et al., 2007).
The loss of the repressive effect of PPARδ by siPPARD in the absence of ligands
might be the reason why the LPC-mediated induction of ANGPTL4 is not significantly
affected by siPPARD (figure 3.6 on page 78). Here, a mixed effect of a siPPARD but
ligand-independent induction and a siPPARD-dependent reduction of ligand effects is
detected.
4.2 LPCs are PPARδ ligands
The ligand-dependent activation of PPARs is the most prominent mechanism how
the nuclear receptors act on their target genes. This multi-step process is still not
fully understood. The heterodimerization with its co-receptor RXR is a requisite for
this action of PPARs (Feige et al., 2005). According to current mechanistical mod-
els for the activation of PPARs by ligands, PPARs are moving along the DNA as
heterodimers searching for their recognition sequence (Feige et al., 2006). Ligand
binding of PPARδ enables the recruitment of a large protein complex consisting of
co-regulators and transcriptional factors. This protein complex slows down the mo-
bility of the PPAR/RXR complex while scanning the DNA and increases the affinity of
that complex to its target sequence (Michalik et al., 2006; Carlberg, 2010; Feige et al.,
2005; Dowell et al., 1997).
This work examined the effects of LPCs as putative PPARδ ligands. Concerning
the ligand binding, PPAR members differ in size and shape of their binding pock-
ets which affects their ligand spectrum. The endogenous ligands of PPARs are FA
>C12 (Xu et al., 1999) and derivatives thereof including prostaglandins, eicosanoids,
leukotrienes, and phospholipids as well as other lipids like retinoic acid (Ehrenborg
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and Krook, 2009; Xu et al., 1999; Chakravarthy et al., 2009; Forman et al., 1997;
Chakravarthy et al., 2009; McIntyre et al., 2003; Oishi-Tanaka and Glass, 2010; Shaw
et al., 2003). Although some overlapping specificities are reported, it should be men-
tioned that not all ligands bind with similar affinity to each PPAR member, as demon-
strated for FA (Forman et al., 1997; Xu et al., 1999) and other ligands. PC(16:0/18:1)
binds specifically to PPARα (Chakravarthy et al., 2009) while retinoic acid is a ligand
of PPARδ only (Shaw et al., 2003).
Because the ligand spectrum of PPARs is broad and includes different kinds of
phospholipids, it was examined if LPCs are putative PPARδ ligands. TR-FRET based
competition assay were used to verify if LPCs are ligands of PPARδ (figure 3.10 on
page 83). Here the potency of LPCs to replace a pan-PPAR ligand from the LBD of
PPARδ was examined. The efficacy of LPCs to compete for the LBD was moder-
ate compared to GW501516, which is in accordance with cell-based studies of this
work: 1 μM GW501516 increased PDK4 mRNA levels 13-fold whereas 10 μM LPC
increased PDK4 mRNA levels 3-fold (figure 3.4 on page 75 and 3.9 on page 81). No
competitive action was shown for PC(16:0/16:0) and αGPC which also failed to in-
duce PDK4 and ANGPTL4 mRNA levels. From the competition assays, ED50 values
of LPC(16:0) and LPC(18:1) were calculated. Both LPCs had similar values at ap-
proximately 30 μM. The ED50 values calculated here should be considered as rough
approximation because for a precise calculation more TR-FRET values of higher LPC
concentrations are needed (Sebaugh, 2011). Nevertheless, the values of LPC and the
corresponding FA (ranging from 5 - 7 μM) (table 3.2 on page 84) are in an comparable
range. This points to a possible relevance of LPCs as endogenous PPARδ ligands.
The functional activation of PPARδ by LPCs as ligands was assessed via EMSAs
(figure 3.8 on page 80), which were adapted in a way that only the recombinant pro-
teins PPARδ and RXRα as transcription factor components were used. This was
necessary, because no significant specific binding to the PPRE using nuclear extracts
could be detected (data not shown). In the presence of LPCs, the DNA binding activity
of PPARδ/RXRα on the consensus PPRE was enhanced to a comparable extend as
with GW501516. With higher concentrations of LPCs, the DNA binding activity was
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increasingly abolished. The reason for that is not clear, but might be the result of an
impairment of the protein structure integrity by the detergent-like action of LPCs. The
lysolipid LPE exerts chaperone-like effects on denaturated citrate synthase and helps
to refold the protein (Kern et al., 2001). Increasing concentrations of LPE increase
the effectiveness of the refolding. In contrast to that, increasing LPC concentrations
are decreasingly effective (Kern et al., 2001). Another possible explanation might be
that LPCs interacted as cationic amphiphils with the PPRE DNA and compromised the
interaction with the PPARδ/RXRα complex. Phospholipid formulations are commonly
used as carriers for nucleic acid for their delivery into cells and therefore are capable
of interacting with DNA (Paukku et al., 1997; MacDonald et al., 1999; Matulis et al.,
2002; Farhood et al., 1995; Hui et al., 1996).
In an other approach to test the functional activation of PPARs, 100 μM LPC(16:0)
and LPC(18:1) were able to significantly increase the recruitment of the C33 co-
activator peptide in a TR-FRET based assay to the LBD of PPARδ with a fold change
of 1.088±0.020 and 1.073±009 (±SEM, n=3 technical), respectively, compared to
solvent control (data not shown). 100 nM GW501516 was strongest with a fold
change of 1.455. To conclude, LPCs can activate the DNA binding activity of the
PPARδ/RXRα complex as direct ligands with functional consequences on the activity
of PPARδ.
4.3 Cellular uptake of LPCs
Since LPCs can act as PPAR ligands, their metabolization to other lipids is not nec-
essary for the activation of PPARδ, but they must enter the cells. The interplay of
internalization, transport, and kinetics of their metabolization was examined.
As already shown in the diploma thesis, the effects of LPCs on ANGPTL4 mRNA
abundance were apparent within less than 2 h of stimulation of HMT (figure 1.9 on
page 36). This finding adds to the observation that a first significant increase of labeled
LPC in HMT was apparent after 30 min after administration (figure 3.3A on page 74)
which could be attributed to LPCs integrated to the membrane or internalized LPCs.
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Notably, it was shown that radioactively labeled LPCs are taken up by aortic endothe-
lial cells within a comparable short time frame (Stoll et al., 1992). This points to a quick
internalization of LPCs that cannot be explained by a relative slow flip-flop rate as ob-
served in other cell-systems with a half-time of several hours (Bergmann et al., 1984).
According to that, a protein-assisted transport is more likely. The only known LPC
transporter MFSD2A, has low expression levels in skeletal muscle (Guemez-Gamboa
et al., 2015; Angers et al., 2008). However, robust mRNA levels are observed in HMT
according to our microarray results. The expression levels of MFSD2A might be suf-
ficient to facilitate the internalization of LPCs.
In summary, LPCs are internalized into the cell in a quick manner and most likely
in a protein-assisted manner. Small changes of the LPC structure, like a difference in
length of two carbon atoms or a double bond, did not have significant impact on the
activation of PPARδ, hence, presumably also not on the kinetics of the internalization.
4.4 Effect of LPC metabolites on PPARδ
It was also evaluated if LPC metabolites can also cause the activation of PPARδ.
This is an important consideration, since many of the metabolite of LPCs (figure 1.5
on page 8) are endogenous PPAR ligands, including FA (table 3.2 on page 84, figure
3.5A on page 76) (Forman et al., 1997; Xu et al., 1999), PC(16:0/18:1) (Chakravarthy
et al., 2009), LPA (McIntyre et al., 2003; Zhang et al., 2004), and cPA (Oishi-Tanaka
and Glass, 2010).
Furthermore, the results of the TLC experiments demonstrated a quick metabolism
of the internalized LPCs to PC (figure 3.3B on page 74). No significant changes of the
FA and LPC fraction were observed, while other LPC-derived metabolites were not
covered by the TLC analysis.
Different LPC metabolites were screened for their ability to affect ANGPTL4 and
PDK4 mRNA abundance (figure 3.9A on page 81). PC(16:0/16:0) and PC(18:1/18:1)
did not increase PDK4 and ANGPTL4 mRNA levels when given extracellularly. This
does not exclude their ability to activate PPARδ when they are formed intracellularly,
105
4 Discussion
but they are reported as relevant ligands of PPARα only in the literature (Chakravarthy
et al., 2009). Palmitate or oleate at equimolar concentrations showed similar re-
sponses on the induction of PDK4 and ANGPTL4 compared to LPCs (figure 3.9 on
page 81). This was not surprising because FA are endogenous PPAR ligands (ta-
ble 3.2 on page 84, figure 3.5A on page 76) and most likely have similar effects con-
cerning the efficacy of the PPAR activation. The glycerol backbone of LPC, as rep-
resented in αGPC did not increase the mRNA levels of PDK4 and ANGPTL4. αGPC
might be too hydrophilic to activate PPARδ.
The LPC derivative cPA(16:0) was reported to be a PPARƔ antagonist (Oishi-
Tanaka and Glass, 2010). In this work, this compound showed a robust induction
of the two target genes. cPA which lacks the positively charged choline part (figure
3.9A on page 81) demonstrated the importance of a negative charged hydrophobic
end opposed to the lipid part for the binding to the PPARδ LBD. This would presum-
ably add other lysolipids like LPE, LPS and LPA to the list of ligands. In fact, LPA
(not tested) was reported to be a PPARƔ agonist (McIntyre et al., 2003; Zhang et al.,
2004).
The strongest effect onPDK4 andANGPTL4mRNA in this experiment was found for
PC(O-16:0/O-1:0) treatment. PC(O-16:0/O-1:0) as an ether is chemically very resis-
tant to hydrolysis under physiological conditions and structurally resembles LPC(16:0)
(figure 3.9A on page 81). This compound can only be metabolized at the head-group
position. PC(O-16:0/O-1:0) was able to increase PDK4 and ANGPTL4 mRNA levels
to a higher extend than LPCs (figure 3.9 on page 81), increased the DNA binding ac-
tivity of PPARδ/RXRα complex in EMSAs (figure 3.23 on page 99), and was able to
replace the pan-PPAR agonist in TR-FRET based competition assays (figure 3.10 on
page 83). PC(O-16:0/O-1:0) is therefore also an PPARδ ligand and emphasized the
importance of the chemical structure of LPCs in the activation of PPARδ as ligand.
And it supports the conclusion that LPCs without further metabolization to FA or PC
can activate PPARδ target genes in HMT.
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4.5 Other signaling pathways might contribute to LPC
effects
The activity of PPARs is regulated by ligand binding and ligand-independent mecha-
nisms. Latter mechanisms might contribute to the LPC-mediated effects on PDK4 and
ANGPTL4. Post-translational modifications like phosphorylation can affect PPARs by
influencing the biological half-life of PPARs, affinity to ligands, heterodimerization with
RXR, intracellular localization, or the affinity to the target DNA sequence (Feige et al.,
2006). Kinases like AMPK, glycogen synthase kinase (GSK), ERK, PKA, and protein
kinase C (PKC, official symbol: PRKC) are able to phosphorylate PPARα/Ɣ at differ-
ent sites (Burns and Vanden Heuvel, 2007). Not much is known about the regulation
of PPARδ by phosphorylation. Some studies have demonstrated that PKA is able to
influence PPARδ activity (Lazennec et al., 2000; Hansen et al., 2001; Krogsdam et al.,
2002). The details of the interaction of PKA and PPARδ are not known and a direct
phosphorylation has not been examined so far. Data obtained during my diploma
thesis suggest that LPCs can inhibit PKA and the phosphorylation of its downstream
target vasodilator-stimulated phosphoprotein (VASP) (Klingler, 2012). Therefore, it
was examined if changes in intracellular cAMP levels as PKA regulating mechanism
might affect PPARδ target genes expression. PDK4 was induced by forskolin in a
H-89-sensitive manner (figure 3.21 on page 97). In my diploma thesis, I had shown
that pertussis toxin (PTX) could increase PDK4 mRNA levels (Klingler, 2012). Simi-
lar to forskolin, PTX also increases intracellular cAMP levels by inhibiting the Gi type
of heterotrimeric G-protein subunits that are coupled to GPCRs (Locht and Antoine,
1995; Carbonetti, 2010; Katada et al., 1983). In contrary, ANGPTL4 was repressed
by forskolin which could not be rescued by H-89 (figure 3.21 on page 97). The data
suggests that, PDK4 is regulated by intracellular cAMP levels, while ANGPTL4 might
be regulated in a complex fashion different from PDK4. According to that difference,
a link between PPARδ and PKA is less likely.
It is known that LPCs are affecting the intracellular Ca2+ flux in endothelial cells, car-
diac myocytes, immune cells like neutrophils and monocytes, and in skeletal muscle
107
4 Discussion
cells by activating Ca2+ channels (Riederer et al., 2010; Ojala et al., 2007; Yokoyama
et al., 2002; Wong et al., 1998; Frasch et al., 2007; Chaudhuri et al., 2003; Rolin et al.,
2014; Wang and Hekimi, 2016; Khan et al., 2010; Boittin et al., 2010). The mecha-
nisms for the activation of the channels by LPCs is not fully clarified but involves PLC
activation in endothelial cells and neutrophils that causes the production of inositol-
3 phosphate (IP3) and subsequent Ca2+ channel activation (Yokoyama et al., 2002;
Frasch et al., 2007). PLCs can be activated by GPCRs like GRP132 and GPR119,
which are known to be activated by LPCs (Frasch et al., 2007; Ning et al., 2008), po-
tentially via Gβ/Ɣ subunit complex (Katz et al., 1992) and via different types of Gα sub-
units (Khan et al., 2010). Therefore, it was tested if the Ca2+ signaling might play a
role in the induction of PDK4 and ANGPTL4, since Ca2+ can activate several kinases
among them are PKC and Ca2+/calmodulin-dependent protein kinase (CAMKK). Fur-
thermore, LPCs can activate PKCζ directly (Siddiqi and Mansbach, 2015) and other
PKC isoforms by other mechanisms (Yea et al., 2009; Motley et al., 2002; Bassa et al.,
1999; Sasaki et al., 1993; Oishi et al., 1988; Liao et al., 2013; Nishizuka, 1995). Such
kinases could potentially affect PPARδ activity by phosphorylation (Burns and Van-
den Heuvel, 2007).
BAPTA-AM used as an intracellular Ca2+-depleting compound, increased PDK4
mRNA abundance with borderline significance and reduced ANGPTL4 mRNA levels.
Ionomycin, that increases intracellular Ca2+ levels had no effects. Thus, only intra-
cellular Ca2+ depletion but not increasing Ca2+ levels affects PDK4 and ANGPTL4
mRNA levels or BAPTA-AM has side effects and changes of intracellular Ca2+ are not
of relevance in this context. In fact, chelation-independent effects of BAPTA-AM are
described in the literature (Furuta et al., 2009). It is therefore assumed that changes
of intracellular Ca2+ levels are not affecting PDK4 and ANGPTL4 mRNA abundance
and PPARδ activity.
A LPC-mediated regulation of PPARδ by phosphorylation via PKA or Ca2+-
dependent kinases is unlikely according to these findings. Manipulations of intra-
cellular cAMP levels therefore affected PPARδ target genes PDK4 and ANGPTL4
independent of PPARδ. It cannot be excluded that LPCs potentially alter intracellular
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secondmessenger levels bymechanisms that involve receptors other than PPARs, for
instance GPR119 (Cornall et al., 2013). That actions potentially can add to PPARδ ef-
fects and can lead to a mixed regulation of PDK4, ANGPTL4 and other effects of LPCs
on HMT reported in this thesis (summarized in figure 4.1 on the next page).
4.6 Consequences of PPARδ activation by LPCs
4.6.1 LPCs protect against lipotoxicity
PPARδ activation has been linked to anti-inflammatory effects (Wahli and Michalik,
2012; Vazquez-Carrera, 2016) during sepsis (Zingarelli et al., 2010) and on lipotoxicity
caused by saturated FAs in skeletal muscle cells (Coll et al., 2010; Salvado et al., 2014;
Wahli and Michalik, 2012).
Lipotoxicity describes a spectrum of pathophysiological events caused by ectopic
lipid overload and maladaptation to this situation (Brookheart et al., 2009; Ritter et al.,
2015) (summarized in figure 4.2 on page 122). An excessive supply of FA from the
circulation leads to an intracellular lipid accumulation that exceeds the natural tissue
capacity (Szendroedi and Roden, 2009). This results in the compensatory increase of
putatively detrimental lipid metabolites. This scenario can evoke consequences like
insulin resistance, chronic low-grade inflammation, ER stress, and apoptosis leading
to organ dysfunction and metabolic diseases in vivo (Schaffer, 2016; Han and Kauf-
man, 2016; Erikci Ertunc and Hotamisligil, 2016; Peter et al., 2009). In vitro, prominent
lipotoxic effects are predominantly induced by saturated FAs. They can enter a cell via
protein-independent routes (flip-flop) and via the assistance of proteins like cluster of
differentiation 36 (CD36) (Bonen et al., 2007) and are metabolized to different lipids,
subsequently. The sole amount of lipids and/or the spectrum of different lipids can
cause disturbances of the lipid composition of all membranes in the cell, especially of
the ER membrane (Hou and Taubert, 2014). This might cause ER stress which can
trigger a process called unfolded protein response (UPR) (Hou et al., 2014; Ariyama
et al., 2010; Hou and Taubert, 2014; Wei et al., 2006). UPR can ultimately lead to
apoptosis (Schroder and Kaufman, 2005; Unger and Orci, 2002).
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Figure 4.1: Signaling pathways of LPCs. This chart summarized the findings of this work and (Klin-
gler, 2012) concerning the signaling pathways of LPCs in HMT (black font and arrows). Findings
of the literature are also included (gray font and arrows). LPCs can either be internalized by trans-
porters like MFSD2A or via flip-flop, or can act via GPCRs like GRP119. Internalized LPCs acti-
vate PPARδ which leads to the transcription of genes like PDK4, ANGPTL4, and CPT1. Signaling
via plasma membrane receptors trigger the activation of small G-protein α, β, and Ɣ subunits and
their individual downstream signaling cascades. Effects of selected treatments on PDK4/ANGPTL4
mRNA abundance in HMT mentioned in this work are summarized in a table. Abbreviations: ADCY
(adenylate cyclase), FABP (FA binding protein), JNK (c-Jun N-terminal kinase), ic (intracellular), IP3
(phosphatidyl inositol-3-phosphate), LPL (lipoprotein lipase), PDH (pyruvate dehydrogenase), PTX
(pertussis toxin), SU (subunit). References: [1] Bergmann et al., 1984, [2] Nguyen et al., 2014, [3]
Hansen et al., 2012, [4] Cornall et al., 2013, [5] Burrier and Brecher, 1986, [6] Armstrong et al.,
2014, [7] Siddiqi and Mansbach, 2015, [8] Burns and Vanden Heuvel, 2007, [9] Yoshida et al., 2002,
[10] Patel et al., 2014, [11] Yea et al., 2009, [12] Hardie et al., 2012, [13] Jiang et al., 2013, [14]
Syrovatkina et al., 2016 [15] Katz et al., 1992.
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However, also single lipid species were reported to be responsible for one or more
aspects of lipotoxicity. The potential candidates are discussed controversially (Ritter
et al., 2015). Among them are acyl CoAs (Li et al., 2010), ceramides (Watson et al.,
2009; Frangioudakis et al., 2013; Summers, 2006), DGs (Macrae et al., 2013; Itani
et al., 2002; Xu et al., 2015; Szendroedi et al., 2014), PAs (Zhang et al., 2015), and
LPCs (Han et al., 2011, 2008; Kakisaka et al., 2012).
Saturated FA can also act on receptors on the cell surface. The most prominent
receptors of long chain FA in this context are toll-like receptor (TLR) 2 and 4 (Pal
et al., 2012; Hwang et al., 2016). Activated TLRs trigger several pathways which lead
to the activation of NFκB via the interleukin-1 receptor-associated kinase 4 (IRAK4)-
IκB kinase (IKK) axis (Leifer and Medvedev, 2016; Hwang et al., 2016) causing the
induction of inflammatory cytokines like IL6 and CXCL3 (Weigert et al., 2004; Anisow-
icz et al., 1991). The activation of the kinase JNK by TLRs and the activation of
especially PKCθ by various pathways cause the phosphorylation of insulin receptor
substrates (IRS) which are downstream of the insulin receptor (IR, official symbol:
INSR) signaling (Taniguchi et al., 2006; Boura-Halfon and Zick, 2009; Hwang et al.,
2016; Ritter et al., 2015). These particular ser/thr phosphorylations of IRS proteins
by these kinases lead to the pathophysiological downregulation of IRS proteins by
different mechanisms. In consequence, all downstream events, like phosphorylation
of AKT, are impaired resulting in insulin resistance of the cell (Boura-Halfon and Zick,
2009).
Treatment with the saturated FA palmitate is a common and efficient way to evoke
lipotoxicity in cell culture systems (Newsom et al., 2015; Kausch et al., 2003; Montell
et al., 2001). The resulting lipid profile has already been resolved in HMT and shows
that amongst others, also LPCs are formed (Li et al., 2013). The question rises if LPCs
could be a factor that contributes to lipotoxicity or if the LPC-mediated activation of
PPARδ acts protective.
In this work, 250 μM palmitate was used to cause an increase of ATF3, IL6, and
CXCL3 mRNA abundance in HMT together with enhanced XBP1 mRNA splicing as
marker of ER stress as aspect of lipotoxicity. LPC pre-incubation ameliorated the
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effects of palmitate (figure 3.14 on page 89) on the inflammatory markers IL6 and
CXCL3 and decreased ER stress observed in decreased ATF3mRNA levels together
with reduced XBP1 mRNA splicing. Hereby, LPCs showed robust anti-inflammatory
activity and are clearly not mediating lipotoxicity. In studies where LPCs are proposed
asmediators of lipotoxicity (Han et al., 2008, 2011; Kakisaka et al., 2012) high amounts
of LPCs were used. At such concentrations toxic effects that relate to unspecific and
detergent-like actions of LPCs can be expected. The stimulation condition used in this
thesis was tested for toxic and detergent-like effects, in order to avoid these effects.
10 μM of LPCs did not result in the release of intracellular LDH and CK (figure 1.7
on page 34) and did not cause the induction of IL6, ATF3, and CXCL3, pointing to a
non-toxic LPC concentration (figure 1.8 on page 35). In one of those studies the acyl
chains of the applied LPCs are not mentioned (Han et al., 2011). This makes it difficult
to compare the results of such studies to this work or to the in vivo situation.
The findings here support the correlations listed in table 1.7 on page 26, where
lower LPCs correlate with higher levels of inflammatory markers which provide a link
to the in vivo situation. Studies of NASH in mice point to a upregulation in LPCATs
by PPARα activation and inflammatory cytokines (Tanaka et al., 2012; Zhao et al.,
2008; Li et al., 2015). This increase of LPCATs reduces plasma LPC levels (Tanaka
et al., 2012). Fatty liver diseases like NASH and NAFLD are strongly associated with
insulin resistance and the metabolic syndrome (Stefan et al., 2008). This gives rise
to the hypothesis that during the metabolic syndrome, the main LPC source liver is
compromised. This leads to reduced serum LPC levels which also prevents their
protective effects and fortifies the low grade inflammation that is often seen during the
metabolic syndrome (Hotamisligil, 2006).
4.6.2 Mechanisms of the anti-inflammatory effects of LPCs
Effects of PPARδ activation
Possible mechanisms of the protection against lipotoxicity by LPCs were examined.
PPARδ activation is known to be protective against lipotoxicity (Cao et al., 2012; Sal-
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vado et al., 2014; Coll et al., 2010; Yang and Yang, 2016). In fact, GW501516 pro-
tected the cells against palmitate-mediated ER stress and inflammation to a similar
extend as LPCs. This indicates that PPARδ activation is sufficient to protect the cells
(figure 3.14 on page 89). Other findings in this work are supporting this hypothesis by
showing that PPARδ antagonism raised basal IL6, ATF3, and CXCL3 mRNA levels
after palmitate stimulation (figure 3.16 on page 91) and reversed the protective effects
of both LPCs on IL6 and CXCL3. Thus, PPARδ activation by LPCs or palmitate itself
could act protective against palmitate-mediated lipotoxicity. The question rises how
PPARδ causes this effect.
PPARs play an important role in the activation of metabolic pathways resulting in an
enhanced substrate oxidation. Enhancement of palmitate oxidation is one important
feature of PPARδ in skeletal muscle (Dressel et al., 2003; Tanaka et al., 2003). CPT1
is an important regulators of FA oxidation and its mRNA abundance was increased by
LPC treatment (figure 3.1 on page 73). Furthermore, FA oxidation was reported to be
one factor that causes protection against lipotoxicity (Henique et al., 2010).
GW501516 as positive control had also only minor effects on palmitate oxidation
in HMT, showing that this cellular model system can increase its FA oxidation only to
a small extend. The effects of LPCs on palmitate oxidation were also moderate (fig-
ure 3.11 on page 85). 5 μM LPC(16:0) had significant effects on palmitate oxidation.
No significant effects were detected for LPC(18:1) treatment. Since only LPC(16:0)
had significant effects but not LPC(18:1), enhanced FA oxidation might contribute but
cannot be the only cause for the anti-lipotoxic effects of LPCs.
PPARs can exert actions that are not related to simple binding of the PPAR/RXR
complex to their target DNA sequence. Such non-genomic mechanisms enable the
crosstalk with other transcription factor pathways. Two main actions has been de-
termined for this non-genomic actions: tethering and squelching (reviewed in (Feige
et al., 2006)).
Tethering describes the ability of PPARs, upon ligand binding, to physically interact
with other transcription factors and removing them from their target DNA sequence or
preventing their interaction with the DNA. The second mechanism involves the inter-
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action of PPARs with transcriptional co-regulators (Bugge and Mandrup, 2010). The
recruitment of co-regulators to PPARsmakes such co-regulators inaccessible for other
transcription factors. This effect is called squelching.
Examples for the two mechanisms could explain some anti-inflammatory actions
of PPARs. PPARα activation can cause the interaction of PPARα with subunits of
the transcription factors NFκB and activator protein-1 which both thereafter are tem-
porarily unable to bind to their target sequence on the IL6 promoter (Delerive et al.,
1999) preventing IL6 induction. It should be noted that NFκB is also a transcription
factor for CXCL3 (Anisowicz et al., 1991) and that CXCL3 might share a similar fate
as IL6. PPARδ activation might act in a similar fashion on IL6 and CXCL3 as PPARα.
This could explain why LPCs and GW501516 pre-treatment of HMT can decrease the
palmitate caused induction of IL6 and CXCL3 (figure 3.14 on page 89).
PPARα activation causes the tethering of the transcription factor CCAAT/enhancer-
binding protein β (aka C/EBPβ, official symbol: CEBPB) away from the promoter of
ORM (Mouthiers et al., 2005). ORM, the important LPC carrier during inflammation
(Ojala et al., 2006) is therefore reduced upon PPARα activation. This might increase
the free LPC concentration and enhance their anti-inflammatory action during satu-
rated FA overload in the serum, found during dyslipidemia as part of the metabolic
syndrome (Laaksonen et al., 2002) until the total LPC concentration declines due to
LPCAT induction in the liver as described earlier (Tanaka et al., 2012). It should be
mentioned, that CEBPB is also an important transcription factor for CRP (Agrawal
et al., 2001). PPARα activation might cause the downregulation of CRP by tethering
of CEBPB and provides a possible explanation how increased LPC levels in the cir-
culation are linked to the downregulation of the CRP gene (table 1.7 on page 26).
All these effects have been found for PPARα. PPARδ could have similar effects.
LPC(16:0) and LPC(18:1) not only activate PPARδ but also the PPARα LBD in lu-
ciferase reporter assays in HMT (data not shown) and it has been reported in the
literature that LPCs activate PPARα in hepatocytes (Takahashi et al., 2014). Accord-
ing to that, LPCs would be able to cause tethering and squelching by either PPARα or
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presumably by PPARδ as putative mechanisms for the reduction of IL6, CXCL3 and
other anti-lipotoxic effects reported in this work.
Target genes of PPARδ could contribute to the protective effect of LPCs, especially
in vivo. ANGPTL4 is an inhibitor of the lipoprotein lipase (LPL aka LIPD) (Robciuc
et al., 2012; Staiger et al., 2009). LPL is expressed in adipocytes and muscle cells
and translocates to the endothelial cells of the blood vessels via transport proteins
(Olivecrona, 2016). LPL is responsible for the hydrolysis of TG in lipoproteins like
chylomicrons and VLDL. ANGPTL4 therefore indirectly reduces the uptake of FAs
by reducing their production by LPL (Robciuc et al., 2012; Lichtenstein et al., 2007;
Sukonina et al., 2006; Yoshida et al., 2002). This might prevent their accumulation in
skeletal muscle cells and potential lipotoxic events.
PDK4 is an important regulator of glucose oxidation. The family of PDK consists
four members: PDK1 - 4. PDKs phosphorylate the pyruvate dehydrogenase complex
(PDH), thereby inhibiting this multi-enzyme complex which catalyzes the oxidative
decarboxylation of pyruvate to acetyl CoA (Patel et al., 2014). Pdk4 knockout mice are
protected against the deleterious effect of a diet enriched in saturated FA (Hwang et al.,
2009). Therefore, PDK4 is presumably not a candidate that mediates the protection
against lipotoxicity.
Effects of AMPK activation
This work describes an increase of FA oxidation by LPC(16:0) (figure 3.11 on
page 85). AMPK and PPARδ synergistically enhance FA oxidation (Kramer et al.,
2007). Thereby, AMPK inhibits the malonyl CoA producing enzyme ACCs and as a
result fortifies FA oxidation (Hardie et al., 2012). It was reported that AMPK activa-
tion can protect against lipotoxicity in several cell types and systems (Cacicedo et al.,
2011; Hong et al., 2014; Mayer and Belsham, 2010; Rodriguez-Calvo et al., 2015;
Jung et al., 2015; Kramer et al., 2007; Salvado et al., 2014; Vazquez-Carrera, 2016;
Henique et al., 2010) but the details of the mechanisms are still unclear. Recently, it
was reported that LPC(18:0) is able to activate AMPK in macrophages (Quan et al.,
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2016; Kim et al., 2015). AMPK activation could be another potential factor in the pro-
tection against lipotoxicity by LPCs.
AMPK consists of three subunits α, β, and Ɣ from which α exists in two (α1 and
α2; official symbols: PRKAA1 and PRKAA2), β in two (β1 and β2, official symbols:
PRKAB1 and PRKAB2), and Ɣ subunit in three isoforms (Ɣ1 - 3, official symbols:
PRKAG1 - 3) (Hardie, 2011). The α subunit harbors the phosphorylation site thr172,
which when phosphorylated can increase the activity of AMPK by a factor of 100 (Suter
et al., 2006). The kinases that are responsible for the phosphorylation of this site are
liver kinase B1 (LKB1) (Hawley et al., 2003) and Ca2+/calmodulin-activated protein
kinase α and β (CamKIIα and CamKIIβ, official symbols: CAMK2A and CAMK2B)
(Hawley et al., 2005; Woods et al., 2005; Hurley et al., 2005). LKB1 is a tumor sup-
pressor gene and is activated by the formation of a protein complex with the pseudok-
inase Ste20-related adapters and the scaffold protein mouse protein-25 (Baas et al.,
2003; Boudeau et al., 2003). Intracellular Ca2+ rise causes the phosphorylation and
activation of CAMK2B. AMPK is also stimulated by the hunger signal AMP. AMP is
able to allosterically activate AMPK, increasing its activity 10-fold and also enables
the phosphorylation of AMPK by binding to the Ɣ subunit (Hawley et al., 1995; Davies
et al., 1995). Likewise, ADP is able to enhance the ability of AMPK to be activated
by phosphorylation but lacks the ability to activate AMPK allosterically (Oakhill et al.,
2011; Xiao et al., 2011). The AMP:ATP ratio indicates the energy status of a cell. In
other words, AMPK is activated upon energy demand (Hardie, 2011; Hardie et al.,
2012).
This work clearly shows, that both LPCs equally trigger the phosphorylation of
AMPK and its downstream target ACC (figure 3.13 on page 87). The kinetics analy-
sis revealed an activation that persists about 4 h and declines to baseline afterwards.
The question rises, how LPCs activate AMPK. PPARδ activation could be one possi-
ble explanation. PPARδ causes the upregulation of uncoupling proteins (Chevillotte
et al., 2001; Villarroya et al., 2007) that reduces ATP production and increases the
AMP:ATP ratio (Kramer et al., 2007), an important signal for AMPK activation. The
microarray results in this work (figure 3.1 on page 73) did not support an increase in
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uncoupling proteins mRNA levels by LPC treatment. This is in accordance with the lit-
erature, showing that FA treatment of HMTs also does not increase uncoupling protein
3 (Staiger et al., 2009). This mechanism could be the case for strong PPARδ agonists
like GW501516, but comparably weak endogenous agonists like FA and LPCs might
require other additional metabolic events that contribute to the activation of AMPK via
an increase of the AMP:ATP ratio. In fact, LPC(18:1) is able to activate GPR119 (Soga
et al., 2005; Overton et al., 2006). GPR119 activation, recently, has been reported to
activate AMPK by increasing the AMP:ATP ratio (Yang et al., 2016). Additionally, the
activation of this receptor was linked to anti-diabetic properties in intestinal and pan-
creatic cells by increasing the release of incretins and insulin and anti-steatotic activity
in hepatocytes by inhibiting lipogenesis via sterol regulatory element binding protein
(Yang et al., 2016). This would endorse the protective properties of LPCs and shows
that AMPK is an important factor for the protective effects of LPCs.
But also altered Ca2+ fluxes might contribute to the AMPK activation. Intracellular
Ca2+ flux is indeed affected by LPCs, as reported by several studies in the literature
(Riederer et al., 2010; Ojala et al., 2007; Yokoyama et al., 2002; Wong et al., 1998;
Inoue et al., 1992; Frasch et al., 2007; Chaudhuri et al., 2003; Rolin et al., 2014; Wang
and Hekimi, 2016).
Taking together, AMPK is presumably activated by LPCs via two pathways: increase
in AMP:ATP ratio by binding to GPR119 or by increases of intracellular Ca2+ levels.
AMPK activation could be an important factor in the protective effects of LPCs on
lipotoxicity.
Another important feature of LPCs are their chemical properties, which affects mem-
brane behavior and also receptor activity. It is reported that LPCs can affect TLR4
translocation and their exposition to ligands like FAs (Jackson et al., 2008). This
could be another important feature of LPCs, how they influence inflammatory path-
ways (Fessler et al., 2009; Senn, 2006).
In summary, it is difficult to point to one single mechanistical pathway for the anti-
inflammatory action of LPCs. It is more likely, that multiple effects of LPCs as signaling
molecule and as cone-shaped amphiphil might play a role and act synergistically.
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4.6.3 Effects of LPCs on glucose uptake
AMPK activation increases both glucose and FA uptake and oxidation (Sakamoto
et al., 2005; Sakamoto and Holman, 2008; Chen et al., 2008; Pehmoller et al., 2009;
Merrill et al., 1997) (Carling et al., 2003). AMPK is known to activate glucose up-
take by an inhibitory phosphorylation of TBC1 domain family member 1 (TBC1D1)
(Pehmoller et al., 2009; Chen et al., 2008). TBC1D1 inhibits SCL2A4 translocation
(Cartee, 2015). This mechanism of the SCL2A4 translocation is independent of in-
sulin but important for the contraction-induced glucose uptake in skeletal muscle via
the Ca2+-AMPK-TBC1D1 axis (Cartee, 2015).
In this work, LPC(16:0) treated L6GLUT4myc cells demonstrated a marginally in-
creased basal glucose uptake in comparison to 100 nM insulin treated cells (fig-
ure 3.12 on page 86). LPC(18:1) had no effects in this experiment. This is in ac-
cordance with finding in adipocytes, demonstrating that LPC(16:0) but not LPC(18:1)
increases 2DOG uptake already after less than 5 min in 3T3-L1 adipocyte (Yea et al.,
2009) and 300 μM LPC(16:0) in insulin resistant adipocytes (Takahashi et al., 2014).
When insulin is present, the effects of LPC(16:0) on glucose uptake were not de-
tectable. It was shown in HMT, that LPCs do not affect AKT phosphorylation upon
insulin stimulation (data not shown). This could explain why there is no effect of LPCs
on insulin-dependent glucose uptake.
Taking together, LPCs only marginally increase basal glucose uptake in L6GLUT4myc
cells. Since AMPK is activated by LPC(16:0) and LPC(18:1) similarly, the mechanism
for this observation is unclear.
4.6.4 Targeting intracellular LPC formation during lipotoxicity
It was reported that during palmitate stimulation, LPCs are rapidly increased in HMT
(Li et al., 2013) and liver cells (Kakisaka et al., 2012). It was shown here that LPC
stimulation can exerts protective effects. Thus, interference with the LPC metabolism
during palmitate stimulation might also have an impact on lipotoxic events and could
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give hints about the efficacy and role of the intracellularly formed LPC on the preven-
tion of an overshooting lipotoxicity.
Silencing of LPCAT would presumably lead to an increase of intracellular LPCs and
was expected to have similar effects as exogenous LPC treatment namely the protec-
tion against lipotoxicity. Indeed, silencing of LPCATs was protective against lipotoxicty
in HMT (figure 3.17 on page 93). Inhibition of iPLA2 should block LPC formation and
fortify lipotoxicity. iPLA2 were chosen as target for inhibition because in the litera-
ture two members PLA2G6A and PLA2G6B are responsible for palmitate-mediated
increase of intracellular LPC content in L6 cells (Han et al., 2011). BEL is a suicide
substrate for iPLA2 (Hazen et al., 1991). It is commonly used in this context but also in-
hibits PLPP and many enzymes that have cysteine residues in the active center (Song
et al., 2006; Balsinde and Dennis, 1996; Balboa et al., 1998; Daniels and Katzenel-
lenbogen, 1986; Mitchell et al., 1998). BEL is a chiral compound. The enantiomers
can discriminate between different iPLA2 subclasses, especially between PLA2G6A
and PLA2G6B. However, neither of the two enantiomers showed effects on lipotoxic-
ity caused by palmitate (figure 3.18 on page 94). FKGK11 has less side effects than
BEL and specifically inhibits iPLA2 (Kokotos et al., 2010; Baskakis et al., 2008). At
10 μM, FKGK11 treatment significantly worsened IL6, ATF3, and CXCL3 mRNA in-
duction caused by palmitate. The more specific approach of silencing of PLA2G6A+B
demonstrated that both lipases are in part mutually regulated (figure 3.19 on page 95).
The mRNA abundances of both lipases were regulated by palmitate treatment and
PLA2G6B mRNA was increased when PLA2G6A was silenced. This complex reg-
ulation caused difficulties in interpreting the effect on IL6, ATF3 and CXLC3 mRNA
abundance. Similar to the finding during the LPCAT knockdown, also here only ef-
fects on IL6, but not on ATF3 and CXCL3 were observed. Nevertheless, silencing of
either PLA2G6A or PLA2G6B significantly intensified IL6 induction caused by palmi-
tate treatment. It should be also pointed out, that the approaches of this section has
not been tested for their effects on intracellular LPC levels.
To conclude, the metabolites that are responsible for lipotoxicity caused by satu-
rated FA are still not completely resolved. This work shows by multiple approaches
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that LPCs are not mediators of lipotoxicity in HMT, but LPC protect against lipotoxic
events (summarized in figure 4.2 on page 122). Furthermore, intracellular formed
LPCs might prevent an exaggerated lipotoxicity.
4.6.5 Effects of LPCs on insulin resistance
Several findings point to a potential insulin-sensitizing effect of LPCs. LPCs are
biomarkers for IGT and T2DM (table 1.6 on page 25) and PPARδ activation can im-
prove diseases associated with the metabolic syndrome, including insulin resistance
(Odegaard et al., 2008; Oliver et al., 2001; Lee et al., 2006). It was shown in this
thesis, that LPC(16:0) can increase basal glucose uptake in L6GLUT4myc cells although
only marginally. Furthermore, LPCs acted in an anti-inflammatory way and protected
against ER stress during lipotoxicity. It is likely that LPCs also prevent impairment of
the insulin signaling by palmitate as an other aspect of lipotoxicity (Ritter et al., 2015).
To this end, it was investigated if cellular insulin resistance, observed as reduced
insulin-mediated phosphorylation of AKT caused by palmitate, can be prevented by
LPC treatment. This work showed that both LPCs differ in their potency concerning
the protection of the insulin signaling pathway (figure 3.15 on page 90). LPC(16:0) but
not LPC(18:1) could prevent palmitate caused reduction of insulin-dependent phos-
phorylation of AKT at ser473. For the site thr308 only LPC(18:1) was protective but
not LPC(16:0). The discrepancy between the two LPCs could be due to the fact that
both phosphorylation sites are targeted by different kinases.
AKT is a serine/threonine kinase that exists in three isoforms and all are partially
activated upon phosphorylation on thr308 and completely activated by the additional
phosphorylation of ser473 (Scheid and Woodgett, 2003). To enable the phosphory-
lation, AKT is recruited to the plasma membrane by binding to PI-3,4,5-trisphosphate
(PIP3) (Bellacosa et al., 1998). PIP3 is a product of the PI-4,5-bisphosphate-3-kinase
(PIK3), which is activated by growth hormone signaling cascades triggered for in-
stance by insulin. PIP3 also activates phosphoinositide-dependent kinase 1 (PDPK1)
which thereafter phosphorylates AKT at thr308. Thr308 is also phosphorylated by
inhibitor of kappa B kinase (IKK) (Guo et al., 2011). Ser473 is phosphorylated by
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mammalian target of rapamycin complex 2 (mTORC2) (Sarbassov et al., 2005; Frias
et al., 2006), PDPK2 (Liao and Hung, 2010), CaMKK (Soderling, 1999), IKK (Guo
et al., 2011), and TANK-binding kinase 1 (TBK1). This shows that many signaling
pathways are between insulin and AKT which all are putatively affected by palmitate
and LPC treatment. How the two tested LPC interfere individually with the pathways
that lead to the phosphorylation of either ser473 or thr308 requires further detailed
studies.
4.7 In vivo relevance of free LPC concentration
The question rises if the conditions used in this thesis sufficiently resemble the in vivo
situation. In vivo, 100 - 300 μM LPCs (section 1.4.3 on page 18) are found in the blood
together with approximately 600 μM (Simard et al., 2006) ALB (ALB:LPC = 1:0.5). The
binding to ALB also reduces some of the physiological effects of LPCs (Klibansky and
De Vries, 1963; Ojala et al., 2006; Mochizuki et al., 1982; Soga et al., 2005; Klingler,
2012). The presence of 68 μM ALB, the major LPC complexing protein, eliminated
the induction of PDK4/ANGPTL4 by 10 μM LPCs (ALB:LPC = 1:0.15), as shown in
my diploma thesis (Klingler, 2012). At this ALB:LPC ratio, there were obviously no
or too less biologically available LPCs. In the cell culture system used in this work
10 μM LPCs were incubated in medium (table 2.13 on page 48) containing ≈5 μM
ALB resulting in an ALB:LPC ratio of 1:2.
In vivo, LPCs are bound by different serum proteins. Other compounds like FA, but
also almost all lipophilic compounds in plasma compete for the binding. While it is
assumed that under physiological conditions the free LPC concentration is small, but
no data on the free concentration exist. To conclude, the free LPC levels are most
likely only small but dynamic. These small LPC levels can have profound effects as
illustrated by this work.
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Figure 4.2: Signaling pathways of lipotoxicity. This chart summarized the findings of this work
concerning the signaling pathways of lipotoxicity (black font/arrows). Findings of the literature are
included (gray font/arrows). Palmitate causes lipotoxicity which includes ER stress, inflammation,
insulin resistance, and apoptosis. This process is triggered by different pathways that involves
the uptake and metabolization of palmitate as well as signaling events activated by the binding
of palmitate to TLRs. Abbreviations: ATF (activating transcription factor), BEL (bromenol lactone),
CD36 (cluster of differentiation 36), IKK (IκB kinase), INSR (insulin receptor), IRAK4 (interleukin-1
receptor-associated kinase 4), IRE1 (inositol-requiring enzyme 1), IRS (insulin receptor substrate),
JNK (c-Jun N-terminal kinases), mTORC2 (mammalian target of rapamycin complex 2), NFκB
(nuclear factor κ-light-chain-enhancer of activated B cells), PDPK1 (phosphoinositide-dependent
kinase-1), PERK (PKR-like endoplasmic reticulum kinase), PIK3 (PI-4,5-bisphosphate 3-kinase),
PIP3 (PI-3,4,5-trisphosphate), TLR (toll-like receptor). References: [1] Bonen et al., 2007, [2] Pal
et al., 2012, [3] Li et al., 2013, [4] Balsinde and Dennis, 1996, [5] Hazen et al., 1991, [6] Baskakis
et al., 2008, [7] Summers, 2006, [8] Li et al., 2010, [9] Zhang et al., 2015, [10] Szendroedi et al.,
2014, [11] Hou et al., 2014, [12] Han and Kaufman, 2016, [13] Kramer et al., 2007, [14] Salvado
et al., 2014, [15] Hwang et al., 2016, [16] Boura-Halfon and Zick, 2009, [17] Weigert et al., 2004.,
[18] Anisowicz et al., 1991, [19] Taniguchi et al., 2006, [20] Scheid and Woodgett, 2003.
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4.8 Outlook: Pharmacological aspects of LPCs
This thesis illustrates the beneficial effects of LPCs in the context of the metabolic
syndrome. On a pharmacological point of view, this would suggest to increase the LPC
concentration to a normal range. PPAR agonist and activators of the nuclear receptors
RXR and retinoic acid receptor were shown to increase the LPC concentration in the
circulation of mice (Takahashi et al., 2014; Weiss et al., 2011; Franko et al., 2016).
According to that, LPCs could increase their own levels in the circulation by activating
PPARs.
In this context, the direct substitution of LPCs when they are reduced could be of
interest. But LPCs have a short half-live in the circulation due to quick uptake and
degradation. Alkyl phospholipids could be a possible application form of LPCs with
prolonged biological half-life (Arnold et al., 1978). Some alkyl phospholipid-related
compounds are already in therapeutic use as it is the case for miltefosin (hexadecyl-
phosphocholine) (Leonard et al., 2001; Fernandez et al., 2014), which recently has
also been shown to activate AMPK in liver and therefore acting protective against hep-
atic steatosis (Fang et al., 2016). To overcome detergent-like effects, a lipid nanopar-
ticle dosage form was successfully tested for miltefosine which reduced complications
by oral and intravenous applications (da Gama Bitencourt et al., 2016).
The main action of LPCs is the activation of PPARs. PPAR activators, especially
PPARα agonists (class of fibrates) and PPARƔ agonists (class of thiazolidinediones
(TZD)s), are of great importance of today’s treatment of the metabolic syndrome. Fi-
brates like fenofibrate are used to counteract dyslipidemia (Tenenbaum and Fisman,
2012). Pioglitazone and rosiglitazone are two TZDs that are under therapeutic use as
insulin-sensitizers for patients with T2DM (Hauner, 2002). TZDs have several side ef-
fects, for instance increased risk of cardiac failure, bone fractures, and bladder cancer
(Nissen and Wolski, 2007; Graham et al., 2010; Vallarino et al., 2013).
In order to intensify and combine the effects of fibrates and TZD and to reduce
side effects, dual PPARα/Ɣ agonist were developed. But the attempts failed due to




PPARδ activation has been proven to be insulin-sensitizing inmousemodels (Zhang
et al., 2016; Lee et al., 2006). PPARδ knockout mice are glucose intolerant, have
lower energy expenditure, and gain more weight during high fat diet compared to wild
type littermates (Lee et al., 2003; Wang et al., 2003). Activation of PPARδ in adipose
tissue can prevent diet-induced obesity (Wang et al., 2003). In fact, GW501516 was
under investigation as a therapeutic (Sprecher et al., 2007; Riserus et al., 2008) but
the trials were stopped because mice developed tumors during the treatment (Gupta
et al., 2004; Pollock et al., 2010). According to that, dual agonists were discussed.
Currently, at least three PPARδ agonists are in clinical trials. The PPARδ agonist
MBX8025 is in phase II (Bays et al., 2011; Choi et al., 2012), PPARδ agonist KD3010
in phase Ib (Dickey et al., 2016; Iwaisako et al., 2012), and the dual PPARα/δ ago-
nist GFT505 (aka elafibranor) in phase III (Staels et al., 2013). MBX8025 is under
investigation to treat dyslipidemia and insulin resistance (Hanf et al., 2014). KD3010
protects against liver fibrosis (Iwaisako et al., 2012) and the neurodegenerative Hunt-
ington’s disease (Dickey et al., 2016). GFT505 counteracts NAFLD and non-alcolic
steatohepatitis (NASH) (Staels et al., 2013; Ratziu et al., 2016), is insulin-sensitizing
(Cariou and Staels, 2014; Cariou et al., 2013, 2011), and lacks the deleterious side
effects of TZDs (Hanf et al., 2014).
From the results in this work, LPCs might be of clinical interest, not only as biomark-
ers but also as PPARδ and putatively also as dual PPARα/δ agonist. As endogenous
ligands with rather moderate efficacy, they harbor the safety of less side effects than
strong synthetic agonists. In the field of TZDs, it was shown that the weaker agonist
pioglitazone has lower side effects than the stronger rosiglitazone (Colca et al., 2014;
Winkelmayer et al., 2008). Strong PPARδ agonists increase PPARδ levels which
might be the reason for unwanted side effects (Zhang et al., 2016).
LPCs also activate AMPK, which makes them an even more attractive pharmaco-
logical target. AMPK has been shown to be important during exercise. Mice lacking
the β subunits of AMPK have reduced exercise capacity (O’Neill et al., 2011). The
combination of AMPK and PPARδ activation can act as an exercise mimetic (Narkar
et al., 2008; Manio et al., 2016; Wall et al., 2016). PPARδ activation not only counter-
124
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acts T2DMand themetabolic syndrome by decreasing fasting insulin/glucose (Riserus
et al., 2008; Lee et al., 2006), dyslipidemia (Sprecher et al., 2007; Riserus et al., 2008)
including liver fat (Riserus et al., 2008), and body weight (Christodoulides et al., 2009;
Wang et al., 2003) but also increases endurance capacity during exercise (Narkar
et al., 2008). Accordingly, LPCs can intensify the effects of exercise by acting on
PPARδ and AMPK, simultaneously.
Apart from PPAR/AMPK activation, LPCs were considered as future carriers for
lipophilic drugs into the brain (Wang et al., 2016a), as immune modulators during im-
munizations (Bach et al., 2010; Perrin-Cocon et al., 2006), or as anti-inflammatory
drugs against sepsis (Yan et al., 2004; Smani et al., 2015; Parra Millan et al., 2016).
With that many possible applications of LPCs it is vital to find out what the exact mech-
anisms of their action are and to unravel the role of single LPC species.
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